{
      "StudyFieldsResponse": {
            "APIVrs": "1.01.05",
            "DataVrs": "2022:10:06 23:25:58.836",
            "Expression": "mesenchymal UC-MSCs",
            "NStudiesAvail": 430108,
            "NStudiesFound": 408,
            "MinRank": 1,
            "MaxRank": 1000,
            "NStudiesReturned": 408,
            "FieldList": [
                  "Acronym",
                  "AgreementOtherDetails",
                  "AgreementPISponsorEmployee",
                  "AgreementRestrictionType",
                  "AgreementRestrictiveAgreement",
                  "ArmGroupDescription",
                  "ArmGroupInterventionName",
                  "ArmGroupLabel",
                  "ArmGroupType",
                  "AvailIPDComment",
                  "AvailIPDId",
                  "AvailIPDType",
                  "AvailIPDURL",
                  "BaselineCategoryTitle",
                  "BaselineClassDenomCountGroupId",
                  "NCTId"
            ],
            "StudyFields": [
                  {
                        "Rank": 1,
                        "Acronym": [
                              "PTC-UC-MSC"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Pentostatin will be given by intravenous infusion at a dose of 1 mg/m2 for 3 consecutive days. Thereafter, three Umbilical Cord Mesenchymal stromal cells (UC-MSC) infusions will be given at weekly interval starting from day 5. We will follow a dose escalating programme with progressively increasing doses of cells until the maximally tolerated dose (MTD) is achieved.\n\nThe dose escalating design will be characterised by the administration of 1x106 /kg UC-MSC per dose per three doses for the first three patients (total up to 3x106/kg). The second three patients will receive 2x106/kg UC-MSC per dose per three doses (total up to 6x106/kg). The third three patients will receive 3x106/kg UC-MSC per dose per three doses (total up to 9x106 cells/kg).\n\nSince three dosages of cells are programmed for each group of 3 patients, a minimum of 9 patients should be studied, unless unacceptable acute infusion related toxicity is observed."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: UMBILICAL CORD DERIVED MESENCHYMAL STROMAL CELLS (UC-MSC)"
                        ],
                        "ArmGroupLabel": [
                              "Umbilical Cord Mesenchymal stromal cells (UC-MSC)"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02032446"
                        ]
                  },
                  {
                        "Rank": 2,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "All patients to receive allogeneic UC-MSCs via intralesional injection"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Human umbilical cord mesenchymal stem cells (UC-MSCs)"
                        ],
                        "ArmGroupLabel": [
                              "Human umbilical cord mesenchymal stem cells (UC-MSCs)"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05039411"
                        ]
                  },
                  {
                        "Rank": 3,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Mesenchymal stromal cell therapy in addition to corticosteroid therapy"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Mesenchymal stromal cell therapy",
                              "Biological: Mesenchymal stromal cell therapy"
                        ],
                        "ArmGroupLabel": [
                              "Mesenchymal stromal cell therapy",
                              "Corticosteroid therapy"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01589549"
                        ]
                  },
                  {
                        "Rank": 4,
                        "Acronym": [
                              "UCMSCs"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Umbilical cord mesenchymal stem cells intravenous injection at a dose of 2 million cells/kg at week 0,week 2,week 4,week 6,week 8 with a duration for treatment for 12 weeks."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Umbilical cord mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "UCMSCs group"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03745417"
                        ]
                  },
                  {
                        "Rank": 5,
                        "Acronym": [
                              "CARE-SSc"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patients receive one intravenous infusion of UCMSC at month 0 and one intravenous infusion of placebo at month 3. Each experimental infusion will consist of 1 million UCMSC/kg suspended in 50 ml of PlasmaLyte A. Each placebo infusion will consist of a similar volume of PlasmaLyte A.",
                              "Patients receive one intravenous infusion of UCMSC at month 0 and one intravenous infusion of UCMSC at month 3. Each experimental infusion will consist of 1 million UCMSC/kg suspended in 50 ml of PlasmaLyte A.",
                              "Patients receive intravenous placebo infusions at months 0 and 3. Each placebo infusion will consist of 50 ml of PlasmaLyte A."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: UCMSC",
                              "Biological: UCMSC",
                              "Other: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "One infusion of UCMSC",
                              "Two infusions of UCMSC",
                              "Placebo infusions"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04356287"
                        ]
                  },
                  {
                        "Rank": 6,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Human umbilical cord mesenchymal stem cells injection is applied for knee OA patients."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Human umbilical cord mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "Human umbilical cord mesenchymal stem cells"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05160831"
                        ]
                  },
                  {
                        "Rank": 7,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patients will receive human umbilical cord mesenchymal stem cells transplantation with a 12 months follow-up."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Human umbilical cord mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "hUC-MSC treatment"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02291926"
                        ]
                  },
                  {
                        "Rank": 8,
                        "Acronym": [
                              "Neptune"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "allogeneic mesenchymal stromal cell infusion"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: mesenchymal stromal cells"
                        ],
                        "ArmGroupLabel": [
                              "mesenchymal stromal cells"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02387151"
                        ]
                  },
                  {
                        "Rank": 9,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Four different doses were set, and three subjects in each dose plan received human umbilical cord mesenchymal stem cell injection successively. Each subject received a single dose of 6.0*10^6, 3.0*10^7, 6.0*10^7, and 9.0*10^7 cells / person."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Human umbilical cord mesenchymal stem cell injection"
                        ],
                        "ArmGroupLabel": [
                              "Dose escalation"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05468502"
                        ]
                  },
                  {
                        "Rank": 10,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Procedure:UC-MSC infusion via peripheral vein. Four times of MSC infusion (1.5x10E6 cells/kg body weight) via peripheral vein will be given to the group 1(once every 4 days).",
                              "Procedure:UC-MSC infusion via peripheral vein. Two times of MSC infusion (1.5x10E6 cells/kg body weight) via peripheral vein will be given to the group 2(once every 7 days).",
                              "Control group with standard medical care. UC-MSC infusion could be considering in this group after 24 weeks' followed-up."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: UC-MSC",
                              "Biological: UC-MSC",
                              "Biological: UC-MSC"
                        ],
                        "ArmGroupLabel": [
                              "MSC group 1",
                              "MSC group 2",
                              "Control group"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03529136"
                        ]
                  },
                  {
                        "Rank": 11,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Injection of twenty million human umbilical cord mesenchymal stem cells into the degenerative disc"
                        ],
                        "ArmGroupInterventionName": [
                              "Other: human umbilical cord mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "Human Umbilical Cord Mesenchymal Stem Cells"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04414592"
                        ]
                  },
                  {
                        "Rank": 12,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patients will receive human umbilical cord mesenchymal stem cells transplantation with a 12 months follow-up."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Human umbilical cord mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "hUC-MSC treatment"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02652351"
                        ]
                  },
                  {
                        "Rank": 13,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Umbilical-cord mesenchymal stromal cells (UC-MSCs)\n\nAllogeneic UC-MSCs 20 x 10e6 diluted on 3 mL of saline solution + 5% of Plasma AB\n\nArm 2a: single infusion group. UC-MSCs at 0 month\n\nArm 2b: double infusion group. UC-MSCs at 0 and 6 months",
                              "Drug: Hyaluronic Acid 3 mL of HA intra-articular injection at baseline and 6 months"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: umbilical-cord mesenchymal stromal cells",
                              "Drug: Hyaluronic Acid"
                        ],
                        "ArmGroupLabel": [
                              "Umbilical-cord mesenchymal stromal cells",
                              "Hyaluronic Acid (HA)"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02580695"
                        ]
                  },
                  {
                        "Rank": 14,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patients will receive human umbilical cord mesenchymal stem cells transplantation with a 12 months follow-up."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Human umbilical cord mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "hUC-MSC treatment"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02790762"
                        ]
                  },
                  {
                        "Rank": 15,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Human umbilical cord mesenchymal stem cells were given to each diabetic nephropathy subject once a month, peripheral intravenous injection, a total of three times"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Human umbilical cord mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "Human umbilical cord mesenchymal stem cells"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04125329"
                        ]
                  },
                  {
                        "Rank": 16,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Intrathecal Transplantation of Umbilical Cord Mesenchymal Stem Cells"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Umbilical Cord Mesenchymal Stem Cells"
                        ],
                        "ArmGroupLabel": [
                              "Umbilical Cord Mesenchymal Stem Cells"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03505034"
                        ]
                  },
                  {
                        "Rank": 17,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [
                              "Yes"
                        ],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Repeated intrathecal administrations of 1x10E6 human umbilical cord mesenchymal stem cells per kg in subjects with spinal cord injury with an interval of one month between each administration"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: human umbilical cord mesenchymal stem cells (hUC-MSCs)"
                        ],
                        "ArmGroupLabel": [
                              "hUC-MSC Transplantation"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [
                              "Female",
                              "Male"
                        ],
                        "BaselineClassDenomCountGroupId": [
                              "BG000",
                              "BG000",
                              "BG000",
                              "BG000",
                              "BG000"
                        ],
                        "NCTId": [
                              "NCT02481440"
                        ]
                  },
                  {
                        "Rank": 18,
                        "Acronym": [
                              "MSCs"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Intervention: two doses of autologous bone marrow (BM) derived Mesenchymal Stromal Cells IV, 7 days apart, 6 and 7 weeks after transplantation in combination with Certican\u00ae (1.5mg/day). Doses of MSCs will be 1-2x10^6 million MSCs per/kg body weight.\n\nAt the time of the second MSC infusion tacrolimus will be withdrawn in 2 weeks (after 1 week dose of tacrolimus wil be halved, after 2 weeks stopped)",
                              "Patients in the control group will receive Certican\u00ae (1.5 mg b.i.d.) and standard dose tacrolimus (through levels 6-8 ng/ml after 6 weeks)."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Mesenchymal Stromal Cells"
                        ],
                        "ArmGroupLabel": [
                              "Mesenchymal Stromal Cells + Everolimus",
                              "Everolimus + Tacrolimus"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "No Intervention"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02057965"
                        ]
                  },
                  {
                        "Rank": 19,
                        "Acronym": [
                              "REDDSTAR"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "mesenchymal stromal cells in collagen scaffold"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: mesenchymal stromal cells"
                        ],
                        "ArmGroupLabel": [
                              "mesenchymal stromal cells"
                        ],
                        "ArmGroupType": [
                              "Other"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03509870"
                        ]
                  },
                  {
                        "Rank": 20,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Mesenchymal stromal cells administered weekly for 4 weeks"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Mesenchymal stromal cells (MSC) for infusion"
                        ],
                        "ArmGroupLabel": [
                              "Mesenchymal stromal cells"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01090817"
                        ]
                  },
                  {
                        "Rank": 21,
                        "Acronym": [
                              "UCMSCBA"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "17 patients with BA underwent Kasai operation and then will received two doses of UC-MSCs at 1x106 cells/kg (body weight) administered via hepatic artery",
                              "17 patients with BA will be conducted Kasai operation only"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Umbilical Cord Derived Mesenchymal Stem Cell (UC -MSC) Transplantation"
                        ],
                        "ArmGroupLabel": [
                              "Umbilical cord blood - derived mesenchymal stem cells",
                              "Control group"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "No Intervention"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04522869"
                        ]
                  },
                  {
                        "Rank": 22,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patients will receive human umbilical cord mesenchymal stem cells transplantation with a 12 months follow-up."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Human umbilical cord mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "hUC-MSC treatment"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02283879"
                        ]
                  },
                  {
                        "Rank": 23,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "In the CABG with hUC-MSC treatment group, 1\u00d710^7 human umbilical cord Mesenchymal Stem Cells were injected to the edge of the myocardial infarction area at 20 points at the same time in CABG.",
                              "CABG was performed under general anesthesia."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Allogeneic Human Umbilical Cord Mesenchymal Stem Cells"
                        ],
                        "ArmGroupLabel": [
                              "CABG with hUC-MSC treatment group",
                              "CABG group"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "No Intervention"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04939077"
                        ]
                  },
                  {
                        "Rank": 24,
                        "Acronym": [
                              "START"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [
                              "No"
                        ],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [
                              "No"
                        ],
                        "ArmGroupDescription": [
                              "A single dose of 10 million cells/kg PBW (predicted body weight) Allogeneic Bone Marrow-Derived Human Mesenchymal Stromal Cells was administered intravenously over approximately 60-80 minutes.",
                              "A single dose of Plasma-Lyte A was administered intravenously over approximately 60-80 minutes."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Allogeneic Bone Marrow-Derived Human Mesenchymal Stromal Cells",
                              "Biological: Plasma-Lyte A"
                        ],
                        "ArmGroupLabel": [
                              "Human Mesenchymal Stromal Cells (hMSCs)",
                              "Plasma-Lyte A (placebo)"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [
                              "<=18 years",
                              "Between 18 and 65 years",
                              ">=65 years",
                              "Female",
                              "Male",
                              "Hispanic or Latino",
                              "Not Hispanic or Latino",
                              "Unknown or Not Reported",
                              "American Indian or Alaska Native",
                              "Asian",
                              "Native Hawaiian or Other Pacific Islander",
                              "Black or African American",
                              "White",
                              "More than one race",
                              "Unknown or Not Reported",
                              "Sepsis with pneumonia",
                              "Sepsis without pneumonia",
                              "Pneumonia without sepsis",
                              "Aspiration only",
                              "Other",
                              "Volume control",
                              "Pressure-regulated volume control",
                              "Other"
                        ],
                        "BaselineClassDenomCountGroupId": [
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002"
                        ],
                        "NCTId": [
                              "NCT02097641"
                        ]
                  },
                  {
                        "Rank": 25,
                        "Acronym": [
                              "SAIL"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Intramuscular Allogeneic Bone marrow-derived Mesenchymal Stromal Cell Injection",
                              "Intramuscular placebo injection"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Allogeneic Mesenchymal Stromal Cell",
                              "Other: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "Allogeneic Mesenchymal Stromal Cell",
                              "Placebo"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03042572"
                        ]
                  },
                  {
                        "Rank": 26,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "A fixed dose of Mesenchymal Stromal Cells (MSCs) will be studied: 1 x 106 cells/kg administered intravenously (IV) weekly for 4 consecutive weeks, with the option of an additional 4 weeks of treatment, at the discretion of the principal investigator."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Allogeneic bone marrow-derived mesenchymal stromal cells"
                        ],
                        "ArmGroupLabel": [
                              "Mesenchymal Stromal Cells (MSCs)"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02150551"
                        ]
                  },
                  {
                        "Rank": 27,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [
                              "Biological: Mesenchymal stromal cells"
                        ],
                        "ArmGroupLabel": [
                              "Mesenchymal stromal cell treatment"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01522716"
                        ]
                  },
                  {
                        "Rank": 28,
                        "Acronym": [
                              "SAMPSON-1"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Intravenous infusion of 1.25-1.5 x 10^6 cells/kg with a maximal dose of 100 x 10^6 cells on days 1 and 3 after study enrollment."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Allogeneic Mesenchymal Stromal Cells"
                        ],
                        "ArmGroupLabel": [
                              "Allogeneic Mesenchymal Stromal Cell infusion"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05286255"
                        ]
                  },
                  {
                        "Rank": 29,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patients will be treated in combination with hUC-MSC and DMARDs with a 12 months follow-up.",
                              "Patients will be treated by Rheumatoid Arthritis With Disease-Modifying Drugs (DMARDs) with a 12 months follow-up."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: hUC-MSC + DMARDs",
                              "Drug: DMARDs"
                        ],
                        "ArmGroupLabel": [
                              "hUC-MSC + DMARDs",
                              "DMARDs"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02643823"
                        ]
                  },
                  {
                        "Rank": 30,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "A single intravenous infusion of ex-vivo expanded autologous MSCs will be performed in patients in addition to the living-donor kidney transplantation.\n\n2x10 elevated to sxth power MSCs per kilogram body weight previously isolated from the same recipient will be infused intravenously the day before the kidney transplant procedure."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Mesenchymal Stromal Cells"
                        ],
                        "ArmGroupLabel": [
                              "Mesenchymal Stromal Cells"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02012153"
                        ]
                  },
                  {
                        "Rank": 31,
                        "Acronym": [
                              "STAT"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "A single dose of 10 million cells/kg predicted body weight (PBW) Allogeneic Bone Marrow-Derived Human Mesenchymal Stromal Cells will administered intravenously over approximately 60-80 minutes.",
                              "A single dose of cell reconstitution media (1:1 mix of 5% human serum albumin and 10% Dextran 40) will administered intravenously over approximately 60-80 minutes."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Human Mesenchymal Stromal Cells",
                              "Biological: Cell Reconstitution Media"
                        ],
                        "ArmGroupLabel": [
                              "Human Mesenchymal Stromal Cells",
                              "Cell Reconstitution Media"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03818854"
                        ]
                  },
                  {
                        "Rank": 32,
                        "Acronym": [
                              "ADSTEM"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "10 patients with RDEB will be selected to receive the intervention - mesenchymal stromal cells."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Mesenchymal stromal cells"
                        ],
                        "ArmGroupLabel": [
                              "Intervention arm"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02323789"
                        ]
                  },
                  {
                        "Rank": 33,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Intraarticular injection of 2\u00d710~7 Umbilical-cord mesenchimal stem cells with plateler Rich Plasma(5ml)",
                              "Intraarticular injection of hyaluronic acid"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Umbilical-cord mesenchymal stromal cells (UC-MSCs)",
                              "Other: Hyaluronic acid"
                        ],
                        "ArmGroupLabel": [
                              "Intervention group",
                              "Control group"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Other"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03166865"
                        ]
                  },
                  {
                        "Rank": 34,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Intrathecal Transplantation of Umbilical Cord Mesenchymal Stem Cells, 1*10^6 cells/kg, once a month for 4 months",
                              "Placebo: Sham operation, 10ml saline, once a month for 4 months"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Umbilical Cord Mesenchymal Stem Cells",
                              "Drug: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "Umbilical Cord Mesenchymal Stem Cells",
                              "Control"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03521336"
                        ]
                  },
                  {
                        "Rank": 35,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Intrathecal Transplantation of Umbilical Cord Mesenchymal Stem Cells, 1*10^6 cells/kg, once a month for 4 months",
                              "Sham operation and 10ml saline as placebos, once a month for 4 months"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Umbilical Cord Mesenchymal Stem Cells",
                              "Drug: Placebos"
                        ],
                        "ArmGroupLabel": [
                              "Umbilical Cord Mesenchymal Stem Cells",
                              "Control"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03521323"
                        ]
                  },
                  {
                        "Rank": 36,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Autologous Adipose-derived Mesenchymal Stromal Cells (aaMSCs) will be administered intrathecally at a single dose in a volume of 5-10 mL, all patients will receive 5 x 10^7 intrathecal aaMSCs at the first injection (Visit 4). Subsequent doses may be reduced to 1 x 10^7 or increased to 1 x 10^8, based on Dose Modification Rules."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Autologous Adipose-derived Mesenchymal Stromal Cells"
                        ],
                        "ArmGroupLabel": [
                              "Mesenchymal Stromal Cells"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03268603"
                        ]
                  },
                  {
                        "Rank": 37,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "The number of mesenchymal stromal cells reached after two culture expansion passages.",
                              "Saline"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Mesenchymal stromal cell",
                              "Biological: Saline"
                        ],
                        "ArmGroupLabel": [
                              "1",
                              "2"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT00644410"
                        ]
                  },
                  {
                        "Rank": 38,
                        "Acronym": [
                              "UC-MSCs"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patients receive Umbilical cord mesenchymal stem cells intravenous infusion for three times with an interval of 4 weeks in the absence of disease progression or unacceptable toxicity",
                              "Patients receive Controlled suspension liquid"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Umbilical cord mesenchymal stem cells",
                              "Biological: Controlled suspension liquid"
                        ],
                        "ArmGroupLabel": [
                              "Umbilical cord mesenchymal stem cells",
                              "Controlled suspension liquid"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02302599"
                        ]
                  },
                  {
                        "Rank": 39,
                        "Acronym": [
                              "MSC-cGvHD"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patients with newly diagnosed cGvHD receive primary treatment plus MSC:\n\nMSC+prednisone+cyclosporine;\nMSC+prednisone+tacrolimus;\nMSC+prednisone+mycophenolate mofetil.",
                              "Patients with newly diagnosed cGvHD receive primary treatment:\n\nPlacebo+prednisone+cyclosporine;\nPlacebo+prednisone+tacrolimus;\nPlacebo+prednisone+mycophenolate mofetil."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Mesenchymal Stromal Cells"
                        ],
                        "ArmGroupLabel": [
                              "Mesenchymal stem cells (MSC)",
                              "Placebo"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02291770"
                        ]
                  },
                  {
                        "Rank": 40,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Subjects will receive one injection of 5 million Autologous Adipose-Derived Mesenchymal Stromal Cells",
                              "Subjects will receive one injection of 20 million Autologous Adipose-Derived Mesenchymal Stromal Cells"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Autologous Adipose-Derived Mesenchymal Stromal Cells",
                              "Drug: Autologous Adipose-Derived Mesenchymal Stromal Cells"
                        ],
                        "ArmGroupLabel": [
                              "5\u00d710^6 AD-MSCs",
                              "20\u00d710^6 AD-MSCs"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03461458"
                        ]
                  },
                  {
                        "Rank": 41,
                        "Acronym": [
                              "RP"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "a total 2 ml volume of Conditioned Medium derived Umbilical Cord Mesenchymal Stem Cell will be injected by peribulbar",
                              "1.8 ml cell preparations are suspended in physiological NaCl until it reaches a total of 2 ml volume of cell suspension. Umbilical Cord Mesenchymal Stem Cell (UC-MSC) suspension will be injected by peribulbar",
                              "1.8 ml cell preparations are suspended in Conditioned Medium (CM) until it reaches total of 2 ml volume of cell suspension. Umbilical Cord Mesenchymal Stem Cell (UC-MSC) + Conditioned Medium (CM) suspension will be injected by peribulbar"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Conditioned Medium (CM)",
                              "Biological: Umbilical Cord Mesenchymal Stem Cell (UC-MSC)",
                              "Biological: Umbilical Cord Mesenchymal Stem Cell (UC-MSC)",
                              "Biological: Conditioned Medium (CM)"
                        ],
                        "ArmGroupLabel": [
                              "Conditioned Medium (CM)",
                              "UC-MSC + NaCl",
                              "UC-MSC+CM"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Active Comparator",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04315025"
                        ]
                  },
                  {
                        "Rank": 42,
                        "Acronym": [
                              "MSC-GvHD"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Intravenous injections for a dose of 1 \u00b1 0.5 x 106 MSC/kg recipient body weight"
                        ],
                        "ArmGroupInterventionName": [
                              "Genetic: Mesenchymal stromal cells"
                        ],
                        "ArmGroupLabel": [
                              "Mesenchymal Stromal Cells (MSC)"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01764100"
                        ]
                  },
                  {
                        "Rank": 43,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "15 enrolled refractory ITP patients will be picked up to infuse hUC-MSCs at the indicated dose."
                        ],
                        "ArmGroupInterventionName": [
                              "Other: Human umbilical cord-derived mesenchymal stem cells (hUC-MSCs)"
                        ],
                        "ArmGroupLabel": [
                              "15 refractory ITP patients"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04014166"
                        ]
                  },
                  {
                        "Rank": 44,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "hUC-MSCs 4*10^5/kg/each time",
                              "hUC-MSCs 8*10^5/kg/each time",
                              "hUC-MSCs 12*10^5/kg/each time"
                        ],
                        "ArmGroupInterventionName": [
                              "Genetic: Human umbilical cord-derived mesenchymal stem cells (hUC-MSCs)",
                              "Genetic: Human umbilical cord-derived mesenchymal stem cells (hUC-MSCs)",
                              "Genetic: Human umbilical cord-derived mesenchymal stem cells (hUC-MSCs)"
                        ],
                        "ArmGroupLabel": [
                              "low dose",
                              "middle dose",
                              "high dose"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04822922"
                        ]
                  },
                  {
                        "Rank": 45,
                        "Acronym": [
                              "STOD3"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Subjects with a diagnosis of Type II or Type III osteogenesis imperfecta who have previously undergone a bone marrow transplant. Intervention: Mesenchymal Stromal Cells.",
                              "Subjects with Type II or III osteogenesis imperfecta who have not undergone a bone marrow transplant. Intervention: Mesenchymal Stromal Cells."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Mesenchymal Stromal Cells",
                              "Biological: Mesenchymal Stromal Cells"
                        ],
                        "ArmGroupLabel": [
                              "Stratum A",
                              "Stratum B"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01061099"
                        ]
                  },
                  {
                        "Rank": 46,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Umbilical Cord Mesenchymal Stem Cells"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Umbilical Cord Mesenchymal Stem Cells"
                        ],
                        "ArmGroupLabel": [
                              "Mesenchymal Stem Cells"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02235844"
                        ]
                  },
                  {
                        "Rank": 47,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patients will receive up to 2 infusions of mesenchymal stem cells.",
                              "Patients will receive supportive care or treatment designated by their treating doctor."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Mesenchymal Stromal Cells",
                              "Other: Supportive Care"
                        ],
                        "ArmGroupLabel": [
                              "Mesenchymal stromal cells",
                              "Control Group"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Other"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04345601"
                        ]
                  },
                  {
                        "Rank": 48,
                        "Acronym": [
                              "ARDS"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Intravenous infusion of 1million UCMSCs per kilogram body weight suspended in 100ml normal saline, infusion duration 30-60min."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: umbilical cord derived mesenchymal stem cells (UCMSCs) suspension",
                              "Biological: normal saline"
                        ],
                        "ArmGroupLabel": [
                              "UCMSCs group"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03608592"
                        ]
                  },
                  {
                        "Rank": 49,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patients receiving regular respiratory distress treatment",
                              "Patients receiving two serial doses of allogeneic and expanded adipose tissue-derived mesenchymal stromal cells"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Allogeneic and expanded adipose tissue-derived mesenchymal stromal cells"
                        ],
                        "ArmGroupLabel": [
                              "Control",
                              "Treatment"
                        ],
                        "ArmGroupType": [
                              "No Intervention",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04348461"
                        ]
                  },
                  {
                        "Rank": 50,
                        "Acronym": [
                              "COSMOS"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "For diagnosis purpose, bone marrow sampling is performed for acute myeloid leukemia patients. 2 milliliters of this sample will be collected and analysed for the COSMOS study.",
                              "Healthy donors are patients undergoing cardio-vascular surgery for their usual support. During this surgery, 2 milliliters of the bone marrow will be collected, and analysed for the COSMOS study."
                        ],
                        "ArmGroupInterventionName": [
                              "Other: Bone marrow analyses",
                              "Other: Bone marrow analyses"
                        ],
                        "ArmGroupLabel": [
                              "Acute Myeloid Leukemia patients",
                              "Healthy donors"
                        ],
                        "ArmGroupType": [],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03233074"
                        ]
                  },
                  {
                        "Rank": 51,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Human umbilical cord mesenchymal stem cells (hUC-MSC) (SCLnow 19#)"
                        ],
                        "ArmGroupInterventionName": [
                              "Procedure: intrauterine injection",
                              "Biological: human umbilical cord mesenchymal stem cell"
                        ],
                        "ArmGroupLabel": [
                              "hUC-MSC intrauterine injection group"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03386708"
                        ]
                  },
                  {
                        "Rank": 52,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Human umbilical cord tissue-derived mesenchymal stem cells administered into the knee joint once",
                              "Human umbilical cord tissue-derived mesenchymal stem cells administered once per day for 3 consecutive days"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Human umbilical cord tissue-derived mesenchymal stem cells",
                              "Biological: Human umbilical cord tissue-derived mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "Intra-articular knee injection of UC-MSC",
                              "IV injection of UC-MSC"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02237846"
                        ]
                  },
                  {
                        "Rank": 53,
                        "Acronym": [
                              "WJ-MSC-AMI"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Wharton's jelly- Derived Mesenchymal Stem Cells Transfer"
                        ],
                        "ArmGroupInterventionName": [
                              "Genetic: intracoronary human umbilical WJ-MSC transfer"
                        ],
                        "ArmGroupLabel": [
                              "WJ-MSC"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01291329"
                        ]
                  },
                  {
                        "Rank": 54,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [
                              "Biological: Mesenchymal stromal cells"
                        ],
                        "ArmGroupLabel": [
                              "Mesenchymal stromal cells"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02215811"
                        ]
                  },
                  {
                        "Rank": 55,
                        "Acronym": [
                              "RA"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patients in UC-MSCs treatment will be infused umbilical cord-derived mesenchymal stem cells intravenously only.",
                              "Patients will be treated by Rheumatoid Arthritis With Disease-Modifying Drugs (DMARDs).",
                              "Patients will be treated in combination with UC-MSC and DMARDS."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Umbilical Cord-Derived Mesenchymal Stem Cells (UC-MSCs)",
                              "Drug: Rheumatoid Arthritis With Disease-Modifying Drugs (DMARDs)",
                              "Biological: UC-MSC+DMARDS"
                        ],
                        "ArmGroupLabel": [
                              "UC-MSCs Treatment",
                              "DMARDS",
                              "UC-MSC+DMARDS"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01547091"
                        ]
                  },
                  {
                        "Rank": 56,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Subjects in this arm will receive 6 times UC-MSCs infusions (each time 1\u00d710^6/kg) within 8 weeks."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: UC-MSCs"
                        ],
                        "ArmGroupLabel": [
                              "Treat Psoriasis Vulgaris with UC-MSCs"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02491658"
                        ]
                  },
                  {
                        "Rank": 57,
                        "Acronym": [
                              "THSW-MSC"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "100mL human umbilical cord mesenchymal stem cell preparation, containing 2.5\u00d710^7 cells.",
                              "100mL human umbilical cord mesenchymal stem cell preparation, containing 5.0\u00d710^7 cells.",
                              "100mL human umbilical cord mesenchymal stem cell preparation, containing 1.0\u00d710^8 cells."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: hUCMSCs",
                              "Biological: hUCMSCs",
                              "Biological: hUCMSCs"
                        ],
                        "ArmGroupLabel": [
                              "Low-dose group",
                              "medium-dose group",
                              "High-dose group"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05442437"
                        ]
                  },
                  {
                        "Rank": 58,
                        "Acronym": [
                              "PRISME"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patient with chronic radiotherapy-induced abdomino-pelvic complications refractory to standard therapy: 12 patients suffering of PRD (LENT-SOMA scale>2)"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Mesenchymal Stromal Cell (MSC) injections"
                        ],
                        "ArmGroupLabel": [
                              "Mesenchymal Stromal Cell (MSC)"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02814864"
                        ]
                  },
                  {
                        "Rank": 59,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Escalating doses of allogeneic MSC subconjunctival injection will be assigned 1,000,000 cells/50 \u00b5L at the low dose level.",
                              "Escalating doses of allogeneic MSC subconjunctival injection will be assigned 3,000,000 cells/150 \u00b5L at the medium dose level.",
                              "Escalating doses of allogeneic MSC subconjunctival injection will be assigned 6,000,000 cells total consisting of injection at 2 sites of 3,000,000 cells/150 \u00b5L each at the high dose level."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Allogeneic MSC",
                              "Biological: Allogeneic MSC",
                              "Biological: Allogeneic MSC"
                        ],
                        "ArmGroupLabel": [
                              "Low dose of allogeneic MSC",
                              "Medium dose of allogeneic MSC",
                              "High dose of allogeneic MSC"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Active Comparator",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04626583"
                        ]
                  },
                  {
                        "Rank": 60,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Umbilical Cord Mesenchymal stem cells (UCMSC) expanded and treated for 1-2 weeks. Then administer 5x10^6 of UCMSC per cm^2 of the cartilage defect.",
                              "Administer hyaluronic acid (30 mg) in a single injection"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: umbilical cord mesenchymal stem cells",
                              "Device: Hyaluronic acid"
                        ],
                        "ArmGroupLabel": [
                              "Mesenchymal stem cell treatment",
                              "Hyaluronic acid treatment"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02776943"
                        ]
                  },
                  {
                        "Rank": 61,
                        "Acronym": [
                              "MANUS"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Intramuscular injection of mesenchymal stromal cells (50 million allogeneic MSCs in 0.9% NaCl and 10% human serum albumin).",
                              "Intramuscular injection of placebo (NaCl 0.9% + 10% human serum albumin)"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Mesenchymal stromal cells",
                              "Other: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "MSC injections",
                              "Placebo injections"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03211793"
                        ]
                  },
                  {
                        "Rank": 62,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "MSCs Participants will receive HUC-MSCs",
                              "Comparator participants will receive saline solution"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: UC-MSC",
                              "Biological: Saline solution"
                        ],
                        "ArmGroupLabel": [
                              "Experimental",
                              "Comparator"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05512988"
                        ]
                  },
                  {
                        "Rank": 63,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Participants will be given umbilical cord mesenchymal stem cells transplantation with a 1 year follow-up."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: human umbilical cord mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "Human umbilical cord mesenchymal stem cells transplantation"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01360164"
                        ]
                  },
                  {
                        "Rank": 64,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Three fixed doses of MSC approximately 48 hours apart.",
                              "Three fixed doses of placebo control approximately 48 hours apart."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Mesenchymal stromal cells",
                              "Other: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "Mesenchymal Stromal Cells",
                              "Placebo"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04466098"
                        ]
                  },
                  {
                        "Rank": 65,
                        "Acronym": [
                              "UCMSC-ALI"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Human umbilical cord MSCs are administrated to patients by intravenous infusion"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: UCMSC group"
                        ],
                        "ArmGroupLabel": [
                              "UCMSC group"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02444455"
                        ]
                  },
                  {
                        "Rank": 66,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "After signed informed consent, patients will receive 3 infusions of (1.5)-3.0 x106/kg BM-MSC (from the same donor) at 3-4 days interval, in addition to the standard of care for COVID-19 disease."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Mesenchymal stromal cells"
                        ],
                        "ArmGroupLabel": [
                              "MSC therapy for severe COVID-19 infection"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04445454"
                        ]
                  },
                  {
                        "Rank": 67,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Subjects in the S50 cohort will receive one injection of 50 million AMSCs.",
                              "Subjects in the S100 cohort will receive one injection of 100 million AMSCs.",
                              "Subjects in the M50 cohort will receive three injections of 50 million AMSCs at one-month intervals.",
                              "Subjects in the M100 cohort will receive three injections of 100 million AMSCs at one-month intervals."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Autologous Adipose-Derived Mesenchymal Stromal Cells",
                              "Drug: Autologous Adipose-Derived Mesenchymal Stromal Cells",
                              "Drug: Autologous Adipose-Derived Mesenchymal Stromal Cells",
                              "Drug: Autologous Adipose-Derived Mesenchymal Stromal Cells"
                        ],
                        "ArmGroupLabel": [
                              "S50",
                              "S100",
                              "M50",
                              "M100"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02805855"
                        ]
                  },
                  {
                        "Rank": 68,
                        "Acronym": [
                              "UCMSC-PQLI"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Human umbilical cord MSCs are administrated to patients by intravenous injection",
                              "Patients will receive normal saline at the same time points as that in experimental group."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: UCMSC group",
                              "Other: Control group(Normal saline)"
                        ],
                        "ArmGroupLabel": [
                              "UCMSC group",
                              "Control group(Normal saline)"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Other"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02444858"
                        ]
                  },
                  {
                        "Rank": 69,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patients are enrolled into one of three escalating dose panels based on the time of enrolment. The first three patients will receive 1 million cells/kg of body weight, the next three patients will receive 3 million cells/kg of body weight, and the final three patients will receive 10 million cells/kg of body weight. Progression through the escalating dose panels is subject to review by an independent Data Safety Monitoring Committee."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Allogeneic Umbilical Cord Tissue-Derived Mesenchymal Stromal Cells"
                        ],
                        "ArmGroupLabel": [
                              "Mesenchymal Stromal Cell Therapy"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04255147"
                        ]
                  },
                  {
                        "Rank": 70,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "pelvic compartment advanced-stage (Kellgren and Lawrence grade 3 or 4) osteoarthritic donors",
                              "age-matched healthy donors"
                        ],
                        "ArmGroupInterventionName": [],
                        "ArmGroupLabel": [
                              "osteoarthritic donors",
                              "healthy donors"
                        ],
                        "ArmGroupType": [],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01038596"
                        ]
                  },
                  {
                        "Rank": 71,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Human Umbilical Cord Mesenchymal Stem Cells (19#iSCLife\u00ae-UT)",
                              "Human Umbilical Cord Mesenchymal Stem Cells (19#iSCLife\u00ae-UT)"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: human umbilical cord mesenchymal stem cell complex collagen",
                              "Biological: human umbilical cord mesenchymal stem cell complex collagen",
                              "Procedure: intrauterine injection"
                        ],
                        "ArmGroupLabel": [
                              "stem cell and collagen transplantation group",
                              "control group"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05495711"
                        ]
                  },
                  {
                        "Rank": 72,
                        "Acronym": [
                              "UCMSC-Heart"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patients in this arm received umbilical cord MSCs by intracoronary injection",
                              "Patients in this arm did not receive any intervention."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: UCMSC group"
                        ],
                        "ArmGroupLabel": [
                              "UCMSC group",
                              "Control group"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "No Intervention"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02439541"
                        ]
                  },
                  {
                        "Rank": 73,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Routine rehabilitation treatments",
                              "Injection of UC-MSCs via the peripheral vein.",
                              "Injection of UC-MSCs via the intrathecal route.",
                              "Injection of UC-MSCs via the nasal route."
                        ],
                        "ArmGroupInterventionName": [
                              "Other: Control group",
                              "Procedure: UC-MSCs",
                              "Procedure: UC-MSCs",
                              "Procedure: UC-MSCs"
                        ],
                        "ArmGroupLabel": [
                              "Control group",
                              "Intravenous UC-MSCs group",
                              "Intrathecal UC-MSCs group",
                              "Intranasal UC-MSCs group"
                        ],
                        "ArmGroupType": [
                              "Other",
                              "Experimental",
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03414697"
                        ]
                  },
                  {
                        "Rank": 74,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Intra-articular Wharton Jelly derived mesenchymal stem cell injection will be given for each patient in 2 doses, 50 million of WJMSC in each dose"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Wharton Jelly derived mesenchymal stem cell"
                        ],
                        "ArmGroupLabel": [
                              "Wharton Jelly mesenchymal stem cell"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02963727"
                        ]
                  },
                  {
                        "Rank": 75,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Basic medication: Decitabine; Allogeneic umbilical cord mesenchymal stem cells.",
                              "Basic medication: Decitabine; placebo: saline."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Allogeneic umbilical cord mesenchymal stem cells",
                              "Drug: Decitabine",
                              "Drug: Decitabine"
                        ],
                        "ArmGroupLabel": [
                              "Experimental group",
                              "Control group"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03184935"
                        ]
                  },
                  {
                        "Rank": 76,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "observe the effectiveness and safety of patients by injecting human umbilical cord mesenchymal stem cells(2*10^7/ml normal saline) and Low temperature plasma vaporization ablation",
                              "observe the effectiveness and safety of patients by injecting normal saline and Low temperature plasma vaporization ablation"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: human umbilical cord mesenchymal stem cell"
                        ],
                        "ArmGroupLabel": [
                              "treatment group A \uff08with mesenchymal stem cell intervention\uff09",
                              "control group B"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "No Intervention"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04104412"
                        ]
                  },
                  {
                        "Rank": 77,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Conventional treatment plus UC-MSCs:\n\nParticipants will receive conventional treatment plus 4 times of UC-MSCs(0.5*10E6 UC-MSCs/kg body weight intravenously at Day 1\uff0cDay 3\uff0cDay 5\uff0cDay7).",
                              "Conventional treatment plus Placebo:\n\nWithout UC-MSCs Therapy but conventional treatment should be received. Participants will receive conventional treatment plus 4 times of Placebo intravenously at Day 1\uff0cDay 3\uff0cDay 5\uff0cDay7)."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: UC-MSCs",
                              "Drug: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "UC-MSCs Treatment Group",
                              "Conventional Control Group"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04273646"
                        ]
                  },
                  {
                        "Rank": 78,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Participants will receive conventional treatment plus a dose of UC-MSC from day 0 through the week 12 study visit. Participants will then be followed until the week 48 study visit",
                              "Participants will receive conventional plus placebo treatment from day 0 through the week 12 study visit. Participants will then be followed until the week 48 study visit."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Conventional plus UC-MSC",
                              "Drug: Conventional plus placebo"
                        ],
                        "ArmGroupLabel": [
                              "Conventional plus UC-MSC",
                              "Conventional plus placebo"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01690247"
                        ]
                  },
                  {
                        "Rank": 79,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Single Treatment Group: Eligible patients will be treated with a Gore Bio-A Fistula Plug that has been coated with autologous mesenchymal stromal cells. This is a drug study, specifically phase 1 study of autologous mesenchymal stromal cells. Single dose of 20 million cells."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Only 1 arm: treatment with MSC-AFP"
                        ],
                        "ArmGroupLabel": [
                              "Only 1 arm: treatment with MSC-AFP"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03014219"
                        ]
                  },
                  {
                        "Rank": 80,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Participants will receive conventional treatment and then be followed until the week 48 study visit.",
                              "Participants will receive conventional treatment plus a dose of UC-MSC and then be followed until the week 48 study visit.",
                              "Participants will receive conventional treatment plus plasma exchange and then be followed until the week 48 study visit.",
                              "Participants will receive conventional treatment plus umbilical cord mesenchymal stem cells transplantation combined with plasma exchange. Participants will then be followed until the week 48 study visit."
                        ],
                        "ArmGroupInterventionName": [
                              "Other: Conventional treatment",
                              "Other: Conventional plus UC-MSC treatment",
                              "Other: Conventional plus PE treatment",
                              "Other: Conventional plus UC-MSC and PE therapy"
                        ],
                        "ArmGroupLabel": [
                              "Conventional treatment",
                              "Conventional plus UC-MSC treatment",
                              "Conventional plus PE treatment",
                              "Conventional plus UC-MSC and PE therapy"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01724398"
                        ]
                  },
                  {
                        "Rank": 81,
                        "Acronym": [
                              "MISTIC"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Doses will be given on days 1, 2, 3, and a fourth, optional dose may be given on day 7 at the discretion of the investigator and the treating physician."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Human Cord Tissue Mesenchymal Stromal Cells (hCT-MSCs)"
                        ],
                        "ArmGroupLabel": [
                              "hCT-MSC infusion"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04549285"
                        ]
                  },
                  {
                        "Rank": 82,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Participants receive mesenchymal stromal cells-derived exosomes with KrasG12D siRNA IV over 15-20 minutes on days 1, 4, and 10. Treatment repeats every 14 days for up to 3 courses in the absence of disease progression or unacceptable toxicity. Participants who respond may continue 3 additional courses."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Mesenchymal Stromal Cells-derived Exosomes with KRAS G12D siRNA"
                        ],
                        "ArmGroupLabel": [
                              "Treatment (iExosomes)"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03608631"
                        ]
                  },
                  {
                        "Rank": 83,
                        "Acronym": [
                              "UCMSC-UC"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Human umbilical cord MSCs are administrated to patients by three intravenous infusion",
                              "Patients will receive normal saline at the same time points as that in experimental group."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: UCMSC group",
                              "Other: Control group(Normal saline)"
                        ],
                        "ArmGroupLabel": [
                              "UCMSC group",
                              "Control group(Normal saline)"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Other"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02442037"
                        ]
                  },
                  {
                        "Rank": 84,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patients in Group MSC-1 received standard medical treatment and infusions of umbilical cord blood mesenchymal stem cells via peripheral veins once a week for 8 weeks.",
                              "Patients in Group MSC-1 received standard medical treatment and infusions of umbilical cord blood mesenchymal stem cells via peripheral veins once a week for 4 weeks.",
                              "Patients in Group Control received standard medical treatment, including bed rest, nutritional supplementation, administration of human serum albumin (10g per day until serum albumin was 35g/L) and plasma (200 ml to 400 ml per day until the international normalized ratio was less than 1.5), anti-viral therapy, glycyrrhizin,S-adenosylmethionine and appropriate treatment for complications (such as infection, encephalopathy, hepatorenal syndrome and intestinal paralysis)."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: umbilical cord blood mesenchymal stem cells",
                              "Drug: umbilical cord blood mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "Group MSC-1",
                              "Group MSC-2",
                              "Group Control"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "No Intervention"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02812121"
                        ]
                  },
                  {
                        "Rank": 85,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "3 patients receiving low dose",
                              "3 patients receiving medium dose",
                              "3 patients receiving high dose",
                              "6 patients"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: ProTrans",
                              "Drug: ProTrans",
                              "Drug: ProTrans"
                        ],
                        "ArmGroupLabel": [
                              "Low dose",
                              "Medium dose",
                              "High dose",
                              "Control"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Experimental",
                              "No Intervention"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03973827"
                        ]
                  },
                  {
                        "Rank": 86,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Preterm infants at high risk for BPD will receive transplantation of hUC-MSCs.",
                              "Preterm infants at high risk for BPD will not receive transplantation of hUC-MSCs"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Transplantation of hUC-MSCs",
                              "Drug: No transplantation of hUC-MSCs"
                        ],
                        "ArmGroupLabel": [
                              "Transplantation of hUC-MSCs",
                              "No transplantation of hUC-MSCs"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Other"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03774537"
                        ]
                  },
                  {
                        "Rank": 87,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [
                              "Biological: Umbilical mesenchymal stem cell (UC-MSCs) infusion",
                              "Drug: traditional therapy"
                        ],
                        "ArmGroupLabel": [
                              "Stem Cell Infusion",
                              "traditional therapy control"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01374854"
                        ]
                  },
                  {
                        "Rank": 88,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "transplant collagen scaffold loaded with UC-MSCs to treat infertility caused by thin endometrium or endometrial scarring"
                        ],
                        "ArmGroupInterventionName": [
                              "Procedure: UC-MSCs therapy"
                        ],
                        "ArmGroupLabel": [
                              "UC-MSCs therapy"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03592849"
                        ]
                  },
                  {
                        "Rank": 89,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "the participants will receive the single-dose UC-MSCs (1\u00d710^6 cells/kg ) in combined with the present treatment.",
                              "the participants will receive the placebo in combined with the present treatment."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: UC-MSCs"
                        ],
                        "ArmGroupLabel": [
                              "UC-MSCs treatment",
                              "no UC-MSCs treatment"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "No Intervention"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03798028"
                        ]
                  },
                  {
                        "Rank": 90,
                        "Acronym": [
                              "SEESUPAD"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Subjects with Alzheimer's Disease Intervention: UCMSCs",
                              "Subjects with Alzheimer's Disease Intervention: Placebo (normal saline)"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: UCMSCs",
                              "Biological: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "UCMSCs",
                              "Placebo"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02672306"
                        ]
                  },
                  {
                        "Rank": 91,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Cells are dissolved in saline and given intravenously over a period of 20-40 min. 100 million cells to subjects < 50 kg and 200 million cells to subjects 50-100 kg (>100 kg is an exclusion criterion).",
                              "Placebo (saline) is given intravenously over a period of 20-40 min."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: the ATMP Protrans",
                              "Biological: the ATMP Protrans"
                        ],
                        "ArmGroupLabel": [
                              "Wharton's jelly derived mesenchymal stromal cells (Protrans)",
                              "Placebo"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05061030"
                        ]
                  },
                  {
                        "Rank": 92,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Intravenously-infused allogeneic, bone marrow-derived mesenchymal stromal cells (MSCs) in children with Osteogenesis Imperfecta Type III that will be infused at 0 months, 4 months, 8 months, 12 months, 16 months, and 20 months, after enrollment."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Bone marrow-derived mesenchymal stromal cells (MSCs)"
                        ],
                        "ArmGroupLabel": [
                              "Children with OI receiving Bone marrow-derived MSCs infusion"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05559801"
                        ]
                  },
                  {
                        "Rank": 93,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "conventional treatment; Allogeneic umbilical cord mesenchymal stem cells (SCLnow 19#) by i.v.",
                              "Conventional treatment"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Allogeneic umbilical cord mesenchymal stem cells (SCLnow 19#)",
                              "Drug: conventional treatment",
                              "Drug: conventional treatment"
                        ],
                        "ArmGroupLabel": [
                              "Treatment group",
                              "Control group"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03180450"
                        ]
                  },
                  {
                        "Rank": 94,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "The dose-escalation methods with a modified continual reassessment at the five dose levels (1x10^6, 10x10^6, 20x10^6, 40x10^6, 80x10^6 cells/kg) will be performed to determine safety and feasibility of allogeneic BM-MSC infusion during pediatric cardiac surgery and the maximum tolerated dose in infants with CHD."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: BM-MSC"
                        ],
                        "ArmGroupLabel": [
                              "Bone marrow-derived mesenchymal stromal cell (BM-MSC)"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04236479"
                        ]
                  },
                  {
                        "Rank": 95,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patients will receive 25 x 10^6 of human umbilical cord-derived mesenchymal stem cells (hUC-MSCs) with standard treatment.",
                              "Patients will undergo marrow cellution surgical procedure."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Human umbilical cord-derived mesenchymal stem cells (hUC-MSCs)",
                              "Procedure: Marrow cellution"
                        ],
                        "ArmGroupLabel": [
                              "Human umbilical cord-derived mesenchymal stem cells (hUC-MSCs)",
                              "Marrow cellution (standard treatment)"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05016011"
                        ]
                  },
                  {
                        "Rank": 96,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Group A was the hormone replacement combined with transplantation of umbilical cord mesenchymal stem cells group(test group).",
                              "Group B was the hormone replacement group (control group)."
                        ],
                        "ArmGroupInterventionName": [
                              "Procedure: transplantation of human UC-MSCs into ovaries of POI patients",
                              "Drug: hormone replacement treatment",
                              "Drug: hormone replacement treatment"
                        ],
                        "ArmGroupLabel": [
                              "UC-MSCs+hormone replacement group",
                              "hormone replacement group"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05308342"
                        ]
                  },
                  {
                        "Rank": 97,
                        "Acronym": [
                              "COVID19"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Intravenous 1*10E6 MSCs/kg body weight Mesenchymal Stromal Cells infusion"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Mesenchymal Stromal Cells infusion"
                        ],
                        "ArmGroupLabel": [
                              "Intervention"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04467047"
                        ]
                  },
                  {
                        "Rank": 98,
                        "Acronym": [
                              "T2DM"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "30 patients with Type 2 Diabetes Mellitus will be enrolled and received mononuclear cells and mesenchymal stem cells by intravenous infusion.",
                              "30 patients with Type 2 Diabetes Mellitus will be enrolled and treated by standard medicines."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: BM-MNC and UC-MSC",
                              "Other: Control"
                        ],
                        "ArmGroupLabel": [
                              "BM-MNC and UC-MSC",
                              "Stand medicines"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Other"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03943940"
                        ]
                  },
                  {
                        "Rank": 99,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "UC-MSC infusion by intravenus, 1*10^8 cells/dose, 2 doses (apart from 24weeks)"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: UC-MSC infusion"
                        ],
                        "ArmGroupLabel": [
                              "UC-MSC infusion"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05106972"
                        ]
                  },
                  {
                        "Rank": 100,
                        "Acronym": [
                              "EMMES"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Single infusion of cryopreserved bone-marrow adult mesenchymal stromal cells followed by placebo infusion at month 6.",
                              "Single infusion of placebo followed by cryopreserved bone-marrow adult mesenchymal stromal cells infusion at month 6."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: XCEL-MC-ALPHA",
                              "Drug: Placebo",
                              "Drug: XCEL-MC-ALPHA",
                              "Drug: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "Treatment A: XCEL-MC-ALPHA/Placebo",
                              "Treatment B: Placebo/XCEL-MC-ALPHA"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02495766"
                        ]
                  },
                  {
                        "Rank": 101,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [
                              "Biological: conventional therapy plus low dose hUC-MSCs treatment",
                              "Biological: conventional therapy plus medium dose hUC-MSCs treatment",
                              "Biological: conventional therapy plus high dose hUC-MSCs treatment"
                        ],
                        "ArmGroupLabel": [
                              "Conventional plus hUC-MSCs treatment (low dose)",
                              "conventional therapy plus hUC-MSCs treatment \uff08medium dose\uff09",
                              "conventional therapy plus hUC-MSCs treatment \uff08high dose\uff09"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01342250"
                        ]
                  },
                  {
                        "Rank": 102,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "In the local treatment group, 60 million umbilical cord MSCs were injected into the diseased intestinal mucosa on the first day. In the combined treatment group, 60 million umbilical cord MSCs were injected into the diseased intestinal mucosa on the first day; on the second day, 1 million cells/kg of body weight were administered intravenously."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Human Umbilical Cord Mesenchymal Stem Cells"
                        ],
                        "ArmGroupLabel": [
                              "MSCs local treatment group/combined treatment group"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05262829"
                        ]
                  },
                  {
                        "Rank": 103,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Super selective intravenous administration of 50 million Allogeneic Human Umbilical Cord Tissue-Derived Mesenchymal Stem Cells (UC-MSC) and intrathecal administration of UC-MSCs in dose of 100 million along with liberation therapy (when associated with CCSVI)"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Allogeneic Human Umbilical Cord Tissue-Derived Mesenchymal Stem Cells",
                              "Other: Liberation therapy"
                        ],
                        "ArmGroupLabel": [
                              "AllogeneicHumanUmbilicalCordTissue-DerivedMesenchymalStemCells"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02587715"
                        ]
                  },
                  {
                        "Rank": 104,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Super selective intravenous administration of 50 million Allogeneic Human Umbilical Cord Tissue-Derived Mesenchymal Stem Cells (UC-MSC) and intrathecal administration of UC-MSCs in dose of 100 million along with liberation therapy (when associated with CCSVI)"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Allogeneic Human Umbilical Cord Tissue-Derived Mesenchymal Stem Cells",
                              "Other: Liberation therapy"
                        ],
                        "ArmGroupLabel": [
                              "AllogeneicHumanUmbilicalCordTissue-DerivedMesenchymalStemCells"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02418325"
                        ]
                  },
                  {
                        "Rank": 105,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Participants will be given rehabilitation therapy plus human umbilical cord mesenchymal stem cells transplantation with one year follow-up"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: human umbilical cord mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "Intervention Group"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01610440"
                        ]
                  },
                  {
                        "Rank": 106,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Intranasal of 3 cc of conditioned medium each, for 3 days in a row and Intra-parenchymal transplantation of 20x10^6 UC-MSCs",
                              "Intra-parenchymal transplantation of 20x10^6 UC-MSCs",
                              "Neurologic and Neutrophic Drugs"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Conditioned Medium",
                              "Biological: Umbilical Cord Mesenchymal Stem Cells",
                              "Biological: Umbilical Cord Mesenchymal Stem Cells",
                              "Procedure: Neurologic and Neutrophic Drugs"
                        ],
                        "ArmGroupLabel": [
                              "Conditioned medium combined with Umbilical cord mesenchymal stem cells treatment",
                              "Umbilical cord mesenchymal stem cells treatment",
                              "Standard treatment (control)"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05008588"
                        ]
                  },
                  {
                        "Rank": 107,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Participants will receive standard of care plus 3 does of UC-MSCs",
                              "Participants will receive standard of care plus 3 does of placebo"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: UC-MSCs",
                              "Biological: Saline containing 1% Human serum albumin\uff08solution without UC-MSCs\uff09"
                        ],
                        "ArmGroupLabel": [
                              "Human Umbilical Cord-Mesenchymal Stem Cells (UC-MSCs)",
                              "Placebo"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04288102"
                        ]
                  },
                  {
                        "Rank": 108,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Low dose group: intra-articular injection with human umbilical cord mesenchymal stem cells (SCLnow 19#)",
                              "High dose group: intra-articular injection with human umbilical cord mesenchymal stem cells (SCLnow 19#)",
                              "No intervention"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Low dose mesenchymal stem cells",
                              "Procedure: Intraarticular injection",
                              "Biological: High dose mesenchymal stem cells",
                              "Procedure: Intraarticular injection"
                        ],
                        "ArmGroupLabel": [
                              "Low dose mesenchymal stem cells",
                              "High dose mesenchymal stem cells",
                              "Control groups"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "No Intervention"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03383081"
                        ]
                  },
                  {
                        "Rank": 109,
                        "Acronym": [
                              "CISS"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "This is a Phase 1 dose escalation clinical trial that constitutes 3 dose cohorts with 3 participants per cohort who will receive intravenous doses of allogeneic bone marrow derived allogeneic mesenchymal stromal cells--0.3 million cells/kg, 1.0 million cells/kg, and 3.0 million cells/kg. We will proceed from the lower dose to the next higher dose if there are no safety concerns for each cohort."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Allogeneic mesenchymal stromal cells"
                        ],
                        "ArmGroupLabel": [
                              "allogeneic mesenchymal stromal cells"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02421484"
                        ]
                  },
                  {
                        "Rank": 110,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "UC-MSCs plus standard of care (SOC).",
                              "Placebo plus SOC."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: UC-MSCs",
                              "Biological: Placebo(solution without UC-MSCs)"
                        ],
                        "ArmGroupLabel": [
                              "Human Umbilical Cord-Mesenchymal Stem Cells (UC-MSCs)",
                              "Placebo"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05224960"
                        ]
                  },
                  {
                        "Rank": 111,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Intravenous infusion with hucMSCs, 9*10^7 cells, 30ml",
                              "Intravenous infusion with hucMSCs, 6*10^7 cells, 30ml",
                              "Intravenous infusion with hucMSCs, 3*10^7 cells, 30ml"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: hucMSCs",
                              "Biological: hucMSCs",
                              "Biological: hucMSCs"
                        ],
                        "ArmGroupLabel": [
                              "High dose group",
                              "Medium dose group",
                              "Low dose group"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03816852"
                        ]
                  },
                  {
                        "Rank": 112,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [
                              "Yes"
                        ],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [
                              "Procedure: Bone marrow transplantation",
                              "Biological: Mesenchymal Stromal Cells"
                        ],
                        "ArmGroupLabel": [
                              "Mesenchymal stromal cells"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [
                              "Female",
                              "Male",
                              "Sickle cell disease",
                              "Thalassemia major"
                        ],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT00957931"
                        ]
                  },
                  {
                        "Rank": 113,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Autologue bone marrow mononuclear cell",
                              "Umbilical cord mesenchymal stem cell"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Bone-marrow aspiration, Intra-pancreatic Catheterisation of BM-MNC",
                              "Biological: Intravenous Infusion of UC-MSC"
                        ],
                        "ArmGroupLabel": [
                              "BM-MNC experimental",
                              "UC-MSC"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04501341"
                        ]
                  },
                  {
                        "Rank": 114,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "A single intravenous infusion (1-2 millions of MSCs per kilogram body weight) of ex-vivo expanded third-party (from healthy donors) MSCs will be performed in patients randomized to the MSC procedure in addition to the kidney transplantation."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Mesenchymal Stromal Cells"
                        ],
                        "ArmGroupLabel": [
                              "Mesenchymal Stromal Cells (MSC)",
                              "No intervention"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "No Intervention"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02565459"
                        ]
                  },
                  {
                        "Rank": 115,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "standard of care (SOC) plus UC-MSCs",
                              "SOC plus placebo."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: UC-MSCs",
                              "Biological: Saline containing 1% Human serum albumin\uff08solution without UC-MSCs\uff09"
                        ],
                        "ArmGroupLabel": [
                              "Human Umbilical Cord-Mesenchymal Stem Cells (UC-MSCs)",
                              "Placebo"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05121870"
                        ]
                  },
                  {
                        "Rank": 116,
                        "Acronym": [
                              "MSC in OB"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [
                              "Other: MSC"
                        ],
                        "ArmGroupLabel": [
                              "MSC"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01175655"
                        ]
                  },
                  {
                        "Rank": 117,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "MSCs Participants will receive antiviral drug, anti-fibrotic drugs and UC-MSCs",
                              "Comparator participants will receive antiviral drug, anti-fibrotic drugs and saline solution"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: UC-MSCs",
                              "Biological: Saline solution"
                        ],
                        "ArmGroupLabel": [
                              "Experimental",
                              "Comparator"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05507762"
                        ]
                  },
                  {
                        "Rank": 118,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "UC-MSCs by peripheral intravenous infusion",
                              "received hormone maintenance therapy"
                        ],
                        "ArmGroupInterventionName": [
                              "Other: UC-MSCs by peripheral intravenous infusion",
                              "Drug: received hormone maintenance therapy"
                        ],
                        "ArmGroupLabel": [
                              "UC-MSCs",
                              "control"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02445547"
                        ]
                  },
                  {
                        "Rank": 119,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Approximately 1x10E6 MSC/kg",
                              "Solution identical to experimental treatment, without the MSC"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Mesenchymal stromal cells",
                              "Other: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "Mesenchymal Stromal cells",
                              "Control group"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04615429"
                        ]
                  },
                  {
                        "Rank": 120,
                        "Acronym": [
                              "COVID_MSV"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Intravenous injection of 1 million MSV cells/Kg in 100 ml of saline",
                              "Intravenous injection of 100 ml of saline containing no cells"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Mesenchymal Stromal Cells",
                              "Other: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "Experimental",
                              "Placebo"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04361942"
                        ]
                  },
                  {
                        "Rank": 121,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patients will receive standard islet transplantation.",
                              "Patients will receive MSCs together with standard islet transplantation."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: autologous mesenchymal stromal cell"
                        ],
                        "ArmGroupLabel": [
                              "Control",
                              "autologous mesenchymal stromal cell"
                        ],
                        "ArmGroupType": [
                              "No Intervention",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02384018"
                        ]
                  },
                  {
                        "Rank": 122,
                        "Acronym": [
                              "Recruiting"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Control group without intervention, whereas they receive conventional stroke treatment that including rehabilitation",
                              "Patients will receive human umbilical cord mesenchymal stem cells transplantation accompanied with conventional treatment including rehabilitation"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Human umbilical cord mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "conventional stroke treatment",
                              "hUC-MSC treatment"
                        ],
                        "ArmGroupType": [
                              "No Intervention",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02580019"
                        ]
                  },
                  {
                        "Rank": 123,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Biological: Mesenchymal stromal cells"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Mesenchymal stromal cells"
                        ],
                        "ArmGroupLabel": [
                              "Mesenchymal stromal cell treatment"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02055625"
                        ]
                  },
                  {
                        "Rank": 124,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Bronchoscopy Five patients will be selected to receive bone-marrow derived mesenchymal stromal cells delivered bronchoscopically right before insertion of one-way endobronchial valves.",
                              "Bronchoscopy Five patients will be selected for treatment with one-way endobronchial valves only, with saline injected prior to valve insertion."
                        ],
                        "ArmGroupInterventionName": [
                              "Procedure: Bronchoscopy",
                              "Procedure: Bronchoscopy"
                        ],
                        "ArmGroupLabel": [
                              "Valves plus cells",
                              "Valves plus saline"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01872624"
                        ]
                  },
                  {
                        "Rank": 125,
                        "Acronym": [
                              "MSC-ROLE"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Intervention: a previously selected dose of MSCs (Phase IIa) will be administered by i.v. infusion at baseline and 6 months of follow-up (total 12 months), to patients with Severe Renal SLE subject also to Standard of Care treatment with Methylprednisolone and Cyclophosphamide followed by Mycophenolate.",
                              "Intervention: A Placebo (infusion vehicle) will be administered by i.v. infusion at baseline and 6 months of follow-up (total 12 months), to patients with Severe Renal SLE subject also to Standard of Care treatment with Methylprednisolone and Cyclophosphamide followed by Mycophenolate."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: MSC treatment",
                              "Drug: Standard of Care",
                              "Drug: Standard of Care",
                              "Drug: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "MSC treatment",
                              "Placebo"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03917797"
                        ]
                  },
                  {
                        "Rank": 126,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Repair of cranial defects by tissue engineering"
                        ],
                        "ArmGroupInterventionName": [
                              "Procedure: Repair of cranial defects by tissue engineering"
                        ],
                        "ArmGroupLabel": [
                              "Repair of cranial defect"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01742260"
                        ]
                  },
                  {
                        "Rank": 127,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Allogenic Umbilical Cord derived stem cells injected intrathecally to enrolled MS patients",
                              "Allogenic Umbilical Cord derived stem cells injected intrathecally to enrolled MS patients along with a supervised physical therapy program",
                              "Supervised physical therapy program without stem cells"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Umbilical cord derived Mesenchymal Stem Cells",
                              "Biological: Umbilical cord derived Mesenchymal Stem Cells",
                              "Other: Supervised physical therapy",
                              "Other: Supervised physical therapy"
                        ],
                        "ArmGroupLabel": [
                              "Injection of Umbilical cord derived UC- MSCs",
                              "injection of UC- MSCs and SPT",
                              "Supervised Physical Therapy (SPT)"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Active Comparator",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03326505"
                        ]
                  },
                  {
                        "Rank": 128,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Escalating doses Dose escalation design with two dose levels. The low dose level involves a single intravenous infusion of \u03b3MSCs at 2x106 cells/kg. The high dose level involves a single intravenous infusion of \u03b3MSCs at 5x106 cells/kg."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Albuterol Sulfate",
                              "Drug: Interferon gamma-primed mesenchymal stromal cells (MSCs)",
                              "Drug: Prednisone"
                        ],
                        "ArmGroupLabel": [
                              "Infusion of \u03b3MSCs"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05035862"
                        ]
                  },
                  {
                        "Rank": 129,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Study participants aged 18 or older who are having an allogeneic blood and marrow transplant (BMT), to treat leukemia, lymphoma or other cancer of the blood will receive an infusion of mesenchymal stromal cells (MSCs).",
                              "Study participants under 18 years of age who are having an allogeneic blood and marrow transplant (BMT), to treat leukemia, lymphoma or other cancer of the blood will receive an infusion of mesenchymal stromal cells (MSCs)."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Interferon gamma (IFN\u03b3)-primed human bone marrow-derived mesenchymal stromal cells",
                              "Drug: Interferon gamma (IFN\u03b3)-primed human bone marrow-derived mesenchymal stromal cells"
                        ],
                        "ArmGroupLabel": [
                              "Adult Population",
                              "Pediatric Population"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04328714"
                        ]
                  },
                  {
                        "Rank": 130,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [
                              "Biological: autologous bone marrow derived mesenchymal stromal cells"
                        ],
                        "ArmGroupLabel": [
                              "cells"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01306513"
                        ]
                  },
                  {
                        "Rank": 131,
                        "Acronym": [
                              "UCMSC"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Group receiving standard COVID-19 treatment and UCMSC infusion",
                              "Group receiving standard COVID-19 treatment and normal saline infusion"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Normoxic Allogenic UCMSC",
                              "Other: Normal saline solution"
                        ],
                        "ArmGroupLabel": [
                              "Treatment",
                              "Control"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Sham Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05132972"
                        ]
                  },
                  {
                        "Rank": 132,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "A single intravenous transplantation of Mesenchymal Stem Cell (Dose A - 1 million cells per kg, Dose B - 5 million cells per kg)"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: transplantation of hUC-MSCs"
                        ],
                        "ArmGroupLabel": [
                              "Mesenchymal Stem Cell"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03873506"
                        ]
                  },
                  {
                        "Rank": 133,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Core decompression surgery; Allogeneic umbilical cord mesenchymal stem cells (SCLnow 19#).",
                              "Core decompression surgery."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Allogeneic umbilical cord mesenchymal stem cells (SCLnow 19#)",
                              "Procedure: core decompression",
                              "Procedure: core decompression"
                        ],
                        "ArmGroupLabel": [
                              "Group 1",
                              "Group 2"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03180463"
                        ]
                  },
                  {
                        "Rank": 134,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "\"ex-vivo\" expanded autologous mesenchymal stromal cells fixed in allogenic bone tissue",
                              "Standard treatment"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: XCEL-MT-OSTEO-ALPHA",
                              "Procedure: Surgery",
                              "Other: autologous iliac crest",
                              "Procedure: Surgery"
                        ],
                        "ArmGroupLabel": [
                              "XCEL-MT-OSTEO-ALPHA and surgery",
                              "Autologous iliac crest and surgery"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Other"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02230514"
                        ]
                  },
                  {
                        "Rank": 135,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "WJ-MSCs will be derived from cord tissue of newborns, screened for HIV1/2, HBV, HCV, CMV, Mycoplasma, and cultured to enrich for MSCs.\n\nWJ-MSCs will be counted and suspended in 25 ml of Saline solution containing 0.5% human serum Albumin, and will be given to patient intravenously."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: WJ-MSCs"
                        ],
                        "ArmGroupLabel": [
                              "WJ-MSCs"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04313322"
                        ]
                  },
                  {
                        "Rank": 136,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Participants will be given conventional therapy plus human cord mesenchymal stem cells transplantation with a 6 months follow-up.",
                              "Participants will be given conventional therapy plus combination of hCBMNCs together with hUCMSCs transplantation with a 6 months follow-up.",
                              "Participants will be given conventional therapy only with a 6 months follow-up."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: human umbilical cord mesenchymal stem cells",
                              "Biological: human cord blood mononuclear cells and human umbilical cord mesenchymal stem cells",
                              "Drug: Conventional therapy"
                        ],
                        "ArmGroupLabel": [
                              "Group1 :Conventional plus hUCMSCs treatment",
                              "Group 2: Conventional plus hCBMNCs and hUCMSCs therapy",
                              "Group 3:Conventional therapy"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01443689"
                        ]
                  },
                  {
                        "Rank": 137,
                        "Acronym": [
                              "COVID-19"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Participants in this group will receive the 2 intravenous (IV) UCMSCs intervention on day 0 and day 3.",
                              "Participants in this group will receive the placebo, a solution of 1% human serum albumin in Plasmalyte A, on day 0 and day 3."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: UCMSCs",
                              "Other: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "Group 1: (UCMSCs)",
                              "Group 2: (Placebo)"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04490486"
                        ]
                  },
                  {
                        "Rank": 138,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Intervention group"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: human umbilical cord mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "Human umbilical cord mesenchymal stem cells transplantation"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01364246"
                        ]
                  },
                  {
                        "Rank": 139,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [
                              "Yes"
                        ],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [
                              "No"
                        ],
                        "ArmGroupDescription": [
                              "Participants in this group will be treated with two infusions of UC-MCSs along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment.",
                              "Participants in this group will be treated with two infusions of vehicle along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Umbilical Cord Mesenchymal Stem Cells + Heparin along with best supportive care.",
                              "Other: Vehicle + Heparin along with best supportive care"
                        ],
                        "ArmGroupLabel": [
                              "UC-MSCs Group",
                              "Control Group"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [
                              "<=18 years",
                              "Between 18 and 65 years",
                              ">=65 years",
                              "Female",
                              "Male",
                              "Hispanic or Latino",
                              "Not Hispanic or Latino",
                              "Unknown or Not Reported",
                              "American Indian or Alaska Native",
                              "Asian",
                              "Native Hawaiian or Other Pacific Islander",
                              "Black or African American",
                              "White",
                              "More than one race",
                              "Unknown or Not Reported",
                              "Positive PRA",
                              "Negative PRA",
                              "Positive PRA",
                              "Negative PRA",
                              "Positive",
                              "Negative",
                              "Borderline",
                              "Positive",
                              "Negative",
                              "Borderline"
                        ],
                        "BaselineClassDenomCountGroupId": [
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002"
                        ],
                        "NCTId": [
                              "NCT04355728"
                        ]
                  },
                  {
                        "Rank": 140,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Umbilical cords from healthy donor are processed with 24 hours after vaginal delivery.\n\nThe cords are delivered in a sterilized jar the laboratory to process. After washing in PBS to remove any contaminating blood, the cord is cut into small pieces. The pieces are minced and digested by enzyme. The UC-MSCs is cultured and expanded using commercially available serum-free and xeno-free medium at 37\u00b0C in a humidified atmosphere with 5% CO2. The UC-MSCs is suspended in 15 ml of saline buffer"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Human umbilical cord-derived mesenchymal stem cell infusion"
                        ],
                        "ArmGroupLabel": [
                              "human umbilical cord-derived mesenchymal stem cell transplantation for patients with liver cirrhosis"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05331872"
                        ]
                  },
                  {
                        "Rank": 141,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "the ucMSCs suspension(3\u00d7 106 cells per kg of the patient's weight) will be instilled through a 6 French end-hole catheter inserted into the infant's endotracheal tube",
                              "Normal saline"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: ucMSCs",
                              "Other: Normal saline"
                        ],
                        "ArmGroupLabel": [
                              "Mesenchymal stem cells",
                              "Control"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01207869"
                        ]
                  },
                  {
                        "Rank": 142,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Human umbilical cord mesenchymal stem cells (1*10^6/kg cells): delivered via peripheral intravenous infusion.",
                              "Placebo:normal saline delivered via peripheral intravenous infusion."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Human umbilical cord mesenchymal stem cells\uff08HUC-MSCs\uff09",
                              "Biological: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "HUC-MSCs Group",
                              "Control Group"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04314011"
                        ]
                  },
                  {
                        "Rank": 143,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "A single intravenous infusion (1-2 millions of MSCs per kilogram body weight) of ex-vivo expanded third-party MSC (from healthy donors) will be performed in patients assigned to the MSC procedure in addition to the liver transplantation."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Mesenchymal Stromal Cells"
                        ],
                        "ArmGroupLabel": [
                              "Mesenchymal Stromal Cells (MSC)",
                              "No treatment."
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "No Intervention"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02260375"
                        ]
                  },
                  {
                        "Rank": 144,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "according to Surviving Sepsis Campaign 2012 Antibiotic therapy Fluid therapy Vasopressors Inotropic therapy Steroids",
                              "MSCs intravenous infusion of 1-2 millions/kg/day will be performed not more than 10 hs after onset of septic shock in patients with severe neutropenia(\u2264 1x10^9/l).\n\naccording to Surviving Sepsis Campaign 2012: Antibiotic therapy Fluid therapy Vasopressors Inotropic therapy Steroids"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Standard therapy of septic shock",
                              "Genetic: Mesenchymal stromal cells",
                              "Drug: Standard therapy of septic shock"
                        ],
                        "ArmGroupLabel": [
                              "Standard therapy of septic shock",
                              "Mesenchymal stromal cells+ standard therapy of septic shock"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01849237"
                        ]
                  },
                  {
                        "Rank": 145,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Basic medication\uff1aAspirin Enteric-coated Tablets & Atorvastatin Calcium\uff1b Allogeneic umbilical cord mesenchymal stem cells",
                              "Basic medication\uff1aAspirin Enteric-coated Tablets & Atorvastatin Calcium; Placebo\uff1asaline"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Allogeneic umbilical cord mesenchymal stem cell",
                              "Drug: Aspirin Enteric-coated Tablets & Atorvastatin Calcium",
                              "Drug: Aspirin Enteric-coated Tablets & Atorvastatin Calcium"
                        ],
                        "ArmGroupLabel": [
                              "Experimental group",
                              "Control group"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03176498"
                        ]
                  },
                  {
                        "Rank": 146,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Infusion of 100 million adipose derived mesenchymal stromal cells from healthy donors",
                              "Infusion of 200 million adipose derived mesenchymal stromal cells from healthy donors",
                              "Infusion of saline"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: adipose derived mesenchymal stromal cells",
                              "Drug: adipose derived mesenchymal stromal cells",
                              "Drug: Saline"
                        ],
                        "ArmGroupLabel": [
                              "Infusion of 100 million ASC",
                              "Infusion of 200 million ASC",
                              "Infusion of placebo"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Active Comparator",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04714801"
                        ]
                  },
                  {
                        "Rank": 147,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Intervention: Mesenchymal stromal stem cells infusion. This is the active investigational intervention, administered intravenously at surgery and day 4 post-transplant in a dose-escalation fashion beginning as 1x10^6 cells for the first dose group, 2x10^6 cells for the second dose group, or 3x10^6 cells for the last dose group. The infusion set-up will be covered to mask the group assignment.\n\nParticipants will also receive BASILIXIMAB (Simulect, for all subjects at a standard dose, 20mg reconstituted with normal saline or 5% dextrose) on the day of surgery and day 3 or 4 post-transplant administered by a member of the anesthesia team; TACROLIMUS (Prograf for maintenance therapy), MYCOPHENOLATE MOFETIL (Cellcept for maintenance therapy), and CORTICOSTEROIDS as routine care.",
                              "Placebo: A normal saline infusion. This is the placebo intervention to occur at surgery and day 4 post-transplant. The infusion set-up will be covered to mask the group assignment. Participants will also receive BASILIXIMAB (Simulect, for all subjects at a standard dose, 20mg reconstituted with normal saline or 5% dextrose) on the day of surgery and day 3 or 4 post-transplant administered by a member of the anesthesia team; TACROLIMUS (Prograf for maintenance therapy), MYCOPHENOLATE MOFETIL (Cellcept for maintenance therapy), and CORTICOSTEROIDS as routine care."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Mesenchymal Stromal Stem Cells (MSCs) Infusion",
                              "Other: Normal Saline (Placebo) Infusion"
                        ],
                        "ArmGroupLabel": [
                              "Mesenchymal Stromal Stem Cells Infusion",
                              "Placebo Infusion"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03478215"
                        ]
                  },
                  {
                        "Rank": 148,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Human Umbilical Cord Derived MSC:\n\nPatients who receive standard of care plus treatment with ex vivo cultured adult human Umbilical Cord Derived Mesenchymal Stem Cells"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Human Umbilical Cord Derived MSC"
                        ],
                        "ArmGroupLabel": [
                              "Human Umbilical Cord Derived MSC"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01754454"
                        ]
                  },
                  {
                        "Rank": 149,
                        "Acronym": [
                              "CIRCA-19"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "25 million cells/unit dose (cumulative dose: 75 million MSCs)",
                              "50 million cells/unit dose (cumulative dose: 150 million MSCs)",
                              "up to 90 million cells/unit dose (cumulative dose: up to 270 million MSCs)"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Mesenchymal Stromal Cells",
                              "Biological: Mesenchymal Stromal Cells",
                              "Biological: Mesenchymal Stromal Cells"
                        ],
                        "ArmGroupLabel": [
                              "Panel 1",
                              "Panel 2",
                              "Panel 3"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04400032"
                        ]
                  },
                  {
                        "Rank": 150,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [
                              "Biological: umbilical cord-derived mesenchymal stem cell",
                              "Other: Comprehensive treatment"
                        ],
                        "ArmGroupLabel": [
                              "Comprehensive treatment plus UC-MSC treatment",
                              "Comprehensive treatment"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Other"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03945487"
                        ]
                  },
                  {
                        "Rank": 151,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "UCMSC: umbilical cord mesenchymal stem cells"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: UCMSC"
                        ],
                        "ArmGroupLabel": [
                              "UCMSC treatment"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02961725"
                        ]
                  },
                  {
                        "Rank": 152,
                        "Acronym": [
                              "scorem-cells"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Revascularization surgery, placement of an extracellular matrix patch without WJ-MSCs and injection of culture medium without WJ-MSCs will be performed.",
                              "Revascularization surgery, placement of an extracellular matrix patch with WJ-MSCs cultured on the epicardial surface and injection of WJ-MSCs around the infarcted zone will be performed."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Wharton's jelly-derived mesenchymal cells",
                              "Biological: Wharton's jelly-derived mesenchymal cells"
                        ],
                        "ArmGroupLabel": [
                              "Comparison/control group",
                              "Experimental group"
                        ],
                        "ArmGroupType": [
                              "Placebo Comparator",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04011059"
                        ]
                  },
                  {
                        "Rank": 153,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Participants will receive conventional treatment plus a dose of MSC from day 0 through the week 12 study visit. Participants will then be followed until 2 years study visit",
                              "Participants will receive conventional plus placebo treatment from day 0 through the week 12 study visit. Participants will then be followed until 2 years study visit"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Conventional plus MSC treatment",
                              "Drug: Conventional plus pacebo treatment"
                        ],
                        "ArmGroupLabel": [
                              "Conventional plus MSC treatment",
                              "Conventional plus pacebo treatment"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01218464"
                        ]
                  },
                  {
                        "Rank": 154,
                        "Acronym": [
                              "MSV_allo"
                        ],
                        "AgreementOtherDetails": [
                              "The only disclosure restriction on the PI is that the sponsor must review results communications prior to public release."
                        ],
                        "AgreementPISponsorEmployee": [
                              "No"
                        ],
                        "AgreementRestrictionType": [
                              "OTHER"
                        ],
                        "AgreementRestrictiveAgreement": [
                              "Yes"
                        ],
                        "ArmGroupDescription": [
                              "Mesenchymal stem cells (MSC) prepared from bone marrow from healthy donor expanded ex vivo for 3-4 weeks. Intraarticular injection of 40 millions MSC.",
                              "Intraarticular injection of hyaluronic acid (60 mg)"
                        ],
                        "ArmGroupInterventionName": [
                              "Other: Allogenic mesenchymal stromal cells injection",
                              "Drug: Hyaluronic Acid"
                        ],
                        "ArmGroupLabel": [
                              "Allogenic mesenchymal stromal cells injection",
                              "Hyaluronic acid (Durolane)"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [
                              "Female",
                              "Male",
                              "American Indian or Alaska Native",
                              "Asian",
                              "Native Hawaiian or Other Pacific Islander",
                              "Black or African American",
                              "White",
                              "More than one race",
                              "Unknown or Not Reported"
                        ],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01586312"
                        ]
                  },
                  {
                        "Rank": 155,
                        "Acronym": [
                              "Disc_allo"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Mesenchymal stem cells (MSC) prepared from bone marrow from healthy donor expanded ex vivo for 3-4 weeks. Intradiscal injection of 25 millions MSC in 2 ml of saline",
                              "Infiltration of paravertebral musculature close to the affected disc(s) with 2 ml of 1% Mepivacaine"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Allogenic Mesenchymal Stromal Cells",
                              "Drug: Mepivacaine"
                        ],
                        "ArmGroupLabel": [
                              "Allogenic Mesenchymal Stromal Cells",
                              "Mepivacaine"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01860417"
                        ]
                  },
                  {
                        "Rank": 156,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "conventional treatment & antiviral treatment",
                              "Participants will receive umbilical cord derived mesenchymal stem cell treatment at day 1 and conventional treatment and antiviral treatment through the one year study visit. Participants will then be followed until one years study visit"
                        ],
                        "ArmGroupInterventionName": [
                              "Other: conventional treatment",
                              "Other: UC-MSC transplantation"
                        ],
                        "ArmGroupLabel": [
                              "conventional",
                              "UC-MSC transplantation"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01728727"
                        ]
                  },
                  {
                        "Rank": 157,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "1.5 x 10^6 umbilical Cord Mesenchymal Stem Cells per body kg will transplant via the intravenous at baseline, and the second transplantation will be performed 3 months after the first transplantation and combination with standard frailty treatment and supplementary medication",
                              "standard frailty treatment and supplementary medication"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Umbilical Cord Mesenchymal Stem Cells transplantation",
                              "Drug: standard frailty treatment and supplementary medication",
                              "Drug: standard frailty treatment and supplementary medication"
                        ],
                        "ArmGroupLabel": [
                              "Treatment (UC-MSC trasnplatation)",
                              "control arm"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Other"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04919135"
                        ]
                  },
                  {
                        "Rank": 158,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Bone marrow derived mesenchymal stromal/stem cells injection during decompressive surgery in patients with Kienb\u00f6ck's disease."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: BM-MSC transplantation"
                        ],
                        "ArmGroupLabel": [
                              "BM-MSC"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02646007"
                        ]
                  },
                  {
                        "Rank": 159,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Received conventional treatment and huc-MSCs once per week for the first month and once per month for 6 months(9 times in total), at a dose of 1\u00d7106 huc-MSCs/kg body weight.",
                              "Received conventional treatment and 50 ml saline once per week for the first month and once per month for 6 months(9 times in total)."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: huc-MSCs",
                              "Drug: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "Conventional treatment, huc-MSCs",
                              "Conventional plus placebo"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02223897"
                        ]
                  },
                  {
                        "Rank": 160,
                        "Acronym": [
                              "ARDS-MSC-205"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Infusion of allogeneic bone marrow derived mesenchymal stromal stem cells (MSC). First three patients receive a singe dose of 1x10^6 MSC/kg dose, next six patients receive a single dose of 2x10^6 MSC/kg."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Mesenchymal Stromal Stem Cells - KI-MSC-PL-205"
                        ],
                        "ArmGroupLabel": [
                              "Mesenchymal Stromal Stem Cell Treatment"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04447833"
                        ]
                  },
                  {
                        "Rank": 161,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Allogeneic mesenchymal Stromal cells: 2 x 10^6/kg body weight MSC in a range of 1.5 x 10^6 MSC/ kg to 2.5 x 10^6 MSC/kg (at a maximum of 200 x10^6 MSC per study participant) with 5% DMSO iv",
                              "Placebo: consisting of a 5% DMSO-solution in isotonic solution",
                              "Allogeneic mesenchymal Stromal cells: 2 x 10^6/kg body weight MSC in a range of 1.5 x 10^6 MSC/ kg to 2.5 x 10^6 MSC/kg (at a maximum of 200 x10^6 MSC per study participant) with 5% DMSO iv",
                              "Placebo: consisting of a 5% DMSO-solution in isotonic solution"
                        ],
                        "ArmGroupInterventionName": [
                              "Genetic: Allogeneic MSC",
                              "Drug: Placebo",
                              "Genetic: Allogeneic MSC",
                              "Drug: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "MSC week 4 and 3 before LVRS2",
                              "Placebo week 4 and 3 before LVRS2",
                              "MSC week 12 and 11 before LVRS2",
                              "Placebo week 12 and 11 before LVRS2"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator",
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04918706"
                        ]
                  },
                  {
                        "Rank": 162,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [
                              "Biological: hUC-MSCs+Injectable collagen scaffold+CABG",
                              "Biological: hUC-MSCs+CABG",
                              "Procedure: CABG"
                        ],
                        "ArmGroupLabel": [
                              "hUC-MSCs+Injectable collagen scaffold+CABG",
                              "hUC-MSCs+CABG",
                              "CABG"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02635464"
                        ]
                  },
                  {
                        "Rank": 163,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Allogeneic Bone Marrow Derived Multipotent Mesenchymal Stromal Cells (MSCs) isolated from hematogenous bone marrow",
                              "Placebo for Allogeneic Bone Marrow Derived Multipotent Mesenchymal Stromal Cells (MSCs)"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Allogeneic Bone Marrow Derived Multipotent Mesenchymal Stromal Cells (MSCs)",
                              "Biological: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "Allogeneic Bone Marrow Derived Multipotent Mesenchymal Stromal",
                              "Placebo"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03522545"
                        ]
                  },
                  {
                        "Rank": 164,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [
                              "Biological: Umbilical cord mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "Umbilical cord mesenchymal stem cells"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02192749"
                        ]
                  },
                  {
                        "Rank": 165,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "The first three subjects (minimum) will receive four weekly infusions of MSCs.",
                              "If no significant side effects are encountered at dose level 1, then subsequent subjects will receive four infusions of MSCs given twice weekly.",
                              "If dose level 2 is well tolerated, then subsequent subjects will receive six infusions MSCs given twice weekly."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Autologous MSCs",
                              "Biological: Autologous MSCs",
                              "Biological: Autologous MSCs"
                        ],
                        "ArmGroupLabel": [
                              "MSC dose level 1",
                              "MSC dose level 2",
                              "MSC dose level 3"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03298399"
                        ]
                  },
                  {
                        "Rank": 166,
                        "Acronym": [
                              "RegenHeart"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patients of the main group will undergo cardiac catheterization with intracoronary administration of 1\u00d710 (7) umbilical cord-derived mesenchymal stromal cells and and will continue to receive optimal pharmacological therapy",
                              "Patients in the control group will only have cardiac catheterization and will continue to receive optimal pharmacological therapy"
                        ],
                        "ArmGroupInterventionName": [
                              "Procedure: Cardiac catheterization",
                              "Biological: Intracoronary administration of the umbilical cord-derived mesenchymal stromal cells",
                              "Procedure: Cardiac catheterization"
                        ],
                        "ArmGroupLabel": [
                              "Main Group",
                              "Control Group"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04325594"
                        ]
                  },
                  {
                        "Rank": 167,
                        "Acronym": [
                              "STROMA-CoV2"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [
                              "Biological: Umbilical cord Wharton's jelly-derived human",
                              "Other: NaCl 0.9%"
                        ],
                        "ArmGroupLabel": [
                              "MSC",
                              "NaCl"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04333368"
                        ]
                  },
                  {
                        "Rank": 168,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "10 patients with sepsis and septic shock and received MSCs&standart therapy",
                              "20 patients with sepsis and septic shock and not received MSCs, only received standart therapy"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "Patients received MSCs",
                              "Patients not received MSCs"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "No Intervention"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05283317"
                        ]
                  },
                  {
                        "Rank": 169,
                        "Acronym": [
                              "ProTrans19+"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Intravenous administration, 1 dose, for 20 minutes",
                              "Intravenous administration, 1 dose, for 20 minutes"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Allogeneic Wharton's jelly-MSCs (WJ-MSC)",
                              "Other: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "Allogeneic Wharton's jelly-MSCs (WJ-MSC)",
                              "Placebo"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04869397"
                        ]
                  },
                  {
                        "Rank": 170,
                        "Acronym": [
                              "IMPACT"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "One dose of 6x10e6 cells/kg administered intravenously.",
                              "Placebo infusion"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Cord Tissue Mesenchymal Stromal Cells",
                              "Other: Placebo Infusion"
                        ],
                        "ArmGroupLabel": [
                              "MSC",
                              "Placebo Infusion"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04089579"
                        ]
                  },
                  {
                        "Rank": 171,
                        "Acronym": [
                              "SEMAD"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [
                              "Biological: Human Umbilical Cord Derived MSC"
                        ],
                        "ArmGroupLabel": [
                              "Human Umbilical Cord Derived MSC"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01547689"
                        ]
                  },
                  {
                        "Rank": 172,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "This is a single treatment group study. All patients will receive treatment of a stem cell coated fistula plug."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: MSC-AFP"
                        ],
                        "ArmGroupLabel": [
                              "MSC-AFP"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03449069"
                        ]
                  },
                  {
                        "Rank": 173,
                        "Acronym": [
                              "MSC Secretome"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Escalating doses of allogenic MSC eye drops will be assigned at the lowest dose level.",
                              "Escalating doses of allogenic MSC eye drops will be assigned at the medium dose level.",
                              "Escalating doses of allogenic MSC eye drops will be assigned at the high dose level."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: MSC Secretome Eye Drops",
                              "Biological: MSC Secretome Eye Drops",
                              "Biological: MSC Secretome Eye Drops"
                        ],
                        "ArmGroupLabel": [
                              "Low dose of allogenic MSC drops",
                              "Medium dose of allogenic MSC drops",
                              "High dose of allogenic MSC drops"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Active Comparator",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05204329"
                        ]
                  },
                  {
                        "Rank": 174,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "1 x 10^6 umbilical Cord Mesenchymal Stem Cells per body kg will transplant via the intravenous at baseline, and the second transplantation will be performed 3 months after the first transplantation and combination with Vietnames MOH procedure",
                              "drug therapy according to Vietnamese MOHS procedure"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Umbilical Cord Mesenchymal Stem Cells transplantation",
                              "Drug: drug therapy according to Vietnamese MOHS procedure",
                              "Drug: drug therapy according to Vietnamese MOHS procedure"
                        ],
                        "ArmGroupLabel": [
                              "Treatment (UC-MSC trasnplatation)",
                              "control arm"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Other"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04433104"
                        ]
                  },
                  {
                        "Rank": 175,
                        "Acronym": [
                              "MSCDTDFU"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Intradermic application of dac-MSCs (1 mL ) in four equidistant points around the ulcer (twice: day 0 and 7) and topical application of fitostimoline every other day",
                              "Intradermic application of MSCs (500,000 cells/mL) in four equidistant points around the ulcer (once: day 0 ) and topical application of fitostimoline every other day",
                              "Topical application of fitostimoline every other day"
                        ],
                        "ArmGroupInterventionName": [
                              "Other: dac-MSCs",
                              "Drug: Fitostimoline",
                              "Other: MSCs",
                              "Drug: Fitostimoline",
                              "Drug: Fitostimoline"
                        ],
                        "ArmGroupLabel": [
                              "dac-MSCs and Fitostimoline",
                              "MSCs and Fitostimoline",
                              "Fitostimoline"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02943486"
                        ]
                  },
                  {
                        "Rank": 176,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [
                              "Biological: human umbilical cord mesenchymal stem cells",
                              "Biological: placebo"
                        ],
                        "ArmGroupLabel": [
                              "group 1",
                              "group 2"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03237442"
                        ]
                  },
                  {
                        "Rank": 177,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "infusion of aUCMSC and Ursodeoxycholic acid therapy",
                              "Ursodeoxycholic acid therapy 15mg/kg/d"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: UCMSC",
                              "Drug: UDCA",
                              "Drug: UDCA"
                        ],
                        "ArmGroupLabel": [
                              "UCMSC",
                              "UDCA"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03516006"
                        ]
                  },
                  {
                        "Rank": 178,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "All patients received treatment of a stem cell coated fistula plug."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: MSC Fistula Plug"
                        ],
                        "ArmGroupLabel": [
                              "MSC Fistula plug: Single Treatment Group"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02807389"
                        ]
                  },
                  {
                        "Rank": 179,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "The volunteers of the experimental group will be given peripheral intravenously a dose of 1.5*10^6/kg human umbilical cord mesenchymal stem cells at 0,8,16,24,32 week.",
                              "The control group will be given the same dose of saline containing human albumin."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: human umbilical cord mesenchymal stem cells",
                              "Other: saline"
                        ],
                        "ArmGroupLabel": [
                              "experimental group",
                              "control group"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04216849"
                        ]
                  },
                  {
                        "Rank": 180,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Single Treatment Group"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: MSC-AFP"
                        ],
                        "ArmGroupLabel": [
                              "MSC-AFP"
                        ],
                        "ArmGroupType": [
                              "Other"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02589119"
                        ]
                  },
                  {
                        "Rank": 181,
                        "Acronym": [
                              "PRIME-HFrEF"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "The volunteers of the experimental group will be given peripheral intravenously a dose of 1.0*10^6/kg human umbilical cord mesenchymal stem cells at 0,6,12 week.",
                              "The control group will be given the same dose of saline containing human albumin."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: human umbilical cord mesenchymal stem cells",
                              "Other: human serum albumin"
                        ],
                        "ArmGroupLabel": [
                              "experimental group",
                              "control group"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04992832"
                        ]
                  },
                  {
                        "Rank": 182,
                        "Acronym": [
                              "GVHD Cyto-MSC"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Cyto-MSC (5 million UCMSCs per kg bodyweight) and standard treatment",
                              "Placebo (normal saline) and standard treatment"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Umbilical cord derived mesenchymal stem cell",
                              "Other: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "Group A",
                              "Group B"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03847844"
                        ]
                  },
                  {
                        "Rank": 183,
                        "Acronym": [
                              "UC-MSCs"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Conventional treatment plus UC-MSCs:\n\nParticipants will receive conventional treatment plus 3 times of UC-MSCs (1*10E6 UC-MSCs/kg body weight/100mL intravenously at week 1, week 2\uff0cweek3).",
                              "Conventional treatment plus Placebo:\n\nWithout UC-MSCs therapy but conventional treatment should be received. Participants will receive conventional treatment plus 3 times of Placebo intravenously at week 1, week 2\uff0cweek3."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: UC-MSCs",
                              "Drug: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "UC-MSCs treatment group",
                              "Placebo control group"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04562025"
                        ]
                  },
                  {
                        "Rank": 184,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "UCMSCs + CM is administered via intrathecal injection",
                              "UCMSCs is administered via intrathecal injection",
                              "Physiotherapy"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Umbilical Cord Mesenchymal Stem Cells",
                              "Biological: Conditioned Medium",
                              "Biological: Umbilical Cord Mesenchymal Stem Cells",
                              "Other: Standard Therapy"
                        ],
                        "ArmGroupLabel": [
                              "UCMSCs + CM",
                              "UCMSCs",
                              "Standard Therapy"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04314687"
                        ]
                  },
                  {
                        "Rank": 185,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Eligible patients will be treated, single treatment group, no placebo arm."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: MSC-AFP"
                        ],
                        "ArmGroupLabel": [
                              "MSC-AFP Single Treatment Group"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03220243"
                        ]
                  },
                  {
                        "Rank": 186,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Aspirin Tablet, 100mg/d; Allogeneic umbilical cord mesenchymal stem cells, 0.5-1*10^6/kg",
                              "Aspirin Tablet, 100mg/d; Placebo"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Allogeneic umbilical cord mesenchymal stem cells (SCLnow 19#)",
                              "Drug: Aspirin Tablet",
                              "Drug: Aspirin Tablet"
                        ],
                        "ArmGroupLabel": [
                              "Group 1",
                              "Group 2"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03186456"
                        ]
                  },
                  {
                        "Rank": 187,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "transplant collagen scaffold loaded with UC-MSCs to treat infertility caused by recurrent intrauterine adhesions"
                        ],
                        "ArmGroupInterventionName": [
                              "Procedure: UC-MSCs therapy"
                        ],
                        "ArmGroupLabel": [
                              "UC-MSCs therapy"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02313415"
                        ]
                  },
                  {
                        "Rank": 188,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "First three subjects enrolled will receive a single infusion of mesenchymal stromal cells based on their individual weight",
                              "Subsequent subjects enrolled will receive two infusions (a week apart) of mesenchymal stromal cells based on their individual weight",
                              "Subsequent subjects enrolled will receive four infusions (a week apart) of mesenchymal stromal cells based on their individual weight"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Autologous mesenchymal stromal cells (MSCs)",
                              "Biological: Autologous mesenchymal stromal cells (MSCs)",
                              "Biological: Autologous mesenchymal stromal cells (MSCs)"
                        ],
                        "ArmGroupLabel": [
                              "Dose Level 1: Infusion of MSCs",
                              "Dose Level 2: Infusion of MSCs",
                              "Dose Level 3: Infusion of MSCs"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02359929"
                        ]
                  },
                  {
                        "Rank": 189,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Transplantation of umbilical cord mesenchymal stem cells (UCMSCs) in patients with fracture and bone nonunion.",
                              "The patients with fracture and bone nonunion who underwent percutaneous injection of placebo."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: UCMSCs",
                              "Biological: Percutaneous"
                        ],
                        "ArmGroupLabel": [
                              "UCMSCs",
                              "Placebo"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02815423"
                        ]
                  },
                  {
                        "Rank": 190,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "UC-MSC transplantation",
                              "Routine treatment"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: UC-MSC",
                              "Biological: Control Group"
                        ],
                        "ArmGroupLabel": [
                              "UC-MSC",
                              "Control Group"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03902067"
                        ]
                  },
                  {
                        "Rank": 191,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "intramedullary injection of 4 x 107 WJ-MSCs (direct injection into the recently fractured vertebra) at baseline (day 0). subcutaneous injection of 20 \u00b5g teriparatide once daily for 6 months, followed by oral administration of anti-resorptive drug for 6 months.",
                              "subcutaneous injection of 20 \u00b5g teriparatide once daily for 6 months, followed by oral administration of anti-resorptive drug for 6 months."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: WJ-MSC",
                              "Drug: Teriparatide",
                              "Drug: Teriparatide"
                        ],
                        "ArmGroupLabel": [
                              "WJ-MSC group",
                              "Teriparatide group"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05018637"
                        ]
                  },
                  {
                        "Rank": 192,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [
                              "Yes"
                        ],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "All patients will be treated with the same treatment: Adult Autologous Mesenchymal Bone Marrow Cell"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Adult Autologous Mesenchymal Bone Marrow Cell"
                        ],
                        "ArmGroupLabel": [
                              "Autologous Mesenchymal Bone Marrow Cell"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [
                              "Female",
                              "Male"
                        ],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02165904"
                        ]
                  },
                  {
                        "Rank": 193,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Participants will receive the treatment according to the treatment principle of severe and critical cases in \"Influenza diagnosis and treatment plan (2019 version)\"",
                              "Participants will receive intravenous infusion of definitive HUC-MSCs (1\u00d710^6 cells/Kg \u00d7 body weight(kg), which was selected by immunomodulatory assay through coculture with BV2 cell) on the basis of the routine treatment."
                        ],
                        "ArmGroupInterventionName": [
                              "Procedure: Routine treatment",
                              "Biological: Human umbilical cord mesenchymal stem cells",
                              "Procedure: Routine treatment"
                        ],
                        "ArmGroupLabel": [
                              "Routine treatment group",
                              "HUC-MSCs adjuvant Group"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04282928"
                        ]
                  },
                  {
                        "Rank": 194,
                        "Acronym": [
                              "MyStromalCell"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Adipose derived stem cells"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: MSC",
                              "Biological: Saline"
                        ],
                        "ArmGroupLabel": [
                              "MSC",
                              "Saline"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01449032"
                        ]
                  },
                  {
                        "Rank": 195,
                        "Acronym": [
                              "COVIDMES"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Wharton-Jelly mesenchymal stromal cells on D1 and D3",
                              "Placebo on D1 and D3"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: XCEL-UMC-BETA",
                              "Other: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "Treatment A",
                              "Treatment B"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04390139"
                        ]
                  },
                  {
                        "Rank": 196,
                        "Acronym": [
                              "RACE"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "During the first part of the study, 11 SDNS pediatric patients will receive 3 intravenous infusions of CB-MSCs at the dosage of 1.5 x 10^6/kg at a time interval of 1 to 2 weeks. The ongoing immunosuppressive treatment will be gradually tapered off after the first CB-MSC administration, as follows:\n\n25% reduction of the ongoing immunosuppressive treatment following the first administration;\n50% reduction of the ongoing immunosuppressive treatment following the second administration;\ninterruption of the ongoing immunosuppressive treatment following the third administration.\n\nIn the case that the hypothesis that P \u2265 0.600 is rejected and therefore the second part of the study will be required, 11 additional pediatric patients with SDNS will be treated with 3 intravenous infusions of CB-MSCs at the dosage of 2x10^6/kg at a time interval of 1 to 2 weeks."
                        ],
                        "ArmGroupInterventionName": [
                              "Other: Cord-blood mesenchymal stromal cells"
                        ],
                        "ArmGroupLabel": [
                              "MSC"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04034316"
                        ]
                  },
                  {
                        "Rank": 197,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Intracoronary infusion of umbilical cord mesenchymal stem cells (UCMSCs)",
                              "Standard medical treatment without umbilical cord mesenchymal stem cells (UCMSCs) infusion"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: umbilical cord mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "UCMSCs",
                              "controls"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "No Intervention"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02666391"
                        ]
                  },
                  {
                        "Rank": 198,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "A group treated with a stromal vascular fraction (SVF) with mesenchymal stromal cells (MSC) injection in the knee joint after an enzymatic digestion of autologous adipose tissue",
                              "A group treated with a mechanically fragmented (using Lipogems device) autologous adipose tissue injection in the knee joint"
                        ],
                        "ArmGroupInterventionName": [
                              "Procedure: Autologous adipose derived Mesenchymal Stromal Cells (MSC) injection into the knee joint",
                              "Procedure: Autologous adipose derived Mesenchymal Stromal Cells (MSC) injection into the knee joint"
                        ],
                        "ArmGroupLabel": [
                              "Enzymatic digestion group",
                              "Mechanical fragmentation group"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04675359"
                        ]
                  },
                  {
                        "Rank": 199,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Participants will receive conventional and treatment with MSCs, MSCs were suspended in 100 mL of normal saline, and the total number of transplanted cells was calculated by 1*10E6 cells per kilogram of weight. This product is generally a course of treatment, a total of 1 time, depending on the condition of the need to be given again at an interval of 1 week.",
                              "Participants will receive conventional treatment and Placebo intravenously."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: UC-MSCs",
                              "Other: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "UC-MSCs treatment group",
                              "Control group"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04339660"
                        ]
                  },
                  {
                        "Rank": 200,
                        "Acronym": [
                              "MSCTPHSCT"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patients treated with mesenchymal stromal cell",
                              "Patients treated without mesenchymal stromal cell"
                        ],
                        "ArmGroupInterventionName": [],
                        "ArmGroupLabel": [
                              "mesenchymal stromal cell",
                              "non-mesenchymal stromal cell"
                        ],
                        "ArmGroupType": [],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05131412"
                        ]
                  },
                  {
                        "Rank": 201,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "The group receive pulse infusion of MSCs and placebo of oral Mycophenolate Mofetil (MMF). The cells of 2 x 10^6/kg body weight are suspended in 100ml saline and infused intravenously.\n\nDexamethasone of 10mg is intravenously injected before 30 minutes of cells infusion.\nA sterile blood transfusion device is used during the venous transfusion, and it is washed with saline before infusion. Take a slow infusion of about 20 drops per minute in the first 15 minutes. Increase to about 60 drops per minute if the patient had no complaints of discomfort.",
                              "The group receive placebo of MSCs and oral Mycophenolate Mofetil of 2.0g/d. ."
                        ],
                        "ArmGroupInterventionName": [
                              "Other: Mesenchymal stem cells",
                              "Drug: Placebo of Mycophenolate Mofetil",
                              "Drug: Mycophenolate Mofetil",
                              "Other: Placebo of Mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "Mesenchymal stem cells",
                              "Mycophenolate Mofetil"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03580291"
                        ]
                  },
                  {
                        "Rank": 202,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "One time infusion of islets plus BM-MSCs at 20x10^6/patient, n=14",
                              "One time infusion of islets plus BM-MSCs at 50x10^6/patient, n=14",
                              "One time infusion of islets only."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Bone marrow-derived mesenchymal stem cells",
                              "Biological: Bone marrow-derived mesenchymal stem cells",
                              "Other: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "BM-MSCs at 20x10^6",
                              "BM-MSCs at 50x10^6",
                              "Placebo"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05095532"
                        ]
                  },
                  {
                        "Rank": 203,
                        "Acronym": [
                              "LYSYME"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [
                              "Drug: Adipose derived stromal cells intravenously injected"
                        ],
                        "ArmGroupLabel": [
                              "Adipose derived stromal cells intravenously injected"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04711200"
                        ]
                  },
                  {
                        "Rank": 204,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Local transplantation stem cell preparation combined with silver ion dressing",
                              "Local trantment with silver ion dressing"
                        ],
                        "ArmGroupInterventionName": [
                              "Procedure: silver ion dressing",
                              "Other: stem cell preparation combined with silver ion dressing"
                        ],
                        "ArmGroupLabel": [
                              "experimental group",
                              "control group"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05319106"
                        ]
                  },
                  {
                        "Rank": 205,
                        "Acronym": [
                              "RIMECARD"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Umbilical cord derived mesenchymal are injected intravenously to Patients.",
                              "Intravenous placebo solution are administrated to Patients."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: ucMSC",
                              "Other: Controls"
                        ],
                        "ArmGroupLabel": [
                              "ucMSC",
                              "Controls"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01739777"
                        ]
                  },
                  {
                        "Rank": 206,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "MSCs Participants will received i. m. HUC-MSCs both lower extremities",
                              "The control group will receive i.v Lipoic Acid Injection"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: HUC-MSCs",
                              "Biological: Lipoic Acid"
                        ],
                        "ArmGroupLabel": [
                              "Experimental",
                              "Comparator"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05507697"
                        ]
                  },
                  {
                        "Rank": 207,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Hormone replacement therapy, placebo transplantation.",
                              "Hormone replacement therapy,HUC-MSCs transplantation."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Placebo transplantation",
                              "Biological: HUC-MSCs transplantation"
                        ],
                        "ArmGroupLabel": [
                              "Control group",
                              "Experimental group"
                        ],
                        "ArmGroupType": [
                              "Placebo Comparator",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03033277"
                        ]
                  },
                  {
                        "Rank": 208,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [
                              "Biological: Low dose UCMSCs",
                              "Biological: Moderate dose UCMSCs",
                              "Biological: High dose UCMSCs"
                        ],
                        "ArmGroupLabel": [
                              "Low dose UCMSCs",
                              "Moderate dose UCMSCs",
                              "High dose UCMSCs"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05151133"
                        ]
                  },
                  {
                        "Rank": 209,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patients will be given tablet (placebo) once for 30 days, IV 0.3 million kg/bb UC-MSCs once, and nasal drop 0.5 ml/day (growth medium) for 30 days.",
                              "Patients will be given tablet (placebo) once for 30 days, IV placebo (NaCl 0.9%) once, and nasal drop 0.5 ml/day (Secretomes) for 30 days.",
                              "Patients will be given tablet (placebo) once for 30 days, IV 0.3 million kg/bb UC-MSCs once, and nasal drop 0.5 ml/day (Secretomes) for 30 days.",
                              "Patients will be given Metformin once for 30 days, IV placebo (NaCl 0.9%) once, and nasal drop 0.5 ml/day (growth medium) for 30 days."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: UC-MSCs",
                              "Biological: Secretomes",
                              "Biological: UC-MSCs and Secretomes",
                              "Biological: Control"
                        ],
                        "ArmGroupLabel": [
                              "WJ-MSCs",
                              "Secretomes",
                              "WJ-MSCs and Secretomes",
                              "Control"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05279768"
                        ]
                  },
                  {
                        "Rank": 210,
                        "Acronym": [
                              "CLT-OA1"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Umbilical cord derived-mesenchymal stromal cells at a dose of 2x10e6 cells / 3mL injected by an intra-articular infiltration of affected knee",
                              "Umbilical cord derived-mesenchymal stromal cells at a dose of 20x10e6 cells / 3mL injected by an intra-articular infiltration of affected knee",
                              "Umbilical cord derived-mesenchymal stromal cells at a dose of 80x10e6 cells / 3mL injected by an intra-articular infiltration of affected knee"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: umbilical cord derived-mesenchymal stromal cells",
                              "Biological: umbilical cord derived-mesenchymal stromal cells",
                              "Biological: umbilical cord derived-mesenchymal stromal cells"
                        ],
                        "ArmGroupLabel": [
                              "CLT low-dose",
                              "CLT medium-dose",
                              "CLT high-dose"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03810521"
                        ]
                  },
                  {
                        "Rank": 211,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "UC-MSC, iv, 1\u00d710^6 cells/kg, once a week, for 4 weeks. Anti-CD25 mAb, iv, 20mg\uff0ctwice in first week and once a week thereafter, 4 weeks. Other treatment would replace it according to clinical experience if aGVHD continue to progress within 3 weeks of treatment or patients are lack of response after 4 weeks of treatment. The treatment would be repeated in another 4 weeks if patients receive partial response after the first 4 weeks of treatment.",
                              "Anti-CD25 mAb, iv, 20mg\uff0ctwice in first week and once a week thereafter, for 4 weeks. Other treatment would replace it according to clinical experience if aGVHD continue to progress within 3 weeks of treatment or patients are lack of response after 4 weeks of treatment. The treatment would be repeated in another 4 weeks if patients receive partial response after first 4 weeks of treatment."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: UC-MSC",
                              "Drug: Anti-CD25 mAb",
                              "Drug: Anti-CD25 mAb"
                        ],
                        "ArmGroupLabel": [
                              "UC-MSC and anti-CD25 mAb",
                              "Anti-CD25 mAb"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04738981"
                        ]
                  },
                  {
                        "Rank": 212,
                        "Acronym": [
                              "SAMCIS"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Allogeneic bone marrow derived mesenchymal stem cells given in one dose 3-10 days after stroke symptom onset",
                              "Infusion of normal saline placebo"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: MSC Infusion",
                              "Biological: Placebo Comparator"
                        ],
                        "ArmGroupLabel": [
                              "MSC infusion",
                              "SHAM infusion"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01922908"
                        ]
                  },
                  {
                        "Rank": 213,
                        "Acronym": [
                              "Keloid"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "A patient will be given UC-MSCs 2 million cells / cm3. After 3 weeks, the patient will be given CM 1 cc / cm3. The maximum size of Keloid is 15 cm per patient.",
                              "A patient will be given CM 1 cc / cm3. After 3 weeks, the patient will be given CM 1 cc / cm3. The maximum size of Keloid is 15 cm per patient.",
                              "A patient will be given Triamcinolone acetonide 40 mg / cc / cm3. After 3 weeks the patient will be given Triamcinolone acetonide 40 mg/cc / cm3. The maximum size of Keloid is 15 cm per patient."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Umbilical Cord-Mesenchymal Stem Cells and Conditioned Medium",
                              "Biological: Conditioned Medium",
                              "Biological: Conditioned Medium",
                              "Biological: Triamcinolone Acetonide"
                        ],
                        "ArmGroupLabel": [
                              "UC-MSCs + CM",
                              "CM + CM",
                              "Triamcinolon acetonide"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04326959"
                        ]
                  },
                  {
                        "Rank": 214,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patients receive standardized treatment, consisting of Oseltamivir and Azithromycin",
                              "Patients receive intravenous infusion of 1x10^6 unit of umbilical-cord derived mesenchymal stem cells (UC-MSCs)/kgBW in 100 cc of 0.9% NaCl for 1 hour, in addition to standardized treatment"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Oseltamivir",
                              "Drug: Azithromycin",
                              "Drug: Oseltamivir",
                              "Drug: Azithromycin",
                              "Biological: Umbilical Cord Mesenchymal Stem Cells"
                        ],
                        "ArmGroupLabel": [
                              "Control Group",
                              "Experiment Group"
                        ],
                        "ArmGroupType": [
                              "Placebo Comparator",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04457609"
                        ]
                  },
                  {
                        "Rank": 215,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patients will receive standard care.",
                              "Patients will receive standard care plus cell therapy.",
                              "Patients will receive standard care plus cell therapy.",
                              "Patients will receive standard care plus cell therapy."
                        ],
                        "ArmGroupInterventionName": [
                              "Other: Mesenchymal stromal cell-based therapy",
                              "Other: Mesenchymal stromal cell-based therapy",
                              "Other: Mesenchymal stromal cell-based therapy"
                        ],
                        "ArmGroupLabel": [
                              "Control",
                              "MSC - low dose (2.5x10\u02c67)",
                              "MSC - intermediate dose (5x10\u02c67)",
                              "MSC - high dose (10x10\u02c67)"
                        ],
                        "ArmGroupType": [
                              "No Intervention",
                              "Experimental",
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04525378"
                        ]
                  },
                  {
                        "Rank": 216,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "The people in this group will receive intravenous MSCs 2 x 10^6/kg as a single dose and standardized treatment of acute ischemic stroke.",
                              "The people in this group will receive placebo and standardized treatment of acute ischemic stroke."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: human umbilical cord mesenchymal stem cells",
                              "Other: standardized treatment",
                              "Biological: Placebo",
                              "Other: standardized treatment"
                        ],
                        "ArmGroupLabel": [
                              "MSCs group",
                              "control group"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04093336"
                        ]
                  },
                  {
                        "Rank": 217,
                        "Acronym": [
                              "MSC"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [
                              "Biological: Mesenchymal Stromal Cells"
                        ],
                        "ArmGroupLabel": [
                              "Mesenchymal Stromal Cells"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03901235"
                        ]
                  },
                  {
                        "Rank": 218,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Participants will receive conventional treatment plus 4 times of 0.5*10E6 UC-MSCs /kg body weight intravenously at Day1, Day3, Day5, Day7).",
                              "Participants will receive conventional treatment plus 4 times of Placebo intravenously at Day1, Day3, Day5, Day7."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: UC-MSCs",
                              "Other: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "UC-MSCs treatment group",
                              "Control group"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04293692"
                        ]
                  },
                  {
                        "Rank": 219,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Participants will receive conventional treatment plus a dose of UC-MSC from day 0 through the week 12 study visit.\n\nParticipants will then be followed until the week 48 study visit.",
                              "Participants will receive conventional plus placebo treatment from day 0 through the week 12 study visit. Participants will then be followed until the week 48 study visit."
                        ],
                        "ArmGroupInterventionName": [
                              "Other: conventional plus UC-MSC treatment",
                              "Other: Conventional plus placebo treatment"
                        ],
                        "ArmGroupLabel": [
                              "Conventional plus UC-MSC treatment",
                              "Conventional plus placebo treatment"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01662973"
                        ]
                  },
                  {
                        "Rank": 220,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Umbilical Cord Mesenchymal Stem Cells (UC-MSCs) 1 x 10^6 cells/kg in normal saline injection",
                              "Umbilical Cord Mesenchymal Stem Cells (UC-MSCs) 3 x 10^6 cells/kg in normal saline injection",
                              "5-25mg Methotrexate orally"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Low-dose UC-MSCs",
                              "Biological: High-dose UC-MSCs",
                              "Drug: Methotrexate"
                        ],
                        "ArmGroupLabel": [
                              "Low-Dose UC-MSCs",
                              "High-Dose UC-MSCs",
                              "Methotrexate"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03424629"
                        ]
                  },
                  {
                        "Rank": 221,
                        "Acronym": [
                              "Lipo-Hip"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patients will be treated with an intra-articular-ultrasound-guided injection of Micro-fragmented adipose tissue containing mesenchymal stromal cells."
                        ],
                        "ArmGroupInterventionName": [
                              "Procedure: Micro-fragmented adipose tissue injection"
                        ],
                        "ArmGroupLabel": [
                              "MF-AT injection"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05465096"
                        ]
                  },
                  {
                        "Rank": 222,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Intraarticular administration of XCEL-M-ALPHA followed by standard rehabilitation program",
                              "Standard rehabilitation program"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: XCEL-M-ALPHA and standard rehabilitation",
                              "Other: Rehabilitation"
                        ],
                        "ArmGroupLabel": [
                              "XCEL-M-ALPHA and standard rehabilitation",
                              "standard rehabilitation"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02033525"
                        ]
                  },
                  {
                        "Rank": 223,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Expanded autologous bone marrow-derived mesenchymal cells (BMMSCs), dose 20 million cells/ovary"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: expanded autologous bone marrow derived MSC"
                        ],
                        "ArmGroupLabel": [
                              "Arm 1"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04815213"
                        ]
                  },
                  {
                        "Rank": 224,
                        "Acronym": [
                              "TEACH"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "The first dosing cohort of 2 participants will receive 12 infusions of 10^4 donor-derived Mesenchymal Stromal Cells (MSCs) cells/kg every 4-weeks.",
                              "If the first 3 infusions of 10^4 donor-derived Mesenchymal Stromal Cells (MSCs) cells/kg are well tolerated, this cohort of 2 participants will receive 12 infusions of 10^5 cells/kg every 4-weeks.",
                              "If the first 3 infusions of 10^5 donor-derived Mesenchymal Stromal Cells (MSCs) cells/kg are well tolerated, this cohort of 2 participants will receive 12 infusions of 10^6 cells/kg every 4-weeks."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Donor-derived Mesenchymal Stromal Cells",
                              "Drug: alemtuzumab",
                              "Drug: belatacept",
                              "Drug: sirolimus",
                              "Drug: mycophenolate mofetil",
                              "Drug: mycophenolate acid",
                              "Drug: prednisone",
                              "Biological: Donor-derived Mesenchymal Stromal Cells",
                              "Drug: alemtuzumab",
                              "Drug: belatacept",
                              "Drug: sirolimus",
                              "Drug: mycophenolate mofetil",
                              "Drug: mycophenolate acid",
                              "Drug: prednisone",
                              "Biological: Donor-derived Mesenchymal Stromal Cells",
                              "Drug: alemtuzumab",
                              "Drug: belatacept",
                              "Drug: sirolimus",
                              "Drug: mycophenolate mofetil",
                              "Drug: mycophenolate acid",
                              "Drug: prednisone"
                        ],
                        "ArmGroupLabel": [
                              "MSCs 10^4 cells/kg+anti-rejection drugs",
                              "MSCs 10^5 cells/kg+anti-rejection drugs",
                              "MSCs 10^6 cells/kg+anti-rejection drugs"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03504241"
                        ]
                  },
                  {
                        "Rank": 225,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "The first 10 consecutive patients will all receive investigational product.",
                              "An interim analysis, for safety will be conducted and reviewed by the Data Safety and Monitoring Board (DSMB) after the first 10 patients have completed treatment and reached the 28 day endpoint. If there are no safety concerns, the trial will proceed with enrollment on the phase 2 portion of the study where the subsequent 40 patients will be randomized in a 1:1 fashion between treatment with MSCs and placebo. The investigational product will be further randomized to the MSCs manufactured by Duke or University of Miami. These products are considered to be comparable.",
                              "An interim analysis, for safety will be conducted and reviewed by the Data Safety and Monitoring Board (DSMB) after the first 10 patients have completed treatment and reached the 28 day endpoint. If there are no safety concerns, the trial will proceed with enrollment on the phase 2 portion of the study where the subsequent 40 patients will be randomized in a 1:1 fashion between treatment with MSCs and placebo"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Human cord tissue mesenchymal stromal cells (hCT-MSC) manufactured by Duke University.",
                              "Biological: Human cord tissue mesenchymal stromal cells (hCT-MSC) manufactured by Duke University.",
                              "Other: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "Open Label infusion of hCT-MSC",
                              "Randomized infusion of hCT-MSC",
                              "Randomized infusion of Placebo"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04399889"
                        ]
                  },
                  {
                        "Rank": 226,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patient: Intravenous infusion of single-dose of Mesenchymal stem cells (MSCs)",
                              "Intravenous infusion of single-dose of Ringer's lactate, albumin and heparin solution"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Mesenchymal stem cell",
                              "Other: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "Treatment",
                              "Placebo"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05433298"
                        ]
                  },
                  {
                        "Rank": 227,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Single infusion of 200 million cells per patient.",
                              "Single infusion with albumin and dmso in sodium chloride (identical concentrations as active treatment)"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: ProTrans: Allogeneic transplantation with WJMSCs",
                              "Drug: Placebos"
                        ],
                        "ArmGroupLabel": [
                              "Allogeneic transplantation with WJMSCs",
                              "Sham transplantation (placebo)"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03406585"
                        ]
                  },
                  {
                        "Rank": 228,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [
                              "Biological: Collagen membrane + HUC-MSCs"
                        ],
                        "ArmGroupLabel": [
                              "Collagen membrane + HUC-MSCs"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02947191"
                        ]
                  },
                  {
                        "Rank": 229,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Participants will receive conventional treatment plus a dose of UC-MSC from day 0 through the week 12 study visit.\n\nParticipants will then be followed until the week 96 study visit.",
                              "Participants will receive conventional plus placebo treatment from day 0 through the week 12 study visit. Participants will then be followed until the week 96 study visit."
                        ],
                        "ArmGroupInterventionName": [
                              "Other: conventional plus UC-MSC treatment",
                              "Other: Conventional plus placebo treatment"
                        ],
                        "ArmGroupLabel": [
                              "Conventional plus UC-MSC treatment",
                              "Conventional plus placebo treatment"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01661842"
                        ]
                  },
                  {
                        "Rank": 230,
                        "Acronym": [
                              "CEL&VAL"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [
                              "Device: Zephyr Endobronchial Valve",
                              "Biological: Marrow-derived mesenchymal stromal cell",
                              "Device: Zephyr Endobronchial Valve"
                        ],
                        "ArmGroupLabel": [
                              "Endobronchial valve + marrow-derived mesenchymal stromal cell",
                              "Endobronchial valve"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04018729"
                        ]
                  },
                  {
                        "Rank": 231,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Adult kidney transplant recipients with subclinical rejection (biopsy-proven antibody-mediated and/or cellular rejection, including borderline rejection) will be administered one low dose of allogeneic A-MSC.",
                              "Adult kidney transplant recipients with subclinical rejection (biopsy-proven antibody-mediated and/or cellular rejection, including borderline rejection) will be administered one high dose of allogeneic A-MSC."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Low dose adipose tissue derived mesenchymal stromal cells (A-MSC)",
                              "Biological: High dose adipose tissue derived mesenchymal stromal cells (A-MSC)"
                        ],
                        "ArmGroupLabel": [
                              "Low Dose Group",
                              "High Dose Group"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05456243"
                        ]
                  },
                  {
                        "Rank": 232,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Autologous MSC, 5\u00d710^7 cells, one injection"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: RegStem"
                        ],
                        "ArmGroupLabel": [
                              "RegStem"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03007576"
                        ]
                  },
                  {
                        "Rank": 233,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "1 single arm: Local injection of autologus MSC product (KI-MSC-PL-204) into scarred vocal fold (0,5-1 million cellls/Vocal fold, maximum 2 million cells if bilateral vocal fold scar)"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: MSC-KI-PL-204"
                        ],
                        "ArmGroupLabel": [
                              "Single arm: MSC administration to vocal fold scar"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04290182"
                        ]
                  },
                  {
                        "Rank": 234,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [
                              "Biological: Umbilical cord mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "Umbilical cord mesenchymal stem cells"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01985464"
                        ]
                  },
                  {
                        "Rank": 235,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Intravenous and intrathecal human umbilical cord tissue-derived mesenchymal stem cells and bone marrow mononuclear cells"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Intravenous and intrathecal human umbilical cord tissue-derived mesenchymal stem cells and bone marrow mononuclear cells"
                        ],
                        "ArmGroupLabel": [
                              "IV and IT UC-MSC and BMMC"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02237547"
                        ]
                  },
                  {
                        "Rank": 236,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "1.5 x 10^6 umbilical Cord Mesenchymal Stem Cells per body kg will be infusion via the intravenous at baseline, and the second transplantation will be performed 3 months after the first transplantation and combination with standard frailty treatment and supplementary medication",
                              "1.5 x 10^6 umbilical Cord Mesenchymal Stem Cells per body kg will be infusion via the intrathecal at baseline, and the second transplantation will be performed 3 months after the first transplantation and combination with standard frailty treatment and supplementary medication",
                              "standard stroke treatment and rehabilitation therapy"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: UC-MSC infusion via intravenous route",
                              "Other: standard stroke treatment and rehabilitation therapy",
                              "Biological: UC-MSC infusion via intrathecal route",
                              "Other: standard stroke treatment and rehabilitation therapy",
                              "Other: standard stroke treatment and rehabilitation therapy"
                        ],
                        "ArmGroupLabel": [
                              "UC-MSC infusion via intravenous route",
                              "UC-MSC infusion via intrathecal route",
                              "control arm"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Other"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05292625"
                        ]
                  },
                  {
                        "Rank": 237,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [],
                        "ArmGroupLabel": [],
                        "ArmGroupType": [],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04366830"
                        ]
                  },
                  {
                        "Rank": 238,
                        "Acronym": [
                              "AMSC-ALS-001"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patients with intrathecal administration of Suspension of human autologous MSC 3P in 1.5 ml"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Suspension of human autologous MSC 3P in 1.5 ml"
                        ],
                        "ArmGroupLabel": [
                              "Autologous Multipotent MSC"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03828123"
                        ]
                  },
                  {
                        "Rank": 239,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patients receive ruxolitinib PO BID for at least 3 days and may consider tapering after 6 months of therapy if response occurs and therapeutic corticosteroid doses have been discontinued.",
                              "Patients receive ruxolitinib PO BID as in Arm 1. Patients also receive lower dose of cb-MSCs IV for up to 60 minutes twice weekly (at least 3 days apart) over 4 consecutive weeks for 8 total doses.",
                              "Patients receive ruxolitinib PO BID as in Arm 1. Patients also receive higher dose of cb-MSCs IV for up to 60 minutes twice weekly (at least 3 days apart) over 4 consecutive weeks for 8 total doses."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Ruxolitinib",
                              "Other: Cellular Therapy",
                              "Drug: Ruxolitinib",
                              "Other: Cellular Therapy",
                              "Drug: Ruxolitinib"
                        ],
                        "ArmGroupLabel": [
                              "Arm 1 (ruxolitinib)",
                              "Arm 2 (ruxolitinib, lower dose ds-MSCs)",
                              "Arm 3 (ruxolitinib, higher dose ds-MSCs)"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04744116"
                        ]
                  },
                  {
                        "Rank": 240,
                        "Acronym": [
                              "ASSIST-CLAD"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "4 doses of Allogeneic bone-marrow derived MSCs (2x106 cells/kg) given intravenously twice weekly for 2 weeks",
                              "Placebo product manufactured to look like MSCs"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Bone-marrow derived MSCs",
                              "Drug: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "Bone-marrow derived MSCs",
                              "Placebo"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02709343"
                        ]
                  },
                  {
                        "Rank": 241,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "A single dose of MSCs injected into the submandibular glands of patients with radiation-induced xerostomia"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Autologous bone-marrow derived, interferon gamma stimulated mesenchymal stromal cells"
                        ],
                        "ArmGroupLabel": [
                              "Treatment with MSCs"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04489732"
                        ]
                  },
                  {
                        "Rank": 242,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Cohort 1: Low-dose BC-U001 Cohort 2: Medium-dose BC-U001 Cohort 3: High-dose BC-U001"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: hUC-MSC infusion (BC-U001)"
                        ],
                        "ArmGroupLabel": [
                              "hUC-MSC infusion (BC-U001)"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04971980"
                        ]
                  },
                  {
                        "Rank": 243,
                        "Acronym": [
                              "ENTRUST"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patients will have a patch of expanded somatic mesenchymal stromal cells (MSCs) seeded onto a decellularised human tracheal-scaffold surgically implanted to repair bronchial fistula."
                        ],
                        "ArmGroupInterventionName": [
                              "Other: BPF-001"
                        ],
                        "ArmGroupLabel": [
                              "Treatment Arm"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04435249"
                        ]
                  },
                  {
                        "Rank": 244,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Cohort 1 will receive two single intravenous dose of UC MSCs of 1.5 million cells per kilogram body weight on their Study Month 0, and Study Month 3.\n\n- Each treatment period was separated by a 4 - week washout to allow the effective systemic elimination of the UC MSCs before subsequent treatment initiation",
                              "Cohort 2 will receive two single intravenous dose of UC MSCs of 1.5 million cells per kilogram body weight on their Study Month 7, and Study Month 10"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Umbilical Cord-Derived Mesenchymal Stem Cell for Male Patients with Sexual Deficiency",
                              "Biological: Umbilical Cord-Derived Mesenchymal Stem Cell for Male Patients with Sexual Deficiency"
                        ],
                        "ArmGroupLabel": [
                              "Umbilical Cord-Derived Mesenchymal Stem Cell, then Placebo (group A)",
                              "Placebo, then Umbilical Cord-Derived Mesenchymal Stem Cell (group B)"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05345418"
                        ]
                  },
                  {
                        "Rank": 245,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Application of IMP on patients wound",
                              "Application of IMP on patients wound",
                              "Application of IMP on patients wound",
                              "Application of IMP on patients wound"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: allo-APZ2-CVU",
                              "Drug: Placebo",
                              "Biological: allo-APZ2-CVU",
                              "Biological: allo-APZ2-CVU"
                        ],
                        "ArmGroupLabel": [
                              "allo-APZ2-CVU (dose group 1: 1 x 10e6 cells/cm\u00b2)",
                              "Placebo",
                              "allo-APZ2-CVU (dose group 2: 3 x 10e6 cells/cm\u00b2)",
                              "allo-APZ2-CVU (dose group 3: 6 x 10e6 cells/cm\u00b2)"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator",
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04971161"
                        ]
                  },
                  {
                        "Rank": 246,
                        "Acronym": [
                              "PREVENT-TAHA"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "In the experimental group, 3-7 days after an acute anterior myocardial infarction treated successfully with primary percutaneous coronary intervention, 120 patients will receive a single intracoronary infusion of 10^7 umbilical cord-derived Wharton's Jelly Mesenchymal Stem Cells (WJ-MSCs) alongside conventional treatment.",
                              "In the control group, after an acute anterior myocardial infarction treated successfully with primary percutaneous coronary intervention, 120 patients will receive only conventional treatment."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Umbilical Cord-Derived Wharton's Jelly Mesenchymal Stem Cells (WJ-MSCs)",
                              "Other: Conventional Treatment",
                              "Other: Conventional Treatment"
                        ],
                        "ArmGroupLabel": [
                              "Cohort 1",
                              "Cohort 2 (Control Group)"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05043610"
                        ]
                  },
                  {
                        "Rank": 247,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Treatment consistsof Mesenchymal Stem Cells administered as a one-time, single-dose therapy via IV infusion at a dose of 1 X 10 8 cells."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Mesenchymal Stem Cells derived from Wharton Jelly of Umbilical cords"
                        ],
                        "ArmGroupLabel": [
                              "COVID-19 patients"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04456361"
                        ]
                  },
                  {
                        "Rank": 248,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [
                              "Biological: Conventional therapy",
                              "Biological: Injectable Collagen Scaffold + HUC-MSCs"
                        ],
                        "ArmGroupLabel": [
                              "Conventional therapy",
                              "Injectable Collagen Scaffold + HUC-MSCs"
                        ],
                        "ArmGroupType": [
                              "Sham Comparator",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02786017"
                        ]
                  },
                  {
                        "Rank": 249,
                        "Acronym": [
                              "MSC-AFP"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Eligible patients will be treated, single treatment group, no placebo arm"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: MSC-AFP"
                        ],
                        "ArmGroupLabel": [
                              "MSC-AFP Single Treatment Group"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03209700"
                        ]
                  },
                  {
                        "Rank": 250,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [
                              "Biological: Conventional therapy plus low dose UCMSCs treatment",
                              "Biological: Conventional therapy plus medium dose UCMSCs treatment",
                              "Biological: Conventional therapy plus high dose UCMSCs treatment"
                        ],
                        "ArmGroupLabel": [
                              "Low dose umbilical cord mesenchymal stem cells (UCMSCs)",
                              "Medium dose UCMSCs",
                              "High dose UCMSCs"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05155657"
                        ]
                  },
                  {
                        "Rank": 251,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Wharton's Jelly (WJ)-Umbilical Cord (UC) Mesenchymal Stromal Cells (ProTrans\u00ae).Study patients 1-3 will receive a single dose of 25 million cells, patients 4-6 will receive 100 million cells and patients 7-9 will receive 200 million cells."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: ProTrans\u00ae"
                        ],
                        "ArmGroupLabel": [
                              "Treatment"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04896853"
                        ]
                  },
                  {
                        "Rank": 252,
                        "Acronym": [
                              "AMI"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Dosage of intravenous route is 2 million MSCs/kg for each subject.",
                              "Dosage of intracoronary route is \u00b150 million MSCs for each subject.",
                              "Standard treatment of acute myocardia infarction"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Mesenchymal Stem Cells",
                              "Biological: Mesenchymal Stem Cells"
                        ],
                        "ArmGroupLabel": [
                              "Intravenous Group",
                              "Intracoronary Group",
                              "Control Group"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "No Intervention"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04340609"
                        ]
                  },
                  {
                        "Rank": 253,
                        "Acronym": [
                              "Merlin"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Selected Mesenchymal Stromal Cells (dose selection and efficacy) - Orbcel-C. dose selection, combination of 0.5, 1.0,2.5 million cells/kg (3 dose levels). IV single-infusion.",
                              "Selected Mesenchymal Stromal Cells (dose selection and efficacy) - Orbcel-C. dose selection, combination of 0.5, 1.0,2.5 million cells/kg (3 dose levels). IV single-infusion."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Orbcel-C",
                              "Biological: Orbcel-C"
                        ],
                        "ArmGroupLabel": [
                              "PSC patients",
                              "AiH patients"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02997878"
                        ]
                  },
                  {
                        "Rank": 254,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Participants will receive conventional treatment and then be followed until the week 72 study visit.",
                              "Participants will receive conventional treatment plus a dose of BM-MSC(each subgroups with a different dose ) and then be followed until the week 72 study visit.",
                              "Participants will receive conventional treatment plus a dose of UC-MSC(each subgroups with a different dose ) and then be followed until the week 72 study visit."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Conventional treatment",
                              "Genetic: Conventional plus BM-MSC treatment",
                              "Genetic: Conventional plus UC-MSC treatment"
                        ],
                        "ArmGroupLabel": [
                              "Conventional treatment",
                              "Conventional plus BM-MSC treatment",
                              "Conventional plus UC-MSC treatment"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01844063"
                        ]
                  },
                  {
                        "Rank": 255,
                        "Acronym": [
                              "WJ-MSC"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "RP patients with progressive visual acuity and visual field loss: before stem cell application.",
                              "RP patients, after stem cell applications."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Wharton's jelly derived mesenchymal stem cell",
                              "Biological: Wharton's jelly derived mesenchymal stem cell"
                        ],
                        "ArmGroupLabel": [
                              "Before application",
                              "After application"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04224207"
                        ]
                  },
                  {
                        "Rank": 256,
                        "Acronym": [
                              "CERES"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Three (3) subjects will be treated with a single administration of 2 x 10^7 (20 million) UCMSCs delivered via peripheral intravenous infusion.",
                              "Three (3) subjects will be treated with a single IV administration of 1 x 10^8 (100 million) UCMSCs delivered via peripheral intravenous infusion.",
                              "Three (3) subjects will be treated with a single IV administration of 2 x 10^7 (20 million) BMMSCs delivered via peripheral intravenous infusion.",
                              "Three (3) subjects will be treated with a single IV administration of 1 x 10^8 (100 million) BMMSCs delivered via peripheral intravenous infusion.",
                              "Participants randomized to receive a single administration of 1 x 10^8 (100 million) UCMSCs delivered via peripheral intravenous infusion.",
                              "Participants randomized to receive a single administration of 1 x 10^8 (100 million) BMMSC delivered via peripheral intravenous infusion.",
                              "Participants randomized to receive a single administration of placebo via peripheral intravenous infusion."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: UCMSCs",
                              "Biological: UCMSCs",
                              "Biological: BMMSCs",
                              "Biological: BMMSCs",
                              "Biological: UCMSCs",
                              "Biological: BMMSCs",
                              "Other: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "Pilot Phase: Group 1 (UCMSCs - 20 million)",
                              "Pilot Phase: Group 3 (UCMSCs - 100 million)",
                              "Pilot Phase: Group 2 (BMMSCs - 20 million)",
                              "Pilot Phase: Group 4 (BMMSCs -100 million)",
                              "Group A (UCMSCs - 100 million)",
                              "Group B (BMMSCs - 100 million)",
                              "Group C (Placebo)"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Experimental",
                              "Experimental",
                              "Experimental",
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03059355"
                        ]
                  },
                  {
                        "Rank": 257,
                        "Acronym": [],
                        "AgreementOtherDetails": [
                              "Publications (abstracts, posters or presentations) must be presented to the Publication Steering Committee for review prior to submission or public display and are not allowed prior to the publication of the primary manuscript, or eighteen (18) months from the conclusion of the Study. PI shall provide Sponsor a copy of any proposed public disclosure at least 30 days prior to submission. Sponsor may ask PI to delay the disclosure for a maximum of 60 days to file proprietary protection."
                        ],
                        "AgreementPISponsorEmployee": [
                              "No"
                        ],
                        "AgreementRestrictionType": [
                              "OTHER"
                        ],
                        "AgreementRestrictiveAgreement": [
                              "Yes"
                        ],
                        "ArmGroupDescription": [
                              "Participants were treated with intravenous (IV) remestemcel-L at a dose of 2\u00d710^6 mesenchymal stromal cells (MSCs)/kilogram (kg) actual body weight at Screening, twice per week, for each of 4 consecutive weeks (initial therapy) given at least 3 days apart and no more than 5 days apart for any infusion. Eligible participants received an additional once per week infusion, for each of 4 consecutive weeks (continued therapy) of remestemcel-L and twice per week infusions, for each of 4 consecutive weeks (aGVHD flare therapy) of remestemcel-L at the same initial therapy dose of 2\u00d710^6 MSCs/kg actual body weight at Screening."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: remestemcel-L"
                        ],
                        "ArmGroupLabel": [
                              "Remestemcel-L 2\u00d710^6 MSCs/kg"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [
                              "Female",
                              "Male",
                              "Hispanic or Latino",
                              "Not Hispanic or Latino",
                              "Unknown or Not Reported",
                              "American Indian or Alaska Native",
                              "Asian",
                              "Native Hawaiian or Other Pacific Islander",
                              "Black or African American",
                              "White",
                              "More than one race",
                              "Unknown or Not Reported"
                        ],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02336230"
                        ]
                  },
                  {
                        "Rank": 258,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "The patients with POF who underwent intraovarian injection of 5 million mesenchymal stem cells.",
                              "The patients with POF who underwent intraovarian injection of 10 million mesenchymal stem cells.",
                              "The patients with POF who underwent intraovarian injection of 15 million mesenchymal stem cells."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Intraovarian injection of Adipose derived Stromal cells (ADSCs)",
                              "Biological: Intraovarian injection of Adipose derived Stromal cells (ADSCs)",
                              "Biological: Intraovarian injection of Adipose derived Stromal cells (ADSCs)"
                        ],
                        "ArmGroupLabel": [
                              "5 million MSC",
                              "10 million MSC",
                              "15 million MSC"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02603744"
                        ]
                  },
                  {
                        "Rank": 259,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [
                              "Drug: allo-APZ2-OTS",
                              "Drug: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "Verum",
                              "Placebo"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05464381"
                        ]
                  },
                  {
                        "Rank": 260,
                        "Acronym": [
                              "EPIC/MSC/IBD"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [
                              "Biological: autologous mesenchymal stromal cell"
                        ],
                        "ArmGroupLabel": [
                              "autologous mesenchymal stromal cells"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01659762"
                        ]
                  },
                  {
                        "Rank": 261,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Participants will be given HRT plus human cord mesenchymal stem cells transplantation with a 12 menstrual Cycle follow-up.",
                              "Participants will be given HRT plus combination of hCBMNCs together with hUCMSCs transplantation with a 12 menstrual Cycle follow-up.",
                              "Participants will be given HRT plus human cord blood mononuclear cells transplantation with a 12 menstrual Cycle follow-up.",
                              "Participants will be given conventional therapy only with a 12 menstrual Cycle follow-up."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: human umbilical cord mesenchymal stem cells",
                              "Biological: hUCMSCs and hCBMNCs",
                              "Biological: human cord blood mononuclear cells",
                              "Drug: Hormone Replacement Therapy"
                        ],
                        "ArmGroupLabel": [
                              "Group1 : HRT plus hUCMSCs treatment:",
                              "Group 2: HRT plus hCBMNCs and hUCMSCs therapy",
                              "Group3 : HRT plus hCBMNCs treatment:",
                              "Group 4:Hormone Replacement Therapy"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01742533"
                        ]
                  },
                  {
                        "Rank": 262,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "participants will receive conventional treatment plus a dose of MSC from day 0 through the week 8 study visit. Participants will then be followed until the 75 months study visit.",
                              "participants will receive conventional plus placebo treatment from day 0 through the week 8 study visit. Participants will then be followed until the 75 months study visit."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: conventional plus MSC treatment",
                              "Drug: conventional plus placebo treatment"
                        ],
                        "ArmGroupLabel": [
                              "conventional plus MSC treatment",
                              "conventional plus placebo treatment"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01220492"
                        ]
                  },
                  {
                        "Rank": 263,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Selected patients with Parkinson's disease were randomly divided into a therapy group and a control group. Umbilical Cord Derived Mesenchymal Stem Cells(UC-MSCs) at a dose of 10-20 million by intravenous infusion.Patients in the therapy group treated once a week with UC-MSCs. Each course of treatment Lasted 3 weeks."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "mesenchymal stem cells"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03550183"
                        ]
                  },
                  {
                        "Rank": 264,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Ex vivo cultured human mesenchymal stem cells from Wharton jelly, in a blinded syringe (initial treatment) / Placebo (month 6)",
                              "Placebo in a blinded syringe (initial treatment) / XCEL-UMC-BETA (month 6)"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: XCEL-UMC-BETA",
                              "Drug: Placebo",
                              "Drug: XCEL-UMC-BETA",
                              "Drug: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "XCEL-UMC-BETA/placebo",
                              "Placebo/XCEL-UMC-BETA"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03003364"
                        ]
                  },
                  {
                        "Rank": 265,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Participants will receive low-dose cell administration",
                              "Participants will receive medium-dose cell administration",
                              "Participants will receive high-dose cell administration"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: MSCTC-0010",
                              "Biological: MSCTC-0010",
                              "Biological: MSCTC-0010"
                        ],
                        "ArmGroupLabel": [
                              "Low Dose MSCTC-0010",
                              "Medium Dose MSCTC-0010",
                              "High Dose MSCTC-0010"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04385056"
                        ]
                  },
                  {
                        "Rank": 266,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [],
                        "ArmGroupLabel": [],
                        "ArmGroupType": [],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03389919"
                        ]
                  },
                  {
                        "Rank": 267,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Intraarticular injection of WJMSC",
                              "Intraarticular injection of WJMSC",
                              "Intraarticular injection of WJMSC"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Intraarticular injection of WJMSC",
                              "Biological: Intraarticular injection of WJMSC",
                              "Biological: Intraarticular injection of WJMSC"
                        ],
                        "ArmGroupLabel": [
                              "osteoarthritis of the knee",
                              "osteoarthritis of the hip",
                              "osteoarthritis of the glenohumeral joint"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Active Comparator",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03866330"
                        ]
                  },
                  {
                        "Rank": 268,
                        "Acronym": [
                              "ASC COVID-19"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "100 million allogeneic adipose-derived mesenchymal stromal cell",
                              "Saline"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Stem Cell Product",
                              "Drug: Stem Cell Product"
                        ],
                        "ArmGroupLabel": [
                              "ASC",
                              "Placebo"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04341610"
                        ]
                  },
                  {
                        "Rank": 269,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "According to Diagnosis and Clinical Management of Pneumonia caused by 2019-nCoV Infection(Trial Version 4), patients enrolled will be divided to serious pneumonia group or critical pneumonia group. All subjects will receive UC-MSCs 3.3 * 107 cell number / 50ml / bag, 3 bags each time. And UC-MSCs will be infused intravenously on the 1st, 3rd, 5th, and 7th days after enrollment, 1 time each day. The efficacy and safety of the treatment, patients' adverse reactions will be monitored."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: UC-MSCs"
                        ],
                        "ArmGroupLabel": [
                              "pneumonia"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04269525"
                        ]
                  },
                  {
                        "Rank": 270,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Multipoint of Transdermal injection into the wrinkles. Injectable filler agent composed of umbilical cord mesenchymal stem cells (UCMSCs) and hyaluronic acid (HA).",
                              "Procedure: Transdermal injection of hyaluronic acid only."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: umbilical cord mesenchymal stem cells and hyaluronic acid",
                              "Drug: hyaluronic acid"
                        ],
                        "ArmGroupLabel": [
                              "UCMSCs-HA",
                              "Control"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02698813"
                        ]
                  },
                  {
                        "Rank": 271,
                        "Acronym": [
                              "MSC-CY"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Cyclophosphamide 50 mg/kg/day at +3, +4 day once daily after BMT Mesenchymal stromal cells 1*10^6/kg at day of recovery"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Cyclophosphamide",
                              "Biological: Mesenchymal stromal cells"
                        ],
                        "ArmGroupLabel": [
                              "MSC+CY"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02270307"
                        ]
                  },
                  {
                        "Rank": 272,
                        "Acronym": [
                              "CME-LEM1"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [
                              "Yes"
                        ],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Autologous bone marrow adult mesenchymal stem cells expanded in vitro. Administered by Intrathecal injection (subarachnoid and intramedullary). Depending on centromedullary post-traumatic injury: bone marrow stromal stem cells administration (MSCs) at the minimum dose of 100x106 followed by subarachnoid administration of 30x106 MSCs,3 months later"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Mesenchymal stromal cell therapy"
                        ],
                        "ArmGroupLabel": [
                              "Mesenchymal stromal cell therapy"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [
                              "Female",
                              "Male"
                        ],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01909154"
                        ]
                  },
                  {
                        "Rank": 273,
                        "Acronym": [
                              "UC-MSCs"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "This study for a six-month trials,Randomized, open, and parallel comparison before and after its own,Stage test includes screening stage, stochastic screening of more than a month difficult to heal wounds 20 people.treatment period and follow-up period.In accordance with chronic wound criteria for the patient,By producing the principle of random number,Were randomly divided into UC-MSCs Gel group or Gel group,The researchers according to the situation of wound healing time and decided to use the secondary treatment,to observe the clinical efficacy and safety.",
                              "This study for a six-month trials,Randomized, open, and parallel comparison before and after its own,Stage test includes screening stage, stochastic screening of more than a month difficult to heal wounds 20 people.treatment period and follow-up period.In accordance with chronic wound criteria for the patient,By producing the principle of random number,Were randomly divided into UC-MSCs Gel group or Gel group,The researchers according to the situation of wound healing time and decided to use the secondary treatment,to observe the clinical efficacy and safety."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: UC-MSCs Gel group",
                              "Other: Gel group"
                        ],
                        "ArmGroupLabel": [
                              "UC-MSCs Gel group",
                              "Gel group"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02685722"
                        ]
                  },
                  {
                        "Rank": 274,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Mesenchymal stromal cell"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: stem cell"
                        ],
                        "ArmGroupLabel": [
                              "Mesenchymal stromal cell"
                        ],
                        "ArmGroupType": [
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT00260338"
                        ]
                  },
                  {
                        "Rank": 275,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Participants will be given rehabilitation therapy plus human cord blood mononuclear cells transplantation with a 6 months follow-up.",
                              "Participants will be given rehabilitation therapy plus combination of hCB-MNCs together with hUC-MSCs transplantation with a 6 months follow-up."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: human cord blood mononuclear cells",
                              "Biological: human cord blood mononuclear cells and human umbilical cord mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "Rehabilitation plus hCB-MNCs treatment",
                              "Rehabilitation plus hCB-MNCs and hUC-MSCs therapy"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01343511"
                        ]
                  },
                  {
                        "Rank": 276,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "91 patients will be involved in this group",
                              "91 patients will be involved in this group"
                        ],
                        "ArmGroupInterventionName": [
                              "Other: hUC-MSCs",
                              "Other: glucocorticoids"
                        ],
                        "ArmGroupLabel": [
                              "hUC-MSCs combined with glucocorticoids group.",
                              "glucocorticoids group"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05531266"
                        ]
                  },
                  {
                        "Rank": 277,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Intravenous infusion of remestemcel-L 2x10^6 MSC/kg of body weight plus standard of care",
                              "Placebo (Plasma-Lyte) plus standard of care"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Remestemcel-L",
                              "Drug: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "Remestemcel-L Plus Standard of Care",
                              "Placebo Plus Standard of Care"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04371393"
                        ]
                  },
                  {
                        "Rank": 278,
                        "Acronym": [
                              "CIS/MSC08"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [
                              "Biological: Mesenchymal stromal cell infusion"
                        ],
                        "ArmGroupLabel": [
                              "Cell therapy"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01275612"
                        ]
                  },
                  {
                        "Rank": 279,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "15 patients will be given autologous bone marrow-derived mesenchymal stem cells (BM-MSC) and mesenchymal stem cell from allogeneic umbilical cord tissue (UC-MSC) combined with platelet-rich plasma (PRP) by intravenous infusion."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: MSC and PRP"
                        ],
                        "ArmGroupLabel": [
                              "MSC and PRP"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03484741"
                        ]
                  },
                  {
                        "Rank": 280,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "SBI-101 device containing 250 million MSCs",
                              "SBI-101 device containing 750 million MSCs",
                              "Sham device containing no MSCs"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: SBI-101",
                              "Biological: SBI-101",
                              "Device: Sham"
                        ],
                        "ArmGroupLabel": [
                              "Low dose cohort",
                              "High dose cohort",
                              "Control"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Sham Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03015623"
                        ]
                  },
                  {
                        "Rank": 281,
                        "Acronym": [
                              "NEPHSTROM"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [
                              "Biological: Mesenchymal Stromal Cells",
                              "Other: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "Bone marrow-derived Mesenchymal Stromal Cells",
                              "Cryostor CS10"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02585622"
                        ]
                  },
                  {
                        "Rank": 282,
                        "Acronym": [
                              "MSV_LE"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Participants will receive a single Intravenous infusion of Mesenchymal Stem Cells (MSV) 1.5 million cells per kg wt suspended in isotonic medium (Physiological saline solution + 1% Human Albumin + 5 mM Glucose). All participants will receive the infusion at the Baseline (Day 0) visit. All participants will continue on their standard-of-care therapy during the trial. GMP-compliant MSV will be prepared by IBGM-University of Valladolid",
                              "Participants will receive a placebo infusion that does not contain any mesenchymal stem cells. The placebo infusion will consist of physiological saline solution + 1% Human Albumin + 5 mM Glucose, which is the same vehicle used to deliver the MSCs in the experimental groups."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Mesenchymal stromal cells (MSC)",
                              "Drug: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "Mesenchymal stromal cells (MSC)",
                              "Placebo"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03673748"
                        ]
                  },
                  {
                        "Rank": 283,
                        "Acronym": [
                              "USPIO-MSC"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "USPIO labeled MSC injection"
                        ],
                        "ArmGroupInterventionName": [
                              "Combination Product: USPIO labeled MSC injection"
                        ],
                        "ArmGroupLabel": [
                              "USPIO labeled MSC injection"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03651791"
                        ]
                  },
                  {
                        "Rank": 284,
                        "Acronym": [
                              "hUC-MSC-SLE"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [
                              "Biological: Human Umbilical Cord derived MSCs",
                              "Drug: Cyclophosphamide"
                        ],
                        "ArmGroupLabel": [
                              "Human Umbilical Cord derived MSCs",
                              "Cyclophosphamide"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01539902"
                        ]
                  },
                  {
                        "Rank": 285,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "ELWB newborns who will receive intranasal exosomes",
                              "ELWB newborns who will not receive intranasal exosomes"
                        ],
                        "ArmGroupInterventionName": [
                              "Other: Exosomes derived from mesenchymal stromal cells (MSCs)"
                        ],
                        "ArmGroupLabel": [
                              "Intranasal exosomes administration",
                              "Control"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "No Intervention"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05490173"
                        ]
                  },
                  {
                        "Rank": 286,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "SBI-101 device containing 250 million MSCs",
                              "SBI-101 device containing 750 million MSCs",
                              "Case control subjects will receive only standard-of-care treatment and will be followed for the same safety assessments as active study participants."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: SBI-101",
                              "Biological: SBI-101"
                        ],
                        "ArmGroupLabel": [
                              "Low dose cohort",
                              "High dose cohort",
                              "Case controls"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "No Intervention"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04445220"
                        ]
                  },
                  {
                        "Rank": 287,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "1 x 10^6 MSCs",
                              "10 x 10^6 MSCs",
                              "50 x 10^6 MSCs"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: 1 x 10^6 MSCs",
                              "Biological: 10 x 10^6 MSCs",
                              "Biological: 50 x 10^6 MSCs"
                        ],
                        "ArmGroupLabel": [
                              "Cohort 1",
                              "Cohort 2",
                              "Cohort 3"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02351011"
                        ]
                  },
                  {
                        "Rank": 288,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [],
                        "ArmGroupLabel": [],
                        "ArmGroupType": [],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04456439"
                        ]
                  },
                  {
                        "Rank": 289,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "The treatment period consists of a single, 28-day cycle. Participants will be treated with ECP 2 to 3 times per week per the discretion of the treating physician. Participants will receive IV infusions of MSCs on days 1 (+ 2 days) and 8 (+/- 2 days). A third dose may be given on day 15 (+/- 2 days) if the principal investigator (PI) and treating physician determine the MSC infusions have benefited the participant.\n\nParticipants will be followed for up to 1 year for assessment of endpoints."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Allogeneic mesenchymal stromal cells (MSCs)",
                              "Biological: Extracorporeal photopheresis (ECP)"
                        ],
                        "ArmGroupLabel": [
                              "MSCs + ECP"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05333029"
                        ]
                  },
                  {
                        "Rank": 290,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "This group would get two doses of mesenchymal stem cell (MSCs) infusion, one day pre transplant and 30 days post transplant. These MSCs would be derived from transplant recipient's bone marrow which are cultured in GMP compliant laboratories for 4-6 weeks.",
                              "This group would get two doses of mesenchymal stem cell (MSCs) infusion, one day pre transplant and 30 days post transplant. These MSCs would be derived from transplant donor's bone marrow which are cultured in GMP compliant laboratories for 4-6 weeks.",
                              "This group would get no stem cell infusion."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Mesenchymal Stem Cells",
                              "Biological: Mesenchymal Stem Cells"
                        ],
                        "ArmGroupLabel": [
                              "Autologus Mesenchymal Stem Cells",
                              "Allogeniec Mesenchymal Stem Cells",
                              "Control without Mesenchymal Stem Cells"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator",
                              "No Intervention"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02409940"
                        ]
                  },
                  {
                        "Rank": 291,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "REDUCED INTENSITY CONDITIONING (RIC):\n\nFlu/Cy/TBI: Patients receive cyclophosphamide IV over 2 hours on day -6 and fludarabine phosphate IV on days -6 to -2 and undergo total-body irradiation on day -1.\n\nFlu/Mel: Patients receive fludarabine daily on days -5 to -2, a single dose of melphalan on day -2, and ATG on day -3 and day-2.\n\nGVHD PROPHYLAXIS: Patients receive cyclosporine PO or IV over 2 hours every 12 hours on beginning on days -5 to 100 with taper beginning on day 100 and mycophenolate mofetil IV or PO BID on days -5 to 100.\n\nTRANSPLANT: Patients undergo a co-transplantation of an intra-osseous umbilical cord blood transplantation and a mesenchymal stem cell transplantation on day 0."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: cyclophosphamide",
                              "Drug: fludarabine phosphate",
                              "Radiation: total-body irradiation",
                              "Drug: cyclosporine",
                              "Drug: mycophenolate mofetil",
                              "Procedure: umbilical cord blood transplantation",
                              "Procedure: mesenchymal stem cell transplantation"
                        ],
                        "ArmGroupLabel": [
                              "Treatment (intra-osseous UCB with hMSC co-transplant)"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02181478"
                        ]
                  },
                  {
                        "Rank": 292,
                        "Acronym": [
                              "NEC15"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "patients affected by avascular necrosis of the Hip classified by Japanese Investigation Committee criteria"
                        ],
                        "ArmGroupInterventionName": [
                              "Procedure: Core decompression procedure"
                        ],
                        "ArmGroupLabel": [
                              "Hip avascular necrosis"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04210440"
                        ]
                  },
                  {
                        "Rank": 293,
                        "Acronym": [
                              "COMET20d"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "A one time only 30-80 mL sample of bone marrow will be collected from both posterior superior iliac crests."
                        ],
                        "ArmGroupInterventionName": [
                              "Procedure: Bone Marrow Harvest"
                        ],
                        "ArmGroupLabel": [
                              "Healthy Volunteer"
                        ],
                        "ArmGroupType": [],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04397471"
                        ]
                  },
                  {
                        "Rank": 294,
                        "Acronym": [
                              "IDUNN"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Participants will receive MC0518 1-2 million cells/ kilogram infusions (based on body weight at the Screening Visit) once a week for 4 weeks (Visit Day 1, 8, 15, and 22). Participants with partial response (PR) on Day 28 will have 2 additional MC0518 infusions administered on Day 29 and 36.",
                              "Participants will receive any one of the following systemic BATs based on the Investigator's decision: mycophenolate mofetil (MMF), extracorporeal photopheresis (ECP), anti-thymocyte globulin (ATG), everolimus, and ruxolitinib (RUX)."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: MC0518",
                              "Biological: BAT"
                        ],
                        "ArmGroupLabel": [
                              "MC0518",
                              "Best Available Therapy (BAT)"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04629833"
                        ]
                  },
                  {
                        "Rank": 295,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Single administration of Autologous Adipose Derived Mesenchymal Stromal Cells into the hip by single ultrasound guided injection",
                              "Two-dose administration (2 x ultrasound guided injections) of Autologous Adipose Derived Mesenchymal Stromal Cells into the hip with one month interval between doses"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Autologous Adipose Derived Mesenchymal Stromal Cells",
                              "Drug: Autologous Adipose Derived Mesenchymal Stromal Cells"
                        ],
                        "ArmGroupLabel": [
                              "Single Injection",
                              "Two Injections"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03608579"
                        ]
                  },
                  {
                        "Rank": 296,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Intravenous bone marrow derived mesenchymal stem cells infusion from related donor to patients with severe aplastic anemia."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "Mesenchymal stem cells"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02247973"
                        ]
                  },
                  {
                        "Rank": 297,
                        "Acronym": [
                              "TACT"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [
                              "Biological: hCT-MSC infusion"
                        ],
                        "ArmGroupLabel": [
                              "hCT-MSC infusion"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04294290"
                        ]
                  },
                  {
                        "Rank": 298,
                        "Acronym": [
                              "ADIPOA-2"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Injection of Autologous adipose derived stem cells (2x106 ASC/5ml). The patient of this group will receive one single administration of the cells and will be followed for 12 months. A final follow up visit will occur at Month 24.",
                              "Injection of Autologous adipose derived stem cells (10x106 ASC/5ml). The patient of this group will receive one single administration of the cells and will be followed for 12 months. A final follow up visit will occur at Month 24.",
                              "0.5% glucose in saline with 4.5% albumin"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Injection (2x106 ASC/5ml).",
                              "Biological: Injection (10x106 ASC/5ml).",
                              "Other: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "2x106 ASC intra-articular injection",
                              "10x106 ASC intra-articular injection",
                              "Placebo"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02838069"
                        ]
                  },
                  {
                        "Rank": 299,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Subjects will undergo peripheral blood stem cell mobilisation and collection with subsequent high-dose chemotherapy. After finalization of high-dose chemotherapy subjects will receive bone marrow derived allogeneic multipotent mesenchymal stromal cells intravenous infusion two hours prior to autologous peripheral blood cells infusion."
                        ],
                        "ArmGroupInterventionName": [
                              "Procedure: Peripheral blood stem cell mobilisation and collection",
                              "Drug: High-dose chemotherapy",
                              "Drug: Bone marrow derived allogeneic MMSCs infusion",
                              "Procedure: Autologous peripheral blood stem cells infusion"
                        ],
                        "ArmGroupLabel": [
                              "allogeneic MMSCs infusion"
                        ],
                        "ArmGroupType": [
                              "Other"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02145923"
                        ]
                  },
                  {
                        "Rank": 300,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Umbilical cord mesenchymal stem cells (SCLnow 19#)",
                              "Umbilical cord mesenchymal stem cells (SCLnow 19#)",
                              "No intervention"
                        ],
                        "ArmGroupInterventionName": [
                              "Procedure: Intravenous infusion",
                              "Biological: umbilical cord mesenchymal stem cell",
                              "Procedure: Intrathecal injection",
                              "Biological: umbilical cord mesenchymal stem cell"
                        ],
                        "ArmGroupLabel": [
                              "Intravenous infusion group",
                              "Intrathecal injection group",
                              "Control groups"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "No Intervention"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03378414"
                        ]
                  },
                  {
                        "Rank": 301,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patients of acute lung injury will be treated by suspention of hUC-MSCs and albumin combined with standard therapies.",
                              "Patients of acute lung injury will be treated by vehicle (albumin) combined with standard therapies."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: human derived umbilical cord derived mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "hUC-MSCs treatment",
                              "non-cell therapy"
                        ],
                        "ArmGroupType": [
                              "Placebo Comparator",
                              "No Intervention"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04951882"
                        ]
                  },
                  {
                        "Rank": 302,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "This group of patients with complete transection of the spinal cord group will then be subdivided into 2 subgroups with of 5 patients each; the 1st subgroup will be the patients with chronic SCI and the 2nd subgroup will be for the patients with subacute SCI. All patients will receive AutoBM-MSCs by a specialized spine surgeon into the spinal medulla.",
                              "This group will then be subdivided into 2 subgroups with of 5 patients each; the 1st subgroup will be the patients with chronic SCI and the 2nd subgroup will be for the patients with subacute SCI. All patients will receive WJ-MSCs by a specialized spine surgeon into the spinal medulla."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Collection and expansion of BM-MSC",
                              "Diagnostic Test: VI-SCI evaluation and patients' follow up",
                              "Biological: Collection and expansion of BM-MSC",
                              "Diagnostic Test: VI-SCI evaluation and patients' follow up"
                        ],
                        "ArmGroupLabel": [
                              "patients with complete transection of the spinal cord",
                              "patients with SCI without total transaction."
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04288934"
                        ]
                  },
                  {
                        "Rank": 303,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "The group of patients receive allogeneic MSCs therapies."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Mesenchymal Stem Cells(MSCs)"
                        ],
                        "ArmGroupLabel": [
                              "The MSCs group"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02706132"
                        ]
                  },
                  {
                        "Rank": 304,
                        "Acronym": [
                              "MSC-AFP"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Only 1 arm: treatment with MSC-AFP"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: MSC-AFP"
                        ],
                        "ArmGroupLabel": [
                              "1"
                        ],
                        "ArmGroupType": [
                              "Other"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01915927"
                        ]
                  },
                  {
                        "Rank": 305,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "once intracavernous injection of 15,000,000 Human Umbilical Cord Mesenchymal Stem Cells",
                              "once intracavernous injection of collagen scaffolds loaded with 15,000,000 Human Umbilical Cord Mesenchymal Stem Cells"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: HUCMSC injection",
                              "Biological: collagen scaffolds/HUCMSC injection"
                        ],
                        "ArmGroupLabel": [
                              "HUCMSC injection",
                              "collagen scaffolds/HUCMSC injection"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02579148"
                        ]
                  },
                  {
                        "Rank": 306,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [
                              "Biological: HUC-MSCs Transplantation",
                              "Biological: HUC-MSCs with Injectable Collagen Scaffold Transplantation"
                        ],
                        "ArmGroupLabel": [
                              "HUC-MSCs Transplantation",
                              "HUC-MSCs with Injectable Collagen Scaffold Transplantation"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02644447"
                        ]
                  },
                  {
                        "Rank": 307,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Trophic factors from umbilical cord mesenchymal stem cells administered intra-nasally"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Trophic factors from umbilical cord mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "Intra-nasal infusion of MTF"
                        ],
                        "ArmGroupType": [
                              "Other"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02192736"
                        ]
                  },
                  {
                        "Rank": 308,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [],
                        "ArmGroupLabel": [],
                        "ArmGroupType": [],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02829216"
                        ]
                  },
                  {
                        "Rank": 309,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Intracavernous injection of 15 million HUC-MSCs.",
                              "Intracavernous injection of injectable collagen scaffold combined with 15 million HUC-MSCs."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: HUC-MSCs",
                              "Biological: Injectable Collagen Scaffold + HUC-MSCs"
                        ],
                        "ArmGroupLabel": [
                              "HUC-MSCs",
                              "Injectable Collagen Scaffold + HUC-MSCs"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02745808"
                        ]
                  },
                  {
                        "Rank": 310,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "The dosage of the intravenous route is 100 million MSCs for each subject."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Allogeneic Umbilical Cord Mesenchymal Stem Cell"
                        ],
                        "ArmGroupLabel": [
                              "intravenous injection of UC-MSC"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04357600"
                        ]
                  },
                  {
                        "Rank": 311,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Trophic factors from umbilical cord mesenchymal stem cells administered intra-articularly.",
                              "Trophic factors from umbilical cord mesenchymal stem cells administered subcutaneously once per week for 12 weeks."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Trophic factors from umbilical cord mesenchymal stem cells",
                              "Biological: Trophic factors from umbilical cord mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "Intra-articular knee injection of MTF",
                              "Subcutaneous injection of MTF"
                        ],
                        "ArmGroupType": [
                              "Other",
                              "Other"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02003131"
                        ]
                  },
                  {
                        "Rank": 312,
                        "Acronym": [
                              "ACCeNT-CP"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [
                              "Yes"
                        ],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Subjects will receive a single intravenous infusion of a maximum of 10x107/kg allogeneic umbilical cord blood (CB) cells",
                              "Subjects will receive three intravenous infusions of 2x106/kg human umbilical cord tissue cells (hCT-MSC), manufactured from allogeneic umbilical cord donors",
                              "Subjects will not receive any study product infusion until after the 12 month assessment. At the 12 month visit, they will receive an infusion of allogeneic umbilical cord blood cells so that all study participants will receive some type of cellular therapy."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Infusion of allogeneic umbilical cord blood",
                              "Biological: Infusion of MSCs",
                              "Biological: Infusion of allogeneic umbilical cord blood"
                        ],
                        "ArmGroupLabel": [
                              "Allogeneic Umbilical Cord Blood",
                              "Cord Tissue Mesenchymal Stromal Cells",
                              "Natural History"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [
                              "Female",
                              "Male",
                              "Hispanic or Latino",
                              "Not Hispanic or Latino",
                              "Unknown or Not Reported"
                        ],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03473301"
                        ]
                  },
                  {
                        "Rank": 313,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "BX-U001 (hUC-MSC suspension) will be tested at dose of 0.75 or 1.5\u00d710^6 cells/kg of body weight via a single IV infusion using a blood transfusion kit.",
                              "The control arm will be given placebo which contains the same cell suspension solution but without cells. Placebo will be given the same way as BX-U001 via a single IV infusion using a blood transfusion kit."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: hUC-MSC suspension",
                              "Biological: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "hUC-MSC treatment",
                              "Placebo control"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03828344"
                        ]
                  },
                  {
                        "Rank": 314,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Blood samples were collected from 100 control with normal pregnancies. Thirty fresh umbilical cord samples of women with healthy pregnancies (n=15) were retrieved during caesarean deliveries and umibilical cord mesenchymal stem cells (UCMSCs) were isolated from Wharton jelly.",
                              "Blood samples were collected from 100 patients with PE. Thirty fresh umbilical cord samples of PE patients (n=15) were retrieved during caesarean deliveries and UCMSCs were isolated from Wharton jelly."
                        ],
                        "ArmGroupInterventionName": [],
                        "ArmGroupLabel": [
                              "Control group",
                              "Preeclampsia group"
                        ],
                        "ArmGroupType": [],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03562715"
                        ]
                  },
                  {
                        "Rank": 315,
                        "Acronym": [
                              "Magnovision"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "WJ-MSC was applied first to the patients after necessary preparations. rEMS application was started 10 days after WJ-MSC application.",
                              "rEMS applications were repeated 10 times with a 1-week interval.",
                              "WJ-MSC was applied only one time for both eyes."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Wharton jelly derived mesenchymal stem cell",
                              "Device: Repetitive electromagnetic stimulation",
                              "Device: Repetitive electromagnetic stimulation",
                              "Biological: Wharton jelly derived mesenchymal stem cell"
                        ],
                        "ArmGroupLabel": [
                              "WJ-MSC combine witf rEMS",
                              "Only rEMS",
                              "Only WJ-MSC"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Active Comparator",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04877067"
                        ]
                  },
                  {
                        "Rank": 316,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "WJ MSC 50*10e6, two doses plus standard treatment with hydroxychloroquine + Lopinavir/Ritonavir or Azithromycin and ventilation support.",
                              "Hydroxychloroquine, lopinavir/ritonavir and ventilation support plus placebo"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Wharton's jelly derived Mesenchymal stem cells.",
                              "Drug: Hydroxychloroquine, lopinavir/ritonavir or azithromycin and placebo (standard therapy)"
                        ],
                        "ArmGroupLabel": [
                              "Mesenchymal stem cell",
                              "Control group"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04390152"
                        ]
                  },
                  {
                        "Rank": 317,
                        "Acronym": [
                              "AIMs"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "A single, intravenous infusion of hCT-MSCs. Targeted dose is 2x10^6 cells/kg with a maximum dose of 10 x 10^7 cells/kg."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: hCT-MSC"
                        ],
                        "ArmGroupLabel": [
                              "hCT-MSC infusion"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04484077"
                        ]
                  },
                  {
                        "Rank": 318,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "0.9% physiological saline",
                              "Low dose allogeneic mesenchymal stem cells derived from adipose tissue",
                              "High dose allogeneic mesenchymal stem cells derived from adipose tissue"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Placebos",
                              "Drug: Low dose allogeneic mesenchymal stromal cells",
                              "Drug: High dose allogeneic mesenchymal stromal cells"
                        ],
                        "ArmGroupLabel": [
                              "Control arm",
                              "Low dose treatment arm",
                              "High dose treatment arm"
                        ],
                        "ArmGroupType": [
                              "Placebo Comparator",
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04466007"
                        ]
                  },
                  {
                        "Rank": 319,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [
                              "Biological: Umbilical Cord Mesenchymal Stem Cell"
                        ],
                        "ArmGroupLabel": [
                              "Umbilical Cord Mesenchymal Stem Cell"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02285673"
                        ]
                  },
                  {
                        "Rank": 320,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Mesenchymal Stem Cells : through peripheral intravenous slowly, every time 6*10^7 (30ml) Other medication of Treatment Group: before the30min of first time to inject stem cells, Intravenous methylprednisone 20mg. All patients require oral nucleoside drugs resistant hepatitis B virus treatment.Use stem cell therapy, by Peripheral iv, 6 * 10 ^ 7 (30 ml)",
                              "Control Group: Using basic contrast ."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Peripheral iv"
                        ],
                        "ArmGroupLabel": [
                              "Treatment Group",
                              "Control Group"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "No Intervention"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03826433"
                        ]
                  },
                  {
                        "Rank": 321,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "The patients with nonunion fracture who underwent percutaneous implantation of bone marrow derived mesenchymal stem cells in combination with platelet lysate product.",
                              "The patients with nonunion fracture who underwent percutaneous injection of placebo."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Percutaneous injection",
                              "Other: Percutaneous injection"
                        ],
                        "ArmGroupLabel": [
                              "MSC recipients",
                              "Placebo"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02448849"
                        ]
                  },
                  {
                        "Rank": 322,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "2.5 x 10^6 MSC per kg will be infused intravenously on Day 1",
                              "Plasmalyte with 0.5% Human Serum Albumin will be infused intravenously on Day 1"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Mesenchymal Stem Cells (MSCs)",
                              "Other: Placebo Infusion (Plasmalyte A with 0.5% human serum albumin)"
                        ],
                        "ArmGroupLabel": [
                              "Group A Treatment",
                              "Group B Placebo"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04061746"
                        ]
                  },
                  {
                        "Rank": 323,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Adipose mesenchymal cells with bone marrow mononuclear cells.\n\nTwo doses with a 6 month interval of allogenic Adipose mesenchymal cells +1 mil/kg of autologous bone marrow mononuclear cells will be injected intravenously.",
                              "Adipose mesenchymal cells with bone marrow mononuclear cells.\n\nTwo doses with a 6 month interval of allogenic Adipose mesenchymal cells +10 mil/kg of autologous bone marrow mononuclear cells will be injected intravenously."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Adipose mesenchymal cells with bone marrow mononuclear cells",
                              "Biological: Adipose mesenchymal cells with bone marrow mononuclear cells"
                        ],
                        "ArmGroupLabel": [
                              "Dose 1 mil/kg",
                              "Dose 10 mil/kg"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02940418"
                        ]
                  },
                  {
                        "Rank": 324,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patients receive allogeneic hMSCs IV over 10-20 minutes once weekly for 4 weeks and standard of care drugs for heart failure.",
                              "Patients receive only standard of care drugs for heart failure."
                        ],
                        "ArmGroupInterventionName": [
                              "Other: Laboratory Biomarker Analysis",
                              "Other: Standard of Care",
                              "Drug: Mesenchymal Stem Cell Transplantation",
                              "Other: Laboratory Biomarker Analysis",
                              "Other: Standard of Care",
                              "Drug: Mesenchymal Stem Cell Transplantation"
                        ],
                        "ArmGroupLabel": [
                              "Arm I (hMSCs)",
                              "Arm II (standard of care drugs)"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02408432"
                        ]
                  },
                  {
                        "Rank": 325,
                        "Acronym": [
                              "PASSIoN"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "All (near-)term newborns \u226536 weeks of gestation with or without clinical symptoms of PAIS but with a magnetic resonance imaging (MRI) confirmed PAIS (in the Middle Cerebral Artery region) will be eligible for this study. Following written parental consent, 10 patients will be included in our study."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Mesenchymal Stem Cells"
                        ],
                        "ArmGroupLabel": [
                              "Mesenchymal Stem Cells"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03356821"
                        ]
                  },
                  {
                        "Rank": 326,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Participants will receive high dose of MSC from Day 0 through the Week 48 study visit. Participants will then be followed until the Week 48 study visit.",
                              "Participants will receive a low dose of MSC treatment from Day 0 through the Week 48 study visit, and then follow-ed up for additional 48 weeks.",
                              "Participants will receive a saline placebo treatment from Day 0 through the Week 48 study visit, and then follow-ed up for additional 48 weeks."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: high dose of MSC",
                              "Drug: low dose of MSC treatment"
                        ],
                        "ArmGroupLabel": [
                              "Drug: high dose of MSC treatment",
                              "low dose of MSC treatment",
                              "low dose of MSC"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01213186"
                        ]
                  },
                  {
                        "Rank": 327,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "The patients with CKD who underwent intravenous injection of MSC."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Intravenous injection"
                        ],
                        "ArmGroupLabel": [
                              "MSC recipient"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02195323"
                        ]
                  },
                  {
                        "Rank": 328,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Eligible subjects will receive a single infusion of hUC-MCS product at the dose of 0.5 million cells/kg in addition to standard of care treatment.",
                              "Eligible subjects will receive a single infusion of hUC-MCS product at the dose of 1 million cells/kg in addition to standard of care treatment.",
                              "Eligible subjects will receive a single infusion of hUC-MCS product at the dose of 1.5 million cells/kg in addition to standard of care treatment.",
                              "Eligible subjects will receive a single infusion of hUC-MCS product at the selected dose from phase 1 in addition to standard of care treatment.",
                              "Eligible subjects will receive a single infusion of placebo control and standard of care treatment."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Human umbilical cord mesenchymal stem cells + best supportive care",
                              "Biological: Human umbilical cord mesenchymal stem cells + best supportive care",
                              "Biological: Human umbilical cord mesenchymal stem cells + best supportive care",
                              "Biological: Human umbilical cord mesenchymal stem cells + best supportive care",
                              "Other: Placebo control + best supportive care"
                        ],
                        "ArmGroupLabel": [
                              "Phase 1 Low-dose Group",
                              "Phase 1 Middle-dose Group",
                              "Phase 1 High-dose Group",
                              "Phase 2a Treatment Group",
                              "Phase 2a Control Group"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Experimental",
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04452097"
                        ]
                  },
                  {
                        "Rank": 329,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "One intrathecal injection of Hematopoietic stem cells and Mesenchymal stem cells derived from allogenic umbilical cord for each group of 36 cases of spastic CP and neurorehabilitation during the 12 months of follow up of clinical evaluation of developmental functions and spasticity",
                              "Comparison of effects of intrathecal injection of MNC and MSC on improvement of developmental functions and spasticity of CP patients"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: MNC",
                              "Biological: MSC",
                              "Procedure: Control",
                              "Biological: MNC",
                              "Biological: MSC"
                        ],
                        "ArmGroupLabel": [
                              "MNC & MSC with Control",
                              "MNC & MSC"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03795974"
                        ]
                  },
                  {
                        "Rank": 330,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "single arm, pneumostem treated infants"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: pneumostem"
                        ],
                        "ArmGroupLabel": [
                              "pneumostem group"
                        ],
                        "ArmGroupType": [
                              "Other"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02274428"
                        ]
                  },
                  {
                        "Rank": 331,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "The patients with FSGS who underwent intravenous injection of AD-MSC."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Intravenous injection"
                        ],
                        "ArmGroupLabel": [
                              "AD-MSC"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02382874"
                        ]
                  },
                  {
                        "Rank": 332,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Adult ex-vivo expanded mesenchymal stromal cells from allogeneic bone marrow, cryopreserved, to combine with fibrin glue and cancellous human bone tissue + endomedullary nailing",
                              "Standard surgical treatment with isolated endomedullary nailing"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: XCEL-MT-OSTEO-BETA",
                              "Procedure: Surgical treatment",
                              "Procedure: Surgical treatment"
                        ],
                        "ArmGroupLabel": [
                              "XCEL-MT-OSTEO-BETA",
                              "Standard treatment"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Other"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02630836"
                        ]
                  },
                  {
                        "Rank": 333,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "2 x 10E6 ASC intra-articular injection (5 ml)",
                              "10 x 10E6 ASC intra-articular injection (5 ml)",
                              "50 x 10E6 ASC intra-articular injection (5 ml)"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Autologous adipose derived stem cells administrated for intra-articular use",
                              "Biological: Autologous adipose derived stem cells administrated for intra-articular use",
                              "Biological: Autologous adipose derived stem cells administrated for intra-articular use"
                        ],
                        "ArmGroupLabel": [
                              "Group 1",
                              "Group 2",
                              "Group 3"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01585857"
                        ]
                  },
                  {
                        "Rank": 334,
                        "Acronym": [
                              "CISS2"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Intravenous infusion of 300 million Allogeneic, Bone Marrow-Derived Human Mesenchymal Stromal Cells",
                              "Intravenous infusion of Placebo, with excipients"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells",
                              "Other: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "Mesenchymal Stromal Cells (MSCs)",
                              "Placebo"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03369275"
                        ]
                  },
                  {
                        "Rank": 335,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patients receive no interventions after rectal cancer treatment.",
                              "Patients receive NeuroRegen scaffold transplantation after rectal cancer treatment.",
                              "Patients receive autologous bone marrow mononuclear cells with NeuroRegen scaffold transplantation after rectal cancer treatment.",
                              "Patients receive allogeneic human umbilical cord mesenchymal stem cells with NeuroRegen scaffold transplantation after rectal cancer treatment."
                        ],
                        "ArmGroupInterventionName": [
                              "Procedure: Laparoscopic surgery",
                              "Device: NeuroRegen scaffold transplantation",
                              "Biological: NeuroRegen scaffold/BMMCs transplantation",
                              "Biological: NeuroRegen scaffold/HUC-MSCs transplantation"
                        ],
                        "ArmGroupLabel": [
                              "Laparoscopic surgery",
                              "NeuroRegen scaffold transplantation",
                              "NeuroRegen scaffold/BMMCs transplantation",
                              "NeuroRegen scaffold/HUC-MSCs transplantation"
                        ],
                        "ArmGroupType": [
                              "Sham Comparator",
                              "Experimental",
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02648386"
                        ]
                  },
                  {
                        "Rank": 336,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "The volunteers of the experimental group will be given peripheral intravenously a dose of 0.75*10^6/ kg human umbilical cord mesenchymal stem cells at 0,1,5,6 week.",
                              "The control group will be given the same dose of saline containing human albumin."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Umbilical Cord Mesenchymal Stem Cells",
                              "Biological: saline"
                        ],
                        "ArmGroupLabel": [
                              "experimental group",
                              "control group"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04441658"
                        ]
                  },
                  {
                        "Rank": 337,
                        "Acronym": [
                              "hCT-MSCs"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Subjects 1-3 will receive a single infusion of hCT-MSCs.",
                              "Subjects 4-6 will receive two infusions of hCT-MSCs.",
                              "Subjects 6-12 will receive three infusions of hCT-MSCs."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: hCT-MSC infusion",
                              "Biological: hCT-MSC infusion",
                              "Biological: hCT-MSC infusion"
                        ],
                        "ArmGroupLabel": [
                              "Single hCT-MSC infusion",
                              "Two hCT-MSC infusions",
                              "Three hCT-MSC infusions"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03099239"
                        ]
                  },
                  {
                        "Rank": 338,
                        "Acronym": [
                              "HELP"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "All patients will receive HMB002 infusion into the peritoneal cavity."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: HMB002"
                        ],
                        "ArmGroupLabel": [
                              "HMB002"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05491135"
                        ]
                  },
                  {
                        "Rank": 339,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patients receive hMSCs IV over 10-20 minutes on days 1, 14, 21, and 28 and standard of care treatment for heart failure in the absence of disease progression or unacceptable toxicity.",
                              "Patients receive hMSCs transendocardially for a total of 15 injections and standard of care treatment for heart failure in the absence of disease progression or unacceptable toxicity.",
                              "Patients receive standard of care treatment for heart failure."
                        ],
                        "ArmGroupInterventionName": [
                              "Other: Best Practice",
                              "Other: Laboratory Biomarker Analysis",
                              "Drug: Mesenchymal Stem Cell Transplantation",
                              "Other: Best Practice",
                              "Other: Laboratory Biomarker Analysis",
                              "Drug: Mesenchymal Stem Cell Transplantation",
                              "Other: Best Practice",
                              "Other: Laboratory Biomarker Analysis"
                        ],
                        "ArmGroupLabel": [
                              "Arm I (hMSCs IV)",
                              "Arm II (hMSCs transendocardially)",
                              "Arm III (standard of care)"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02962661"
                        ]
                  },
                  {
                        "Rank": 340,
                        "Acronym": [
                              "ADSCs-BWs"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "The patients receive ALLO-ADSCs. Biological is applied by surface application over perforated (1:3) autologous skin graft following the covering with hypoadhesive bandage. This procedure is carried out twice - once simultaneously with a skin grafting procedure and 2-3 days following autodermoplasty, while bandaging",
                              "All patients will be subjected to standard stepped treatment of burn wounds:\n\nInfusion therapy aimed to eliminate disorders of homeostasis during burn shock and burn toxemia;\nSystemic antibiotic therapy for preventing infectious complications;\nAdequate analgesia and sedation;\nDecompression necrotomy in the first 24 hours following the burn trauma;\nNecrectomy simultaneously with imposition of lyophilized xenografts performed in the first 1-5 days after applying burn;\nAutologous skin grafting 3-5 days after performed xenografts with the perforation coefficient 1:3"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: ALLO-ASCs"
                        ],
                        "ArmGroupLabel": [
                              "ALLO-ASCs",
                              "The standard treatment"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "No Intervention"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03113747"
                        ]
                  },
                  {
                        "Rank": 341,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "The patients with ultra filtration failure (UFF) underwent AD-MSC injection.",
                              "The patients with ultra filtration failure (UFF) underwent Placebo injection."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Intravenous injection",
                              "Biological: Intravenous injection"
                        ],
                        "ArmGroupLabel": [
                              "AD-MSC",
                              "Placebo"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02801890"
                        ]
                  },
                  {
                        "Rank": 342,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Salivary sample collection, quality of life survey, salivary gland imaging, bone marrow aspiration"
                        ],
                        "ArmGroupInterventionName": [
                              "Procedure: Bone Marrow Aspiration",
                              "Diagnostic Test: Ultrasound Imaging of Salivary Glands",
                              "Other: Salivary Assay",
                              "Other: Quality of Life Instruments"
                        ],
                        "ArmGroupLabel": [
                              "Participants with Xerostomia"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04007081"
                        ]
                  },
                  {
                        "Rank": 343,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "low dose hUMSCs or high dose hUMSCs",
                              "best dose of hUMSCs (from cohort 1) or placebo"
                        ],
                        "ArmGroupInterventionName": [
                              "Procedure: stereotactic surgery",
                              "Biological: hUMSCs",
                              "Procedure: stereotactic surgery",
                              "Biological: hUMSCs",
                              "Biological: placebo"
                        ],
                        "ArmGroupLabel": [
                              "Cohort 1",
                              "Cohort 2"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04074408"
                        ]
                  },
                  {
                        "Rank": 344,
                        "Acronym": [
                              "STREAMS"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "1-2 x106 MSCs/kg administered at Week 0",
                              "Suspension media administered at Week 0"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Mesenchymal stem cells",
                              "Drug: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "mesenchymal stem cells",
                              "Placebo"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Sham Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01606215"
                        ]
                  },
                  {
                        "Rank": 345,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "UMSC01 cells mixed with normal saline will be administered to patients after the onset of heart attack."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Allogeneic umbilical cord mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "UMSC01"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04056819"
                        ]
                  },
                  {
                        "Rank": 346,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "The patient will receive multiple injections in one session during the study. The injections will take place in the chronic wound bed and in the third distal part of the treated shin (in the form of a ring).\n\nMaximal amount of ABMD-MSC cells injected: 10-20*10^6 cells (up to volume of 20mL, depending on the wound size & patient weight)."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: ABMD-MSC"
                        ],
                        "ArmGroupLabel": [
                              "ABDM-MSC"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01686139"
                        ]
                  },
                  {
                        "Rank": 347,
                        "Acronym": [
                              "MSC"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Under sterile conditions, the patient will be locally anesthetized in the affected tooth area; the root canal of the affected tooth will be exposed and prepared to perform the MSC / MSC-Endo / PRP implant. At the same time, the culture medium supernatant is removed from each tube and the MSC / MSC-Endo \"button (pellet)\" is resuspended in autologous platelet-rich plasma (PRP). Subsequently to the MSC / MSC-Endo / PRP suspension, 5% CaCl2 and thrombin will be added. Immediately, and before the clot forms, 20 microliters of the MSC / MSC-Endo / PRP suspension will be placed in the root canal, covered with a collagen membrane. Subsequently, the obturation procedure with bioceramics will be carried out at the level of the pulp chamber, ionomeric glass to protect the bioceramic and later composite resin to restore the tooth."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Allogenic transplant of BM-MSC in a root canal from patients with immature apexes and pulpar necrosis and apical periodontitis"
                        ],
                        "ArmGroupLabel": [
                              "Allogenic transplant of BM-MSCs"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04545307"
                        ]
                  },
                  {
                        "Rank": 348,
                        "Acronym": [
                              "AMSC_UC"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "interventions: The MSCs of 5\u00d710*7 will be given in different sites within colonic submucosa at a total 100 ml with the use of the colonoscope. Once every week\uff0ca total of two times. Conventional drug therapy (5-amino-salicylic acid or glucocorticoid) is used",
                              "interventions:Conventional drug therapy (5-amino-salicylic acid or glucocorticoid) is used"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Adipose-cord mesenchymal stromal cells (A-MSCs)",
                              "Other: Conventional drugs",
                              "Other: Conventional drugs"
                        ],
                        "ArmGroupLabel": [
                              "Intervention group",
                              "Control group"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Other"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03609905"
                        ]
                  },
                  {
                        "Rank": 349,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Mesenchymal Stem Cells (MSCs) 1 x 10^6 cells/kg in Plasma-Lyte A solution",
                              "Mesenchymal Stem Cells MSCs 5 x 10^6 cells/kg in Plasma-Lyte A solution",
                              "Placebo Infusion (Plasma-Lyte A solution only)"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Low Dose Mesenchymal Stem Cells (MSCs)",
                              "Drug: High Dose Mesenchymal Stem Cells (MSCs)",
                              "Drug: Placebo Infusion"
                        ],
                        "ArmGroupLabel": [
                              "Low Dose Mesenchymal Stem Cells (MSCs)",
                              "High Dose Mesenchymal Stem Cells (MSCs)",
                              "Plasma Lyte A Solution"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02633163"
                        ]
                  },
                  {
                        "Rank": 350,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Mesenchymal stem cell will be given to preterm infants with BPD.",
                              "Mesenchymal stem cell will be not given to preterm infants with BPD."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Transplantation of mesenchymal stem cell",
                              "Drug: No transplantation of mesenchymal stem cell"
                        ],
                        "ArmGroupLabel": [
                              "Transplantation of Mesenchymal Stem Cell",
                              "No Transplantation of Mesenchymal Stem Cell"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03558334"
                        ]
                  },
                  {
                        "Rank": 351,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Mesenchymal stem cell will be given to participants with moderate and severe bronchopulmonary dysplasia.",
                              "Mesenchymal stem cell will be not given to participants with moderate and severe bronchopulmonary dysplasia."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Transplantation of mesenchymal stem cell",
                              "Drug: No Transplantation of Mesenchymal Stem Cell"
                        ],
                        "ArmGroupLabel": [
                              "Transplantation of Mesenchymal Stem Cell",
                              "No Transplantation of Mesenchymal Stem Cell"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03601416"
                        ]
                  },
                  {
                        "Rank": 352,
                        "Acronym": [
                              "LC"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "only apply for conventional medical therapy without any cell therapy",
                              "combination of conventional therapy with umbilical mesenchymal stem cells intravenous injection, (4x107/40ml, once per three months, four times in one year)"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Conventional therapy",
                              "Biological: mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "Conventional therapy",
                              "mesenchymal stem cells"
                        ],
                        "ArmGroupType": [
                              "Sham Comparator",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01573923"
                        ]
                  },
                  {
                        "Rank": 353,
                        "Acronym": [
                              "MSCIMS"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [
                              "Procedure: MSC Treatment"
                        ],
                        "ArmGroupLabel": [
                              "MSC Treatment"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT00395200"
                        ]
                  },
                  {
                        "Rank": 354,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "UMSC01 cells mixed with normal saline will be administered to patients after the onset of stroke."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: UMSC01"
                        ],
                        "ArmGroupLabel": [
                              "UMSC01"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04434768"
                        ]
                  },
                  {
                        "Rank": 355,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [
                              "Biological: Umbilical cord mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "Umbilical cord mesenchymal stem cells"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02034188"
                        ]
                  },
                  {
                        "Rank": 356,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [
                              "Biological: Autologous mesenchymal stem cells",
                              "Biological: Autologous mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "Early treatment with mesenchymal stem cells",
                              "Delayed treatment with mesenchymal stem cells"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01730547"
                        ]
                  },
                  {
                        "Rank": 357,
                        "Acronym": [
                              "MSCGVHD"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [],
                        "ArmGroupLabel": [],
                        "ArmGroupType": [],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT00749164"
                        ]
                  },
                  {
                        "Rank": 358,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Placenta Derived Mesenchymal Stem Cell administered into the knee joint once",
                              "Sodium hyaluronate administered into the knee joint once"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Placenta Derived Mesenchymal Stem Cell",
                              "Drug: Sodium Hyaluronate"
                        ],
                        "ArmGroupLabel": [
                              "Placenta Derived Mesenchymal Stem Cell",
                              "sodium hyaluronate"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03028428"
                        ]
                  },
                  {
                        "Rank": 359,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Participants will receive a single IV infusion of Mesenchymal Stem Cells (MSCs) 1 x 10^6 cells/kg in Plasma-Lyte A solution. All participants will receive the infusion at the Baseline (Day 0) visit. All participants will continue on their standard-of-care therapy during the trial."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Low Dose Mesenchymal Stem Cells (MSCs)"
                        ],
                        "ArmGroupLabel": [
                              "Drug: Low Dose Mesenchymal Stem Cells ( MSCs)"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03171194"
                        ]
                  },
                  {
                        "Rank": 360,
                        "Acronym": [
                              "UMSC01"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "UMSC01 cells mixed with normal saline will be administered to patients after COVID-19 infection.",
                              "Normal saline will be administered to patients after COVID-19 infection."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Allogeneic umbilical cord mesenchymal stem cells",
                              "Biological: Controlled normal saline"
                        ],
                        "ArmGroupLabel": [
                              "UMSC01",
                              "Placebo"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05501418"
                        ]
                  },
                  {
                        "Rank": 361,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Routine rehabilitation treatment for chronic spinal cord injury and Intravenous injection of 100 mL 0.9% saline solution.",
                              "intravenous administration of 100 mL of cell suspension containing 5\u00d7107 hUC-MSCs",
                              "lumbar administration of a solution prepared by 5 mL of cell suspension containing 5\u00d7107 hUC-MSCs and 5 mL of cerebrospinal fluid",
                              "hUC-MSCs (100,000 cells/\u03bcL) were injected via 4 points in the edge of injured spinal cord (2 points in the upper edge and 2 points in the lower edge), 16 \u03bcL hUC-MSCs/point.",
                              "intravenous administration of 100 mL of cell suspension containing 5\u00d7107 hUCB-MSCs",
                              "lumbar administration of a solution prepared by 5 mL of cell suspension containing 5\u00d7107 hUCB-MSCs and 5 mL of cerebrospinal fluid",
                              "hUCB-MSCs (100,000 cells/\u03bcL) were injected via 4 points in the edge of injured spinal cord (2 points in the upper edge and 2 points in the lower edge), 16 \u03bcL hUCB-MSCs/point."
                        ],
                        "ArmGroupInterventionName": [
                              "Other: Stem cell transplantation",
                              "Other: Stem cell transplantation",
                              "Other: Stem cell transplantation",
                              "Other: Stem cell transplantation",
                              "Other: Stem cell transplantation",
                              "Other: Stem cell transplantation",
                              "Other: Stem cell transplantation"
                        ],
                        "ArmGroupLabel": [
                              "Rehabilitation control group",
                              "hUC-MSCs intravenous administration group",
                              "hUC-MSCs lumbar administration group",
                              "hUC-MSCs local administration group",
                              "hUCB-MSCs intravenous administration group",
                              "hUCB-MSCs lumbar administration group",
                              "hUCB-MSCs local administration group"
                        ],
                        "ArmGroupType": [
                              "Other",
                              "Experimental",
                              "Experimental",
                              "Experimental",
                              "Experimental",
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04213131"
                        ]
                  },
                  {
                        "Rank": 362,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "1 million umbilical Cord Mesenchymal Stem Cells per body kg will transplant via the intravenous at baseline, and the second transplantation will be performed 1 week after the first transplantation"
                        ],
                        "ArmGroupInterventionName": [
                              "Combination Product: stem cell transplantation"
                        ],
                        "ArmGroupLabel": [
                              "Stem cell transplantation"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04062136"
                        ]
                  },
                  {
                        "Rank": 363,
                        "Acronym": [
                              "CIRCA-19 RCT"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "3 daily doses of up to 90-million cells/unit dose (cumulative dose of up to 270 million UC-MSCs)",
                              "3 daily doses of up to 90-million cells/unit dose (cumulative dose of up to 270 million UC-MSCs)"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: UC-MSCs",
                              "Biological: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "MSCs Arm",
                              "Placebo Arm"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04865107"
                        ]
                  },
                  {
                        "Rank": 364,
                        "Acronym": [
                              "ALSTEM"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "It is planned that IMP administration will be performed three times for each enrolled patient. IMP administration could be performed only if the patients does not have any contraindications for lumbar puncture."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Mesenchymal stem cells isolated from Wharton's jelly"
                        ],
                        "ArmGroupLabel": [
                              "Treatment arm"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04651855"
                        ]
                  },
                  {
                        "Rank": 365,
                        "Acronym": [
                              "UMSC01"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "UMSC01 cells mixed with normal saline will be administered to patients after the onset of diagnosis of multiple sclerosis.",
                              "For IV administration, normal saline will be administered to patients after the onset of diagnosis of multiple sclerosis. For IT administration, sham puncture procedure will partially penetrate without reaching subarachnoid space, and no spinal fluid will be drawn."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Allogeneic umbilical cord mesenchymal stem cells",
                              "Biological: Control group"
                        ],
                        "ArmGroupLabel": [
                              "UMSC01",
                              "Placebo"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Sham Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05532943"
                        ]
                  },
                  {
                        "Rank": 366,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "A qualified enrolled donor will have an aspirate bone marrow draw."
                        ],
                        "ArmGroupInterventionName": [
                              "Procedure: Bone marrow aspirate"
                        ],
                        "ArmGroupLabel": [
                              "Bone Marrow Aspirate"
                        ],
                        "ArmGroupType": [
                              "Other"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01463475"
                        ]
                  },
                  {
                        "Rank": 367,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Intravenous autologous bone marrow derived mesenchymal stem cells infusion to patients with Parkinson's disease."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: bone marrow derived mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "MSC"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01446614"
                        ]
                  },
                  {
                        "Rank": 368,
                        "Acronym": [
                              "MSC"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Intravenous combined with intrathecal administration of autologous bone marrow derived mesenchymal stem cells to patients with spinal cord injury."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: bone marrow derived mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "MSC"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01446640"
                        ]
                  },
                  {
                        "Rank": 369,
                        "Acronym": [
                              "MSC"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Intravenous bone marrow derived mesenchymal stem cells infusion from related donor to patients with relapsed/refractory aplastic anemia."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: bone marrow derived mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "MSC"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01305694"
                        ]
                  },
                  {
                        "Rank": 370,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Subject will receive the combined product of autologous cartilage cells and allogeneic AMSCs in a fibrin glue carrier."
                        ],
                        "ArmGroupInterventionName": [
                              "Combination Product: Autologous Chondrocytes in their Pericellular Matrix (Chondrons) Coimplanted with Allogeneic Adipose-Derived Mesenchymal Stromal Cells (AMSCs) in a Fibrin Glue Carrier"
                        ],
                        "ArmGroupLabel": [
                              "CartiLage Auto/Allo IMplantation for Focal Hip Cartilage Defects"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05553132"
                        ]
                  },
                  {
                        "Rank": 371,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Generated clinical-grade MSC 10 mg chlorpheniramine Po.;100 mg hydrocortisone iv.;10 mg metoclopramide im.;30 min before administration of the cells .\n\nMSC a day-case 2\u00b70\u00d7106 cells/kg i.v. 15min Infused normal saline 500 Ml over 4 h i.v.",
                              "Patients with progressive and refractory NMO treated with regular methods"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Autologous mesenchymal stem cells",
                              "Biological: Autologous mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "Autologous mesenchymal stem cells group",
                              "Control group"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02249676"
                        ]
                  },
                  {
                        "Rank": 372,
                        "Acronym": [
                              "NurOwn"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Single autologous MSC-NTF cells treatment by combined intramuscular and intrathecal administration",
                              "Combined intramuscular and intrathecal placebo administration"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Autologous MSC-NTF cells",
                              "Biological: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "Autologous MSC-NTF cells",
                              "Excipient"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02017912"
                        ]
                  },
                  {
                        "Rank": 373,
                        "Acronym": [
                              "CHAMP"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Amputation performed at 7 days post allogeneic bone marrow derived mesenchymal stem cell injections.",
                              "Amputation performed with no MSC administration. Subjects will be followed for incidence of infection and wound healing status to week 24 as a comparator to the Active/Treatment group.",
                              "Tissue Collection Group:\n\nAmputation performed with no MSC administration. Subjects will not be followed after amputation is performed. Tissue collection will occur at time of amputation.",
                              "Patients undergoing lower extremity bypass grafting procedure. Skeletal muscle samples of the sartorius and anterior tibial muscle will be collected for comparison to treatment group. No study testing, nor follow up visits will occur.",
                              "Patients undergoing a standard of care surgical procedure under anesthesia. Core needle biopsies will be collected from the anterior tibial muscle at the time of surgical procedure. No study testing, nor follow up visits will occur."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Allogeneic bone marrow derived mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "Active/Treatment Group",
                              "Observation Group 1",
                              "Observation Group 2",
                              "Observation Group 3",
                              "Control Group 4"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "No Intervention",
                              "No Intervention",
                              "No Intervention",
                              "No Intervention"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02685098"
                        ]
                  },
                  {
                        "Rank": 374,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [
                              "Biological: Cotransplant with MSCs"
                        ],
                        "ArmGroupLabel": [
                              "HSC",
                              "MSC+HSC"
                        ],
                        "ArmGroupType": [
                              "No Intervention",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04247945"
                        ]
                  },
                  {
                        "Rank": 375,
                        "Acronym": [
                              "AMETHYST"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Participants will receive a single dose of GEM00220 at 15 million cells",
                              "Participants will receive a single dose of GEM00220 at 60 million cells",
                              "Participants will receive a single dose of GEM00220 at 150 million cells"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: GEM00220",
                              "Biological: GEM00220",
                              "Biological: GEM00220"
                        ],
                        "ArmGroupLabel": [
                              "Treatment Arm - Low Dose",
                              "Treatment arm - Mid dose",
                              "Treatment arm - High dose"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04961658"
                        ]
                  },
                  {
                        "Rank": 376,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "The first cohort of three patients will receive a single dose in the first 48 postnatal hours.",
                              "If there are no safety concerns after the first cohort of 3 subjects are infused then the second cohort of three patients will receive two doses, with the first dose given in the first 48 postnatal hours and the second dose given approximately two months after the first dose."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Infusion of hCT-MSC",
                              "Biological: Infusion of hCT-MSC"
                        ],
                        "ArmGroupLabel": [
                              "First cohort of 3 subjects enrolled",
                              "Second cohort of 3 subjects enrolled"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03635450"
                        ]
                  },
                  {
                        "Rank": 377,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "use of mesenchymal stem cells as therapeutic intervention for spinal cord injury patients by autologous transplantation"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "Autologous mesenchymal stem cells"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02482194"
                        ]
                  },
                  {
                        "Rank": 378,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "After randomization, patients will be allocated to receive conventional treatment:\n\nBasiliximab 20mg dose for adults and 10mg for children, 1 time a week or every 3 days if worsens the stage of GVHD until reaching Very Good Partial Response (VGPR) or for a maximum of 4 doses, whichever comes first.\nIf after the item (1) will not obtained VGPR: Infliximab 5 to 10 mg/kg dose, 1 time a week, four weeks or even VGPR.",
                              "Patients in the study group will receive two infusions of MSC per week during two weeks and 1 more MSC infusion (2 + 2 + 1 scheme). Dosage: 2x10E6/Kg"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: conventional treatment",
                              "Biological: mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "conventional treatment",
                              "mesenchymal stem cells"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02770430"
                        ]
                  },
                  {
                        "Rank": 379,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patients age 18 or older with evidence consistent with a tear of the acetabular labrum and breakdown of the chondrolabral junction and consent to arthroscopic labral tear repair.\n\nBMAC application at the time of arthroscopic labral repair.",
                              "Patients age 18 or older with evidence consistent with a tear of the acetabular labrum and breakdown of the chondrolabral junction and consent to arthroscopic labral tear repair.\n\nNo BMAC application at the time of arthroscopic labral repair."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: BMAC"
                        ],
                        "ArmGroupLabel": [
                              "BMAC Application",
                              "No BMAC Application"
                        ],
                        "ArmGroupType": [],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03909139"
                        ]
                  },
                  {
                        "Rank": 380,
                        "Acronym": [
                              "WJ-ICMP Tria"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Intracoronary infusion WJMSCs or placebo in patients with ischemic heart failure",
                              "Intravenous infusion WJMSCs or placebo in patients with ischemic heart failure."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: WJMSCs Vs. placebo",
                              "Biological: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "Intracoronary infusion WJMSCs",
                              "Intravenous infusion WJMSCs"
                        ],
                        "ArmGroupType": [
                              "Placebo Comparator",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02368587"
                        ]
                  },
                  {
                        "Rank": 381,
                        "Acronym": [
                              "SEESCMMSCTSD"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Applications of medical collagen membrane with umbilical cord derived mesenchymal stem cells (MSC).",
                              "Application of medical collagen membrane only."
                        ],
                        "ArmGroupInterventionName": [
                              "Device: Medical Collagen Membrane with MSC",
                              "Device: Medical Collagen Membrane"
                        ],
                        "ArmGroupLabel": [
                              "Medical Collagen Membrane with MSC",
                              "Medical Collagen Membrane"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02672280"
                        ]
                  },
                  {
                        "Rank": 382,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [],
                        "ArmGroupLabel": [],
                        "ArmGroupType": [],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04432545"
                        ]
                  },
                  {
                        "Rank": 383,
                        "Acronym": [
                              "UwmWjmscAls"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Intervention: Biological: Cell-based therapy of allogeneic Wharton's jelly-derived mesenchymal stem cells which are transplanted intrathecally (via a standard lumbar puncture) into the ALS subjects."
                        ],
                        "ArmGroupInterventionName": [
                              "Other: Biological: Cell-based therapy"
                        ],
                        "ArmGroupLabel": [
                              "Allogeneic WJ-MSCs injection"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02881476"
                        ]
                  },
                  {
                        "Rank": 384,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Metformin + Placebo.",
                              "Metformin + Placebo"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Placebos",
                              "Drug: Semaglutide"
                        ],
                        "ArmGroupLabel": [
                              "Group A Placebo",
                              "Group B Active"
                        ],
                        "ArmGroupType": [
                              "Placebo Comparator",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04126603"
                        ]
                  },
                  {
                        "Rank": 385,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [],
                        "ArmGroupLabel": [],
                        "ArmGroupType": [],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01143168"
                        ]
                  },
                  {
                        "Rank": 386,
                        "Acronym": [
                              "OA"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "After arthroscopy intervention, patient will be given 10 million UC-MSCs and 2 cc Secretome twice with 2 weeks interval via intra-articular injection.",
                              "After arthroscopy intervention, patient will be given 2 cc Secretome, 10 million UC-MSCs, and 2 cc Secretome with 2 weeks interval via intra-articular injection.",
                              "Without arthroscopy intervention, patient will be given 10 million UC-MSCs and 2 cc Secretome twice with 2 weeks interval via intra-articular injection.",
                              "Without arthroscopy intervention, patient will be given 2 cc Secretome, 10 million UC-MSCs, and 2 cc Secretome with 2 weeks interval via intra-articular injection."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Arthroscopy with Mesenchymal Stem Cells + Secretome + Secretome",
                              "Biological: Arthroscopy with Secretome + Mesenchymal Stem Cells + Secretome",
                              "Biological: Non Arthroscopy with Mesenchymal Stem Cells + Secretome + Secretome",
                              "Biological: Non Arthroscopy with Secretome + Mesenchymal Stem Cells + Secretome"
                        ],
                        "ArmGroupLabel": [
                              "Arthroscopy + Booster",
                              "Arthroscopy + Pre-Conditioning",
                              "Non Arthroscopy + Booster",
                              "Non Arthroscopy + Pre-Conditioning"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04314661"
                        ]
                  },
                  {
                        "Rank": 387,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Dose I of Wharton Jelly Mesenchymal stem cells (WJ-MSC) Two intracavernous injections of 20 million of WJ-MSC cells will be given to erectile dysfunction patients at baseline and 4th week of follow up."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Wharton Jelly Mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "Dose I"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02945449"
                        ]
                  },
                  {
                        "Rank": 388,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Dose I of Wharton Jelly Mesenchymal stem cells (WJ-MSC) Two intracavernous injections of 20 million of WJ-MSC cells will be given to erectile dysfunction patients at baseline and 4th week of follow up"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Wharton Jelly Mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "Dose 1"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03751735"
                        ]
                  },
                  {
                        "Rank": 389,
                        "Acronym": [
                              "ADMSP"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "AD-MSCs\uff08adipose-derived multipotent mesenchymal stem cells \uff09 intravenous injection at a dose of 0.5 million cells/kg at week 0,week 4\uff0cweek 8 with a duration for treatment for 12 weeks."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: adipose-derived multipotent mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "AD-MSCs group"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03265613"
                        ]
                  },
                  {
                        "Rank": 390,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "AD-MSCs\uff08adipose-derived multipotent mesenchymal stem cells \uff09 intravenous injection at a dose of 2 million cells/kg at week 0, week 2, week 4, week 6, week 8 with a duration for treatment for 12 weeks. The topical treatment in the study was calcipotriol ointment(Dovonex;LEO Laboratories Ltd, Ireland) twice daily for 12 weeks."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Calcipotriol ointment",
                              "Biological: adipose-derived multipotent mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "AD-MSCs plus Calcipotriol ointment group"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03392311"
                        ]
                  },
                  {
                        "Rank": 391,
                        "Acronym": [
                              "WANICHD"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "The investigators performed a double-blind, placebocontrolled trial, randomly assigning 100 patients with coronary artery disease to have standard of care plus placebo. Participants allocated to each study arm in a 1:1:1 ratio, to investigate the therapeutic efficacy and safety of WJMSCs in patients with coronary artery disease.\n\nAssigned Interventions:\n\nBiological/Vaccine: Biological/Vaccine: WJMSCs Vs.placebo",
                              "The investigators performed a double-blind, placebocontrolled trial, randomly assigning 100 patients with coronary artery disease to compare standard of care plus placebo to standard of care plus one time or three times in doses of 1x106 /kg of WJMSCs. Participants allocated to each study arm in a 1:1:1 ratio, to investigate the therapeutic efficacy and safety of WJMSCs in patients with coronary artery disease.\n\nBiological/Vaccine:\n\nWJMSCs Vs.placebo",
                              "The investigators performed a double-blind, placebocontrolled trial, randomly assigning 100 patients with coronary artery disease to compare standard of care plus placebo to one time or three times at 30-day intervals for equal doses of 1x106 /kg of WJMSCs. Participants allocated to each study arm in a 1:1:1 ratio, to investigate the therapeutic efficacy and safety of WJMSCs in patients with coronary artery disease.\n\nBiological/Vaccine:\n\nWJMSCs Vs.placebo"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Intravenous infusion human umbilical Wharton's jelly-derived mesenchymal stem Cell or placebo PBS",
                              "Biological: Intravenous infusion human umbilical Wharton's jelly-derived mesenchymal stem Cell or placebo PBS",
                              "Biological: Intravenous infusion human umbilical Wharton's jelly-derived mesenchymal stem Cell or placebo PBS"
                        ],
                        "ArmGroupLabel": [
                              "Placebo Infusion PBS",
                              "Single dose Infusion WJMSCs",
                              "Infusion WJMSCs multiple doses"
                        ],
                        "ArmGroupType": [
                              "Placebo Comparator",
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04551456"
                        ]
                  },
                  {
                        "Rank": 392,
                        "Acronym": [
                              "ARTROCELL"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Treatment with 40 millions of autologous autologous adult mesenchymal stem cells from expanded bone marrow administered intra-articularly.",
                              "Treatment with 40 millions of adult allogeneic expanded bone marrow mesenchymal stem cells administered intra-articularly.",
                              "Hyaluronic Acid 60mg/3ml administered intra-articularly."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Autologous MSCs",
                              "Drug: Allogenic MSCs",
                              "Drug: Hyaluronic Acid"
                        ],
                        "ArmGroupLabel": [
                              "Autologous Mesenchymal Stromal Cells (MSC)",
                              "Allogenic Mesenchymal Stromal Cells (MSC)",
                              "Active Control"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05086939"
                        ]
                  },
                  {
                        "Rank": 393,
                        "Acronym": [
                              "ExoOA-1"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Intra-articular knee injection of exosomes (3-5 x 10e11 particles) derived from allogeneic mesenchymal stromal cells. Single dose."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Exosomes (sEVs)"
                        ],
                        "ArmGroupLabel": [
                              "Experimental group - sEVs"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05060107"
                        ]
                  },
                  {
                        "Rank": 394,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [
                              "Procedure: Oral mucosa biopsy",
                              "Procedure: Sinus lift with implantation of tissue engineered construction",
                              "Device: Dental implant"
                        ],
                        "ArmGroupLabel": [
                              "Tissue engineered construction implantation"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02209311"
                        ]
                  },
                  {
                        "Rank": 395,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "'Ex vivo expanded cord blood cells"
                        ],
                        "ArmGroupInterventionName": [
                              "Other: Ex vivo expanded cord blood cells"
                        ],
                        "ArmGroupLabel": [
                              "Expanded"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01624701"
                        ]
                  },
                  {
                        "Rank": 396,
                        "Acronym": [
                              "TACTICAL"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Phase I of the trial aims to establish the recommended MSCTRAIL dose when given in combination with cisplatin/pemetrexed chemotherapy in metastatic non-small cell lung cancer (NSCLC) patients",
                              "Cisplatin 75mg/m2 and Pemetrexed 500mg/m2 on day 1 followed by MSCTRAIL (at the recommended phase 2 dose) on day 2. This schedule will be repeated after 21 days for 3 cycles.\n\nPatients will then receive a further 1-3 cycles of pemetrexed/ cisplatin alone. They may then be eligible for maintenance pemetrexed according to clinical response as directed by their Oncologist in line with local standard of care.",
                              "cisplatin 75mg/m2 and pemetrexed 500mg/m2 on day 1 and placebo on day 2. This will be repeated after 21 days for up to 3 cycles.\n\nPatients will then receive a further 1-3 cycles of pemetrexed/ cisplatin alone. They may then be eligible for maintenance pemetrexed according to clinical response as directed by their Oncologist in line with local standard of care."
                        ],
                        "ArmGroupInterventionName": [
                              "Genetic: MSCTRAIL",
                              "Genetic: MSCTRAIL",
                              "Drug: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "Phase 1 - RP2D finding study",
                              "Phase 2 Intervention Arm",
                              "Phase 2 Control Arm"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03298763"
                        ]
                  },
                  {
                        "Rank": 397,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "A single IV infusion of ULSC's in patients with DM or PM"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Umbilical Cord Lining Stem Cells"
                        ],
                        "ArmGroupLabel": [
                              "Treatment Arm"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04723303"
                        ]
                  },
                  {
                        "Rank": 398,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [
                              "Biological: ASC enriched lipofilling",
                              "Biological: Standard Lipofilling"
                        ],
                        "ArmGroupLabel": [
                              "ASC",
                              "Control"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03258164"
                        ]
                  },
                  {
                        "Rank": 399,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Pre-filled syringe with 4 \u00b1 1 mL containing WJ-MSC in a balanced saline solution supplemented with human albumin.",
                              "Pre-filled syringe with 4 \u00b1 1 mL containing a balanced saline solution supplemented with human albumin"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: WJ-MSC (XCEL-UMC-BETA)",
                              "Drug: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "WJ-MSC (XCEL-UMC-BETA)",
                              "Placebo"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05054803"
                        ]
                  },
                  {
                        "Rank": 400,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Three Intrathecal administrations of NurOwn\u00ae (MSC-NTF cells) at bi-monthly intervals",
                              "Three Intrathecal administrations of Placebo at bi-monthly intervals"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: NurOwn\u00ae (MSC-NTF cells)",
                              "Other: Bone Marrow aspiration",
                              "Other: Placebo",
                              "Other: Bone Marrow aspiration"
                        ],
                        "ArmGroupLabel": [
                              "NurOwn\u00ae (MSC-NTF cells)",
                              "Placebo"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03280056"
                        ]
                  },
                  {
                        "Rank": 401,
                        "Acronym": [
                              "PFCD"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Direct injection of adult allogeneic bone marrow derived mesenchymal stem cells, at a dose of 75 million cells into perianal fistula(s) at baseline with a possible repeat injection at 3 months if not completely healed from the first injection.",
                              "Direct injection of normal saline. If not completely healed after 6 months, participants will then cross over to the treatment group to receive a direct injection of adult allogeneic bone marrow derived mesenchymal stem cells, at a dose of 75 million cells into perianal fistula(s)"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Mesenchymal Stem Cells",
                              "Other: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "Mesenchymal Stem Cells",
                              "Placebo"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04519671"
                        ]
                  },
                  {
                        "Rank": 402,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "AD-MSCs: adipose-derived multipotent mesenchymal stem cells intravenous injection at a dose of 2 million cells/kg of body weight at week 0, week 2, week 4, week 6, week 8 with a duration for treatment for 12 weeks.\n\nThe basic treatment is oral PSORI-CM01 Granule plus calcipotriol ointment (Dovonex;LEO Laboratories Ltd, Ireland) for topical use twice daily for 12 weeks."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Calcipotriol ointment",
                              "Drug: PSORI-CM01 Granule",
                              "Biological: adipose-derived multipotent mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "Experimental group"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04275024"
                        ]
                  },
                  {
                        "Rank": 403,
                        "Acronym": [
                              "OLT"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Traditional debridement and microfracture treatment adding a platelet-poor plasma (PPP) scaffold embedded in allogenic stromal mesenchymal cells derived from the umbilical cord in patients with osteochondral lesions of the talus.",
                              "Traditional debridement and microfracture treatment in patients with osteochondral lesions of the talus."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Allogenic stromal mesenchymal cells derived from the umbilical cord",
                              "Procedure: Debridement and microfracture",
                              "Procedure: Debridement and microfracture"
                        ],
                        "ArmGroupLabel": [
                              "Debridement and microfracture in LOC + Cells",
                              "Debridement and microfracture in LOC"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03905824"
                        ]
                  },
                  {
                        "Rank": 404,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Fifteen (15) subjects will be treated with three intravenous infusion (IV) of 5 x 10^5 UCMSCs per Kg body weight delivered via peripheral intravenous infusion on days 1, 3 and 5 besides the standard care (SOC).",
                              "Five (5) subjects will be treated under Standard of Care (SOC) ."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Intravenous Infusions of Stem Cells"
                        ],
                        "ArmGroupLabel": [
                              "Group 1 : Treatment",
                              "Group 2: standard care"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "No Intervention"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04437823"
                        ]
                  },
                  {
                        "Rank": 405,
                        "Acronym": [
                              "AURA"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patients in this group will received conventional microfracture treatment as indicated for isolated cartilage defects and defined by the inclusion criteria.",
                              "Patients in this group will also receive microfracture for the treatment of isolated cartilage defects in combination with arthroscopic synovial brushing to access and release synovial MSCs into the joint space."
                        ],
                        "ArmGroupInterventionName": [
                              "Procedure: Microfracture",
                              "Device: Arthroscopic synovial brushing"
                        ],
                        "ArmGroupLabel": [
                              "Control group",
                              "Intervention group"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02696876"
                        ]
                  },
                  {
                        "Rank": 406,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Human Umbilical Cord Derived-Mesenchymal Stem Cells, Single treatment by intravenous infusion."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: UMC119-06"
                        ],
                        "ArmGroupLabel": [
                              "UMC119-06"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04347967"
                        ]
                  },
                  {
                        "Rank": 407,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "TH-SC01 24 mL suspension of 120 million cells as a perilesional injection, once on Day 0."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: TH-SC01"
                        ],
                        "ArmGroupLabel": [
                              "TH-SC01"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04939337"
                        ]
                  },
                  {
                        "Rank": 408,
                        "Acronym": [
                              "VIVAAA"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "In a randomized fashion, the MSCs, in the appropriate dose, will be shipped to the performance site where the MSCs will be thawed, diluted and administered. The thawed MSCs with be administered within 4 hours to subjects in a monitored setting with telemetry and pulse oximetry. Patients will be premedicated with hydrocortisone and diphenhydramine. All subjects will be monitored throughout the infusion procedure with vital signs and pulse oximetry at 15 minutes prior to infusion and ending 2 hours post procedure. They will also be evaluated for clinical signs of pulmonary distress. All patients will be admitted overnight for continued observation. The patient will be examined the following day and discharged home.",
                              "In a randomized fashion, the MSCs, in the appropriate dose, will be shipped to the performance site where the MSCs will be thawed, diluted and administered.The thawed MSCs with be administered within 4 hours to subjects in a monitored setting with telemetry and pulse oximetry. Patients will be premedicated with hydrocortisone and diphenhydramine. All subjects will be monitored throughout the infusion procedure with vital signs and pulse oximetry at 15 minutes prior to infusion and ending 2 hours post procedure. They will also be evaluated for clinical signs of pulmonary distress. All patients will be admitted overnight for continued observation. The patient will be examined the following day and discharged home.",
                              "In a randomized fashion, the Plasmalyte A will be shipped to the performance site where it will be thawed and administered. The Plasmalyte A will be administered within 4 hours to subjects in a monitored setting with telemetry and pulse oximetry as will be performed on active groups in order to protect the blinding of this study. Patients will be pre-medicated with hydrocortisone and diphenhydramine. All subjects will be monitored throughout the infusion procedure with vital signs and pulse oximetry at 15 minutes prior to infusion and ending 2 hours post procedure. They will also be evaluated for clinical signs of pulmonary distress. All patients will be admitted overnight for continued observation. The patient will be examined the following day and discharged home."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: MSCs",
                              "Drug: Placebo",
                              "Biological: MSCs",
                              "Drug: Placebo",
                              "Biological: MSCs",
                              "Drug: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "Intravenous infusion of 1 million allogenic MSC's/Kg",
                              "Intravenous infusion of 3 million allogeneic MSCs/kg",
                              "Intravenous infusion of Plasmalyte A (placebo)"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Active Comparator",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02846883"
                        ]
                  }
            ]
      }
}